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 Cobalamin, also known as vitamin B12, is an essential nutrient for many different 
organisms including mammals, fish, birds, nematodes, and a variety of bacteria. However, 
cobalamin is only synthesised by a few bacteria and archaea. Organisms that cannot 
synthesise cobalamin de novo must obtain it from their diet. In humans, the cobalamin 
uptake mechanism has been studied in detail, but in many organisms, such as 
Caenorhabditis elegans, no method of transport has been defined, and their need for 
cobalamin is recognised by a cobalamin deficiency phenotype.  
 Corrin ring modified fluorescent analogues of cobyric acid and ribose conjugated 
fluorescent analogues of cobalamin were synthesised in order to follow the uptake and 
localisation of these corrinoids in a variety of organisms. Both the C5 corrin-ring modified 
and the ribose conjugated analogues were absorbed by Salmonella enterica, using the B12 
uptake system (Btu) and could be converted into active coenzyme forms. The imaging of 
these fluorescent analogues enabled the identification of the coelomocytes in C. elegans as 
a possible storage cell for cobalamin. However, the C5 cobyric acid analogue was not 
recognised which suggests that the C. elegans cobalamin transport mechanism is specific 
for complete corrinoid molecules. Lepidium sativum, garden cress, was shown to take up 
both cobalamin analogues from the roots and store it in the vacuoles of the cotyledons in 
seedlings, even though plants have no cobalamin requirement. In contrast, Arabidopsis 
thaliana did not transport any of the cobalamin analogues. 
 Cobalamin deficiency has been implicated in impeding disease progression in a 
number of diseases, such as tuberculosis. The Mycobacterium tuberculosis cobalamin 
uptake protein, BacA, has only recently been identified, and there is still much to learn 
about the relationship between M. tuberculosis and cobalamin. Incubations of a cobalamin 
dependent strain of M. tuberculosis, ǻPHW(, with a selection of cobalamin biosynthesis 
intermediates showed that cobyric acid is the earliest intermediate to be taken up and 
converted into the cofactor form. The C5 corrin ring modified cobyric acid fluorescent 
analogue is also capable of rescuing this ǻPHW( strain, and is taken up faster than the ribose 
conjugated cobalamin analogue. Overall, the research outlined in this thesis demonstrates 
that fluorescent corrinoid analogues can be used to follow the journey of cobalamin in a 
broad range of different organisms and systems. 
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Now soars the russet pheasant like a flare,  
And like a flame you glimmer unto me.  
 
Now slinks the cat like a silent shadow, 
And your midnight coat shines on to me. 
 
Now flies the silent meteor on, and leaves  
A shining furrow, as thy thoughts in me. 
-0RGLILHGIURPµ7KH3ULQFHVV3DUW¶ 
By Alfred, Lord Tennyson 
 
 







































































An introduction to 
cobalamin biosynthesis, 
uptake, and the chemical 
synthesis of analogues 
  





1.1 Cobalamin as a vitamin  
Cobalamin (vitamin B12) is an essential molecule for many organisms across a wide 
variety of phyla. Although numerous organisms require cobalamin, only some bacteria and 
archaea can synthesise it (Clardy et al. 2011; Raux et al. 2000). This means that the majority 
of organisms, including humans, must obtain a regular source of cobalamin through their diet 
(Clardy et al. 2011; Raux et al. 2000). This is not difficult, as very small quantities of 
cobalamin are needed for maintaining normal function, in humans the daily requirement for 
cobalamin is 1µg per day (Martens et al. 2002; Kuzminski et al. 2016). Cobalamin is 
indispensable for proper brain function and is also involved in cell maintenance, DNA 
synthesis, neural development and upkeep as well as being involved in red blood cell 
production, amongst other uses (Battaglia-Hsu et al. 2009; Ames 2001; Fenech 2001). Some 
cobalamin deficiencies are caused by dietary restriction e.g. veganism, and others by a lack or 
mutation in the uptake and transport system. A deficiency in cobalamin can lead to pernicious 
anaemia, hyper-homocysteinemia and many other ailments (Selhub 1999; Marsh 1999). 
Patients with pernicious anaemia must take cobalamin supplements or have regular 
intravenous injections to circumvent the lack of transport. There are two types of pernicious 
anaemia, A, an auto immune disease which targets a cobalamin transporter, intrinsic factor 
(IF), or B, a non-autoimmune gastritis which is usually associated with Helicobacter pylori 
infection (Toh et al. 1997). If cobalamin deficiency is left untreated patients may develop 
depression, neurological damage, heart and organ failure, leading to death (Nielsen et al. 
2012). Excess cobalamin is stored in the liver (Allen 2008). This store of cobalamin is 
thought to be the reason why cobalamin deficiency manifests after a significant time gap 
(sometimes years) from when the cobalamin absorption process breaks down (Allen 2008). 
1.1.1 Discovery and structure of cobalamin 
The discovery of cobalamin started with the identification of pernicious anaemia as an 
ailment in 1835. Then, in the early 1920s, Whipple observed that feeding raw liver to dogs 
with anaemia reversed the symptoms (Whipple and Roschelle-Robbins 1925). Around the 
same time, Minot and Murphy found that patients suffering from pernicious anaemia could be 
cured by including a whole liver in their diet (Martens et al. 2002). They attributed this cure to 
an extrinsic factor contained within the liver, but it was not until the late 1940s that the 
cherry-red coloured cobalamin was isolated from liver and firsWGHVFULEHGDVµYLWDPLQ%12¶
(Banerjee and Ragsdale 2003). Around the same time cobalamin was discovered in many 





other foodstuffs including milk, eggs, meat in general, and also in some bacterial cultures. In 
1956 Dorothy Hodgkin and her group solved the crystal structure of cobalamin revealing a 
FRPSOH[PROHFXOHODWHUGHVFULEHGDVµQDWXUH¶VPRVWEHDXWLIXOFRHQ]\PH¶ (Stubbe 1994; 
Hodgkin et al. 1956).   
Cobalamin is a member of the modified tetrapyrrole family. It is unique within this 
family because of its molecular asymmetry caused by the extrusion of carbon 20 (C20) of the 
macrocycle, giving rise to a contracted ring system (Figure 1.1.1.1) (Schroeder et al. 2009; 
Moore and Warren 2012). It is also the only molecule in this family to coordinate a cobalt ion 
at its centre. The molecule name is generated from this cobalt ion and its vitamin status 
combining to give: cobal(t) (vital) amin(e), cobalamin. Other modified tetrapyrroles include 
chlorophyll and haem, which coordinate magnesium and iron in the centre of their macrocycle 
respectively. The members of the cyclic tetrapyrrole family are known for their distinctive 
colours: chlorophyll is green, haem is red and cobalamin is cherry red. These colours, and the 
pivotal functions of these molecules, led to the cyclic tetrapyrrole family being referred to as 
µWKHSLJPHQWVRIOLIH¶(Blanche et al. 1995). 
The structure of cobalamin is comple[EXWFDQEHEURNHQGRZQLQWRWKUHHSDUWVWKHȕ
XSSHUFREDOWOLJDQGWKHĮOLJDQGRUQXFOHRWLGHORZHUORRSDQGFRELQDPLGH)LJXUH
7KHȕOLJDQGFKDQJHVGHSHQGLQJRQWKHFRfactor form. In adenosylcobalamin it is an 
adenosyl group, which is a coenzyme for the cobalamin-dependent isomerases, such as 
methyl malonyl coenzymeA mutase (MCM) (Banerjee et al. 2009). Exchanging the adenosyl 
group for a methyl group produces the cofactor form of cobalamin, methylcobalamin, which 
is used by cobalamin-dependent methyltransferases, as exemplified by methionine synthase, 
MetH (Banerjee et al. 2009). Cyanocobalamin, the commercial form of vitamin B12,  has a 
F\DQLGHJURXSDVWKHȕOLJDQG7KHF\DQLGHLVQRWDQDWXUDOOLJDQGLWLVDGGHGWRDLGH[WUDFWLRQ
of cobalamin from bacterial cultures during purification. 
 The numbering system used for cobalamin is detailed in Figure 1.1.1.1 using 
adenosylcobalamin as the example. The carbons of the corrin ring are numbered in light 
purple whilst the sidechains are referred to by letters, a-g (orange), as are the pyrrole rings, A-
'WHDO7KHXSSHUȕOLJDQGLVLQUHGDQGWKHORZHUĮ ligand is the nucleotide loop composed 
of the ribophosphate (purple) and dimethyl benzimidazole (DMB) (green). The dotted line 
LOOXVWUDWHVWKHERQGZKLFKFDQIRUPIURPWKH'0%WRWKHFREDOWLRQNQRZQDV³EDVHRQ´
binding (Mathews et al. 2007). In some forms of cobalamin, and during binding to some 





Figure 1.1.1.1: The two dimensional structure of adenosylcobalamin, colour coding the different 
groups. The corrinoid in black is equivalent to cobinamide, an intermediate of biosynthesis.The carbons 
of the corrin ring are numbered in light purple, lower case lettered labelling of the side chains are in 
orange, and capital lettered naming of the pyrrole rings are in teal. The adenosyl group, representing the 
upper, or ȕ, ligand to the cobalt ion LVLQUHGDQGWKHORZHUĮ, ligand to the cobalt ion is the nucleotide 
loop. This is comprised of the ribophosphate (purple) and DMB (dimethyl benzimidazole) (green). The 
structure is drawn in the ³base on´ configuration indicated by the dotted linecoordinating the cobalt. It is 
important to note the ring contraction between C1 and C19 indicative of the corrin ring; the excised 
carbon is referred to as C20 and is only present in the early intermediates. 
Į ligand 
ȕ ligand 
proteins, this bond is broken (Wuerges et al. 2006)7KLVLVNQRZQDVWKH³EDVHRII´
conformation (Wuerges et al. 2006). It is important to note that the carbon atom at position 20 
(C20) is not shown in Figure 1.1.1.1 as it has been extruded during the biosynthesis of 
cobalamin. Prior to extrusion, C20 formed a methylene bridge between C19 and C1 on the 
left side of the corrin ring, opposite C10. The contracted corrin ring formed by the cyclic 
tetrapyrrole system tightly coordinates the cobalt ion.  





 DMB is the most commonly studied lower base, however, it is not the only form: 
adenine, phenol, p-cresol, and 5-methylbenzimidazole, amongst others, can all be substituted 
for DMB (Yi et al. 2012). In humans, the DMB form is the only one recognised by the 
transport mechanism and, consequently, the only one known to work with human cobalamin-
dependent proteins (Clardy et al. 2011). Other organisms, such as some cyanobacteria, prefer 
adenine as the base, known as pseudo-cobalamin, and some monera preferentially synthesise 
pseudo-cobalamin over cobalamin (Fyfe and Friedmann 1969; Helliwell et al. 2016).  
1.2 Cobalamin biosynthesis 
There are broadly two routes for cobalamin biosynthesis; the Early insertion 
DQDHURELFSDWKZD\DQGWKH/DWHLQVHUWLRQDHURELFSDWKZD\7KHµ(DUO\¶DQGµ/DWH¶UHIHUWR
the relative stage at which the cobalt is inVHUWHGLQWRWKHPDFURF\FOHZKLOVWµDQDHURELF¶DQG
µDHURELF¶DOOXGHWRWKHUHTXLUHPHQWRIPROHFXODUR[\JHQIRUWKHULQJFRQWUDFWLRQPHFKDQLVP 
1.2.1 The Late insertion Pathway 
The Late insertion pathway was the first of the two biosynthetic pathways to be solved 
and has been studied for many years (Raux et al. 1996; Maggio-Hall and Escalante-Semerena 
1999) )LJXUH8URSRUSK\ULQRJHQ,,,XUR¶JHQ,,,WKHSURJHQLWRURIDOOPRGLILHG
tetrapyrroles, is converted to precorrin-2 by methylation at positions C2 and C7 using S-
adenosyl-mHWKLRQLQH6$0DVWKHPHWK\OGRQRU7KHGLJLWVXFFHHGLQJWKHµSUHFRUULQ¶UHIHUV
to the number of SAM derived methyl groups bound directly to the corrin ring (including the 
C20 methyl group even after extrusion). Precorrin-2 is methylated at C20 by CobI, using a 
SAM donated methyl group, to produce precorrin-3A. This is the first committed step in the 
biosynthesis of cobalamin, and is a key requirement for the subsequent extrusion of C20 
(Warren et al. 2002). The next enzymes, CobG and CobJ, catalyse the extrusion of C20. 
These reactions not only characterise cobalamin as having a unique asymmetrical macrocycle, 
but also define the /DWHLQVHUWLRQSDWKZD\DVDQ³DHURELF´URXWH7KLVLVEHFDXVH&RE*LVD
mono-oxygenase, and transfers a hydroxyl group derived from molecular oxygen to the C20 
position to form a tertiary alcohol. The acetate sidechain, aVXEVHTXHQWO\IRUPVDȖODFWRQH
ring, to produce precorrin-3B (Schroeder et al. 2009). CobJ then promotes ring contraction by 
catalysing a masked pinacol rearrangement, as well as transferring a methyl group to C17 
using SAM as the donor molecule (Schroeder et al. 2009). The product of these reactions is 
precorrin-4.  CobM and CobF both transfer SAM derived methyl groups to C11 and C1 
respectively, which synthesises precorrin-6A. CobK reduces the double bond between C18 





and 19 to form precorrin-6B using reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) as the electron donor. Following this, CobL catalyses the transfer of methyl groups 
to C5 and C15, as well as the decarboxylation of C12. These are the last methyl transfer 
reactions and are both SAM dependent. The C11 methyl group is migrated to C12 by CobH to 
produce hydrogenobyrinic acid (HBA). CobH is the last enzyme to alter any of the chemical 
groups directly attached to the corrin ring. All of the subsequent reactions affect the 
VLGHFKDLQVRUDUHUHODWHGWRWKHFREDOWLRQHLWKHULWVLQVHUWLRQRUWKHQDWXUHRIWKHȕOLJDQG  
CobB catalyses the amidation of sidechains a and c, using glutamine as the amide 
donor. Next, the cobalt chelation complex, CobNST, inserts cobalt into the macrocycle. This 
is a slow and very metabolically expensive reaction, potentially using 15 molecules of 
adenosine triphosphate (ATP) to insert one cobalt ion (Heldt et al. 2005). This central cobalt 
LVUHGXFHGDQGDQDGHQRV\OJURXSLVDGGHGDVWKHȕOLJDQGE\&RE5DQG&RE2UHVSHFWLYHO\
In the majority of organisms which utilise the Late insertion pathway, these two reactions 
must be complete before CobQ will proceed to amidate sidechains, b, d, e, and g, producing 
adenosyl cobyric acid (Warren et al. 2002). The final enzymes, CobD, P and V, catalyse the 
incorporation of the lower loop onto sidechain f of adenosyl cobyric acid. CobD attaches the 
aminopropanol phosphate to the propionic acid sidechain forming adenosyl-cobinamide. 
Succeeding this, CobP converts cobinamide into adenosyl-GDP-cobinamide, firstly by 
phosphorylating the hydroxyl group of the aminopropanol, using ATP as the donor molecule, 
and then, transferring a GMP moiety from GTP onto the phosphate group (Cohen 2014). 
CobV transfers Į-ribazole phosphate (or Į-ribazole) onto the first phosphate group to produce 
cobalamin-¶-SKRVSKDWH7KLV¶-phosphate is subsequently removed to form 
adenosylcobalamin (Cohen 2014). 
The nomenclature used in Figure 1.2.1.1 is specific for Pseudomonas denitrificans and 
may be different in other organisms. However, in general the genes of the Late insertion 
SDWKZD\DUHSUHIL[HGµcob¶ 







Figure 1.2.1.1: The Late insertion pathway. This is an abridged representation of cobalamin 
biosynthesis, starting from uroporphorinogen III and showing the modifications (red) catalysed by each 
of the pathway enzymes (blue) to produce adenosyl cob(III)yric acid. The enzymes and cofactors 
required to convert adenosyl cob(III)yric acid into adenosylcobalamin are represented by the 5 arrows. 





1.2.2 The Early insertion pathway 
The Early insertion pathway has only been elucidated in the last few years (Moore and 
Warren 2012; Frank et al. 2005) (Figure 1.2.2.1). This was partly because the intermediates 
produced are oxygen sensitive and very unstable, due to the early incorporation of the cobalt 
ion into the macrocycle (Moore, Lawrence, et al. 2013). This pathway also begins with the 
FRQYHUVLRQRIXUR¶JHQ,,,LQWRSUHFRUULQ-2. The C14-15 bond of precorrin-2 is oxidised by 
SirC, using nicotinamide adenine dinucleotide (NAD+) as a cofactor, to produce factor-II. 
Factor-II, also known as sirohydrochlorin, is the oxidised form of precorrin-2. The numbers 
after the name of the intermediate are in Roman numerals and again represent the number of 
methyl groups that have been added to the macrocycle.  
 
Cobalt is inserted into factor-II by CbiX, a cobaltochelatase, to form cobalt factor-II. 
Unlike the Late insertion chelatase this reaction does not require ATP or oxygen, but, apart 
Figure 1.2.2.1: The Early insertion pathway. This abridged representation of the Early insertion 
pathway begins with the conversion of precorrin-2 to factor-II, the first committed step in cobalamin 
biosynthesis (Frank et al. 2005), up to cob(II)yrinic acid.  From here cobalamin de novo synthesis is the 
same as the Late insertion pathway. The changes in structure are shown in red, whilst the enzymes are in 
black, with their cofactors in pink. 





from this, little is known about the cobalt chelation reaction (Frank et al. 2005; Moore and 
Warren 2012). Cobalt factor-II is subsequently methylated at C20 and C17 by CbiL and CbiH, 
respectively, both in a SAM-dependent manner. CbiH also catalyses the C20 extrusion, ring 
FRQWUDFWLRQUHDFWLRQE\SURPRWLQJWKHIRUPDWLRQRIDį-lactone between rings A and D, and it 
is thought that the 4Fe-4S centre of CbiH is involved in the reduction of cobalt factor-III to 
cobalt precorrin-4, but little is known about the mechanism of this reduction reaction (Moore, 
Biedendieck, et al. 2013). The next enzyme, CbiF, is another SAM dependent 
methyltransferase, methylating C11 to produce cobalt precorrin-5a. CbiG is an enzyme unique 
to the early insertion pathway (Moore, Lawrence, et al. 2013),WLVWKRXJKWWRRSHQWKHį-
lactone ring, leaving C1 free to accept the methyl group transferred by CbiD. CbiD is a 
protein with no known similarity to any other characterised enzyme (Moore, Lawrence, et al. 
2013). Despite it being a SAM-dependent methyltransferase it does not have the characteristic 
canonical GXGXG sequence in the N-terminus of the protein (Roessner et al. 2005). However, 
it has been shown that CbiD methylates the C1 position in a SAM-dependent manner (Moore, 
Lawrence, et al. 2013). CbiJ reduces the double bond between C18 and C19 using NADPH as 
a cofactor to form cobalt precorrin-6b. The last two SAM mediated methyl transfers are 
catalysed by CbiET. This is a fused protein in Bacillus megaterium but exists as two separate 
proteins in Methanobacterium thermoautotrophicum: CbiE catalyses the methylation of C5 
and CbiT the methylation of C15 and the decarboxylation of C12. CbiC subsequently 
catalyses the migration of the C11 methyl group to C12 to form cobyrinic acid. CbiA 
promotes the amidation of sidechains a and c to make cobyrinic acid-a, c-diamide, which then 
follows the same pathway as in the Late insertion pathway to produce cobalamin (Moore and 
Warren 2012). 
1.3 Cobalamin-dependent enzymes 
 Cobalamin is classified as a vitamin in humans because deficiency causes detrimental 
effects to life. These include demyelinating nerves, gastrointestinal dysfunction, hyper-
segmentation of neutrophils, and potentially dementia, although the connection with the latter 
is inconclusive (Nielsen et al. 2012; Andrès et al. 2004; Werder 2010). Humans have two 
cobalamin-dependent enzymes: methyl malonyl coenzymeA mutase (MCM), and methionine 
synthase (encoded by metH in Escherichia coli and Mycobacterium tuberculosis, and by cblG 
in Homo sapiens) (Nielsen et al. 2012; Willard et al. 1978; Banerjee and Ragsdale 2003; 
Gopinath, Moosa, et al. 2013; Banerjee et al. 2009; Dobson et al. 2002; Gonzalez et al. 1992). 
MCM requires adenosylcobalamin to catalyse the isomerisation of methylmalonyl coenzyme 





A to succinyl coenzymeA in mitochondria (Clardy et al. 2011; Brown 2005; Andrès et al. 
2004). The cobalamin-dependent methionine synthase is dependent on the methylcofactor to 
methylate L-homocysteine to produce L-methionine in the cytosol (Brown 2005; Stubbe 
1994). In some organisms there is a methylcobalamin independent methionine synthase 
(encoded by metE in E. coli  and M. tuberculosis, and by cblE in H. sapiens (Gonzalez et al. 
1992; Gopinath, Moosa, et al. 2013; Banerjee et al. 2009; Dobson et al. 2002)) which is active 
when cobalamin is not available (Figure 1.3.1), but it is transcriptionally terminated in the 
presence of cobalamin due to the existence of a cobalamin riboswitch upstream of the metE 
gene (Warner et al. 2007). It has been shown in E. coli that MetH has a catalytic turnover of 
1500 molecules per minute and is over 100 times more active than MetE (12.3 molecules per 
minute) revealing a clear metabolic advantage of using the cobalamin-dependent enzyme 
when possible (Gonzalez et al. 1992; Jeter et al. 1984). From now on the cobalamin-
dependent methionine synthases will be referred to as MS in humans, MetH in all other 
organisms, and the independent equivalent as MetE.  
  
In many bacteria, cobalamin-associated genes, for instance those encoding cobalamin 
biosynthetic enzymes or cobalamin-dependent enzymes, are regulated, in part, by upstream 
riboswitches (Rodionov et al. 2003). Riboswitches are short regions of RNA (in bacteria) 
preceding, or within, the regulated gene (Warner et al. 2007; Vitreschak et al. 2003). They can 
either regulate at the transcriptional or translational level and both are dependent upon ligand 
Figure 1.3.1: The two different mechanisms of methionine synthesis. A schematic representation of 
the reactions catalysed by the cobalamin-dependent, MetH, and independent, MetE, enzymes. Changes in 
structure are coloured in red.  





binding. In the case of metE, adenosylcobalamin acts as the ligand. When adenosylcobalamin 
LVERXQGWRWKHµ%12 HOHPHQW¶WKHFREDODPLQUHJXODWHGULERVZLWFKWKH51$IROGVDQGIRUPVD
ligand-stabilised pseudoknot (Vitreschak et al. 2003; Rodionov et al. 2003). This interacts 
with the antisequestor or antiterminator regions (which are sometimes part of the pseudoknot 
itself) and instigates the formation of a ribosome sequester hairpin or terminator in 
translational or transcriptional regulation, respectively (Vitreschak et al. 2003). For the metE 
gene this equates to a decrease in transcription, resulting in lower protein production in the 
presence of adenosylcobalamin.  
1.4 Transport of cobalamin 
 As mentioned previously there are many different organisms that require cobalamin, 
but only some bacteria and archaea synthesise it de novo. Therefore, cobalamin requiring 
organisms, including many bacteria, algae, nematodes, birds, fish and mammals, must acquire 
cobalamin from cobalamin producing organisms (Grossman 2016; Helliwell et al. 2016; 
Greibe, Fedosov, and Nexo 2012; Greibe, Fedosov, Sorensen, et al. 2012; Bito et al. 2013; 
Nielsen et al. 2012). Different organisms have different methods of transporting cobalamin, of 
which the bacterial uptake systems are the most extensively studied.  
M. tuberculosis has a single known transporter, BacA, which was identified in 2013 
(Gopinath, Venclovas, et al. 2013). This spans the single membrane of M. tuberculosis, 
transporting cobalamin from the waxy lipid rich coat of the bacterium exterior, into the 
cytoplasm (Figure 1.4.1) (Bansal-mutalik and Nikaido 2014; Gopinath, Venclovas, et al. 
2013). BacA is an ATP binding cassette (ABC) protein, predicted to be a homodimer. 
Although most ABC importers work cooperatively with a high affinity substrate binding 
























In gram-negative bacteria import requires a few more proteins.  In E. coli, the Ton-B 
dependent BtuB is the outer membrane transporter which imports cobalamin to the periplasm. 
BtuF then tightly binds it and trafficks it to the BtuC/D complex on the inner membrane. BtuF 
has an extremely high affinity for cobalamin (15 nM) whereas BtuC/D alone does not bind 
free cobalamin well (Lewinson et al. 2010). However, upon the association of BtuF to 
BtuC/D, BtuC/D causes BtuF to release the bound cobalamin which is internalised (Lewinson 
et al. 2010). Using ATP, BtuF then dissociates from BtuC/D allowing BtuF to bind free 
cobalamin and for the process to be repeated (Lewinson et al. 2010) (Figure 1.4.2). BtuD is an 
ABC protein, like BacA, whereas BtuC is a transmembrane protein (Cadieux et al. 2002). 
 
Figure 1.4.1: The structure of the Mycobacterium 
tuberculosis cell wall. The single, plasma membrane 
is covered in lipoarabinomannans (LAM), 
lipomannans (LM), and phosphatidylinositol (PIM). 
The presence of these is what causes M. tuberculosis 
to be impervious to Gram staining. Instead the 
bacterium is classified as acid-fast. This figure was 
reproduced with permission from Park and Bendelac 
2000. 






 In algae only one protein, CBA1, has been implicated in cobalamin uptake, although 
the role of this protein and the mechanism of uptake is unknown (Helliwell et al. 2016). Plants 
have no designated cobalamin uptake mechanism as they do not need it. However, it has been 
shown that some plants, e.g. soya bean, can take up cobalamin from their environment 
(Watanabe et al. 2013). 
C. elegans has a cobalamin deficiency phenotype, which indicates that it requires 
cobalamin (Bito et al. 2013). The origin of the cobalamin is likely to be the bacterial food 
source, but the uptake system is currently not known. 
 Zebrafish (Danio rerio) have one identified cobalamin binding protein which is 
excreted in large quantities into the ambient water to sequester cobalamin (Greibe, Fedosov, 
and Nexo 2012). Similarly, rainbow trout (Oncorhynchus mykiss) also have one known 
extracellular cobalamin binding protein, which is distributed through various tissues in the 
fish particularly in the kidney and roe (Greibe, Fedosov, Sorensen, et al. 2012). Both of the 
proteins identified in these fish behave like intermediaries of the three known extracellular 
mammalian cobalamin binding proteins (see Section 1.4.1) (Greibe, Fedosov, and Nexo 2012; 
Greibe, Fedosov, Sorensen, et al. 2012). 
  
 
Figure 1.4.2: The mechanism of cobalamin import in  E. coli.This mechanism proposed in (and 
reproduced with permission from) Lewinson et al. 2010 shows BtuF, the protein on top, binding 
cobalamin, the black 8 shape, and trafficking it to the BtuC/D complex. Cobalamin is then transported 
through BtuC, transmembrane section, and BtuD, ATP binding protein at the bottom. Upon the 
hydrolysis of ATP to ADP, BtuF is realeased from the complex and available for periplasmic cobalamin 
binding. 





1.4.1 Cobalamin absorption in Homo sapiens 
The human cobalamin uptake system is more complex than those of the organisms 
discussed previosly. Humans can absorb cobalamin at different points during digestion 
(Nielsen et al. 2012) (Figure 1.4.1.1). Haptocorrin (HC), the initial cobalamin binding protein 
(also called R-protein or transcobalamin I) is in many bodily fluids including plasma and 
VDOLYD2QFH+&LVERXQGWRFREDODPLQLWµHVFRUWV¶LWWKURXJKWKHXSSHUJDVWURLQWHVWLQDOWUDFW
















In the duodenum the HC is degraded by pancreatic enzymes and the cobalamin passes 
onto intrinsic factor (IF). IF serves as the first quality control point as it specifically binds 
cobalamin (with DMB as the lower base), whereas HC will bind cobinamide and other 
Figure 1.4.1.1: Overview of uptake and transport of 
cobalamin in humans. In the upper gastrointestinal tract, 
cobalamin is released from food and is bound by HC. The HC 
is degraded in the duodenum and cobalamin is captured by IF. 
Further down the gut, in the terminal ileum, IF-bound 
cobalamin is endocytosed by cubam. Inside these enterocytes, 
IF is degraded and cobalamin is released to plasma by MRP1. 
In plasma, cobalamin is bound to HC or TCII (Nielsen et al. 
2012). This figure was reproduced with permission from 
Nielsen et al. 2012. 





intermediates too (Nielsen et al. 2012). Once bound the IF-cobalamin complex travels down 
the gut to the terminal ileum where it is absorbed into cells via the IF-cobalamin receptor, 
cubam, a complex between cubilin and amnionless (Clardy et al. 2011). IF is then degraded in 
the cells of the intestinal lining (enterocytes) and cobalamin
 
is excreted by multidrug 
resistance protein (MRP) 1 into the bloodstream where it is picked up by transcobalamin II 
(TCII) or HC. Although the HC bound cobalamin
 
accounts for about 80 % of cobalamin in the 
bloodstream, only the TCII-cobalamin complex is internalised via the transcobalamin receptor 
(TCR) (Banerjee et al. 2009). This is most likely because TCII only binds completed 
cobalamin, ensuring that no incomplete forms of cobalamin are present in the cell. The TCII-
cobalamin complex is degraded in the lysosome of cells, and the cobalamin is exported into 
the cytosol, whereupon it is either converted into a methyl cofactor, or transported into the 
mitochondria.  
1.5 Links between disease and cobalamin  
 The causes of cobalamin deficiency are widespread. Some causes are intrinsic, such as 
a lack of a cobalamin transporter, some are self-imposed lifestyle choices, and others are due 
to infection or disease. Low dietary cobalamin intake resulting from lifestyle choices, such as 
veganism, can cause deficiency in adults as well as in breastfed infants, and even if the child 
subsequently adopts an omnivorous diet they are at greater risk of developing deficiency. 
These children may have stunted growth due to their childhood deficiency (Allen 2008).  
Polymorphisms in the cobalamin uptake proteins e.g. TCII, or an autoimmune 
response to a transport protein e.g. IF (pernicious anaemia), result in malabsorption either 
from the bloodstream into cells or from the intestine into the enterocytes, respectively. 
Consequently cobalamin is depleted or absent from the bloodstream and deficiency occurs. 
There are also several mutations which obstruct the conversion of cobalamin into either one 
or both of the cofactor forms (Figure 1.5.1). Depletions in methionine synthase (MS) activity 
can cause homocystinuria, whilst reduced MCM activity can cause methylmalonic aciduria. 
Disruptions in MS and MCM can result in both disorders (Froese and Gravel 2010). 






Many parasites, such as Diphyllobothrium latum, a fish tapeworm, starve the host of 
cobalamin by absorbing it directly frRPWKHKRVWV¶JXWH. pylori, is a gram-negative spiral 
bacterium, which infiltrates the interface of the gastric epithelial cells and mucosa resulting in 
gastritis and gastric atrophy (Allen 2008). This reduces IF production causing cobalamin 
malabsorption from the gut into the blood, leading to deficiency (Allen 2008).  
The levels of cobalamin, particularly methylcobalamin decrease with age, especially 
in the frontal cortex, and are depleted in autistic and schizophrenic patients as well (Zhang et 
al. 2016). Cobalamin deficiency has also been implicated in increasing the risk of cognitive 
Figure 1.5.1: Eight defects in intracellular processing of cobalamin in humans. The 
complementation groups, shown in blue, are positioned at sites of metabolic blocks (red). Cobalamin 
intermediates are also in red. Cbl-5GHQRWHVDFREDODPLQZLWKDQXQGHILQHGJURXSDWWKHȕSRVLWLRQRQWKH
cobalt ion, whilst Me and Ado refer to methyl and adenosyl, respectively. Three complementation 
groups, cblF, cblC and cblD, correspond to blocks in steps that are common to the synthesis of both 
cofactors with resulting deficiency of MS and MCM activities. Patients from these groups have combined 
homocystinuria and methylmalonic aciduria. Three groups, cblD variant 1, cblE and cblG, have blocks in 
the cytosolic pathway leading to methyl-cobalamin (MeCbl) synthesis or apo-MS, and result in deficient 
MS activity and homocystinuria. The final groups, cblD variant 2, cblA, cblB and mut, affect steps 
occurring in the mitochondrion leading to adenosyl-cobalamin (AdoCbl) synthesis or apo-MCM and 
result in deficient MCM activity and methylmalonic aciduria (Froese and Gravel 2010). This figure was 
reproduced with permission from Froese and Gravel 2010. 





LPSDLUPHQWGLVRUGHUVVXFKDV$O]KHLPHU¶VRUGHPHQWLD(Spence 2016). There are also 
suggestions that cobalamin deficiency due to diet increases the likelihood of M. tuberculosis 
infection (Chanarin and Stephenson 1988; Bakhshi et al. 2010). Conversely, M. tuberculosis 
infection has been cited to cause pernicious anaemia and a paper published in the early 1930s 
proposes antagonism between the two (Ramagopalan et al. 2013; Barron 1933). It has been 
reported that the expression of the adenosylcobalamin requiring ribonucleotide reductase 
(type II) is upregulated in M. tuberculosis during latent infection (see Section 1.7) (Gopinath, 
Moosa, et al. 2013; Boshoff and Barry 2005). Therefore, M. tuberculosis may have a high 
demand for cobalamin during disease progression.  
There is also evidence to suggest patients suffering from pernicious anaemia and 
chronic myeloid leukaemia (CML) exhibit retarded CML progression. Providing such patients 
with cobalamin hastened CML progression whilst withholding cobalamin treatment improved 
their condition (Corcino et al. 1971; Mclean et al. 1997). Patients with breast cancer have 
been reported to become cobalamin deficient, and cancer cells were shown to exhibit an 
unusually high requirement for cobalamin in order to support DNA synthesis prior to cell 
division (Lee and Grissom 2009; Hogenkamp et al. 1999). In addition, some cancer cells 
(human colorectal adenocarcinoma, for example) have a decreased proliferation rate when 
deprived of cobalamin (Lai et al. 2011). 
1.6 Cobalamin in therapeutics 
Since the initial identification of cobalamin as an essential molecule, the biosynthesis 
and chemical synthesis of cobalamin has been researched extensively resulting in the 
elucidation of the two biosynthesis pathways (Moore and Warren 2012; Raux et al. 2000; 
Eschenmoser 1988; Heldt et al. 2005; Raux et al. 1996). This has spawned a variety of 
cobalamin related research including the assembly of different cobalamins (Hazra et al. 2013), 
the structure of cobalamin used by different organisms (Helliwell et al. 2016; Greibe, Fedosov, 
and Nexo 2012; Greibe, Fedosov, Sorensen, et al. 2012), the chemistry of cobalamin 
'HUHYHQ¶NRYHWDO:LGQHUHWDO6KHOODQG/DZUHQFH, and the relationship 
between cobalamin and disease (Zhang et al. 2016; Young et al. 2015). Through these more 
specific research areas, the window to the world of cobalamin modification and potential 
therapeutics has opened (Shell and Lawrence 2015; Brown 2005; Clardy et al. 2011). 
Cobalamin is an ideal molecule for therapeutics. It is water soluble, has no known 
toxicity, has known links to many diseases, is indispensable to most organisms, and therefore, 





it is unlikely that mutational arrest of cobalamin uptake will occur (Waibel et al. 2008). The 
idea of using cobalamin as a therapeutic is not new. Radioactive 57Co-cobalamin was shown 
to accumulate in transplanted mice tumours nearly 50 years ago (Flodh and Ullberg 1968). In 
the 1980s, an anilide of cobalamin was shown to successfully treat acute myelogenous 
leukaemia, albeit in one patient (Herbert 1983). The anilide analogues were produced by 
chemical hydrolysis of the amide groups on the sidechains of cobalamin, to form acids, 
followed by esterification with a aniline, C6H5NH2, an amino group attached to a phenyl 
group (E. L. Smith et al. 1955; Anton et al. 1980; Robinson 1966). Since then research into 
the production of cobalamin analogues as therapeutics increased dramatically. Chemical 
modifications of cobalamin were used to determine the possible points of conjugation, or 
substitution, and how these affected the binding to TCII and other cobalamin transport 
proteins (Figure 1.6.1) (Pathare et al. 1996). When these analogues were tested in binding 
assays, the results showed that modifications to the cobalt ion, 5-O-ribose moiety, and the e 
sidechain did not significantly decrease binding to TCII. The b sidechain conjugates 
decreased binding to an intermediate degree, whereas alterations to the c and d sidechains of 
ring B dramatically decreased binding (Pathare et al. 1996). Further research conducted by the 
same group revealed that conjugates on the e sidechain may be taken into the murine 
lymphoma BW5147 cells but do not support proliferation (Mclean et al. 1997). Previous 
reports have shown that e analogues cause reduction in MCM and MS activities, and increase 
methylmalonic acid and homocysteine levels, which suggest that cobalamin metabolism 
would be a good target for anti-proliferative drugs, and cobalamin analogues could be used to 

























One Swiss study used a radioactive technetium (99mTc) in an organometallic tracer 
conjugated to the b sidechain to target tumours in murine models (Waibel et al. 2008). Earlier 
attempts at such experiments used 57Co or 111In to label tumours but, although successful, 
these also resulted in high accumulation of radioactivity in normal tissue (Flodh and Ullberg 
1968). However, in the Swiss study they used the discovery that tumours expressed high 
levels of cytoplasmic and membrane bound HC to synthesise analogues which did not bind 
TCII but did bind HC (Kim et al. 1993). TCII is usually the protein which facilitates cellular 
internalisation of cobalamin, but using this TCII non-binding analogue they found it targeted 
to tumours, with very little non-specific accumulation (Waibel et al. 2008). These analogues 
were used in a clinical trial to locate tumours in cancer patients which showed that tumour 
visualisation is possible, although the sensitivity is low and non-specific accumulation occurs 
(Sah et al. 2014). 
A different study attempted to use fluorophores conjugated to the 5-O-ribose moiety 
on the lower loop to identify rapidly dividing cancer cells, with a view to aiding surgeons to 
discern cancerous tissue from healthy tissue (Lee and Grissom 2009). Stable cobalamin 
 
Figure 1.6.1: Possible sites of conjugation or substitution on cobalamin. This schematic 
was derived from Pathare et al. 1996. It is important to note that there are no sites shown 
which modify the corrin macrocycle directly.  





conjugates were produced, however, binding kinetics were not tested for the human 
cobalamin transport proteins. Previous studies have attached a fluoURSKRUHWRWKHȕOLJDQGRI
cobalt before but these analogues suffer from photochemical instability due to the low 
dissociation energy of the Co-C bond, which falls within the range of visible photons 
(Smeltzer et al. 2001; Martin and Finke 1992). 
A recent study DOVRXVHGWKHȕOLJDQGRIFREDOWEXWWKLVWLPHWRFRQMXJDWHGGUXJVXVLQJ
a light labile bond to trigger the release of the drug to target tumour cells (Shell and Lawrence 
2015)/LSLGDWHGIOXRURSKRUHDQWHQQDHZHUHSDLUHGZLWKȕOLJDQGGUXJFRQMXJDWHGFREDODPLQV
and loaded onto erythrocytes, which were subsequently incubated with target adherent HeLa 
cell lines. These were illuminated at the appropriate wavelength causing the drug to be 
released and migrate into the HeLa cells (W. J. Smith et al. 2014). This has only been shown 
in culture and, as with all photo-dynamic treatments, it is limited by the distance of light 
penetration. A summary of all the various cobalamin analogues that have been made is given 
in Table 1.6.2. 
Table 1.6.2: Summary of all the previously synthesised cobalamin analogues described in the 
text 
Position of 
modification Modification Date Authors 
Cobalt ion 
Replaced with 57Co, 58Co or 60Co 1968 Flodh, H and Ullberg, S.  
Unspecified 
sidechain Aniline (C6H5NH2) 1956, 1980 
Smith, EL et al , 
Herbert, V  
e sidechain 
Exchange NH2 for N(CH3)2 1991 Stabler, S et al  
e sidechain 
Exchange NH2 for OH in cobinamide 1993 Kolhouse, J et al  
¶-O-ribose Exchange H for 
CO(CH2)2CONH(CH2)12NH2 1996 
Pathare, PM et 
al  
¶-O-ribose 
Exchange H for COCH2CH2COOH 1996 
Pathare, PM et 
al  






modification Modification Date Authors 
&REDOWȕ
ligand CH2CH2CH2NHCO(CH2)5NH-Biotin 1996 Pathare, PM et al  
&REDOWȕ
ligand CH2CH2CH2NH2 1996 
Pathare, PM et 
al  
b sidechain 
Exchange NH2 for OH 1996 
Pathare, PM et 
al  
b sidechain 
Exchange NH2 for NH(CH2)12NH2 1996 Pathare, PM et al  
b sidechain Exchange NH2 for NH(CH2)12NH-
Biotin 1996 
Pathare, PM et 
al  
c sidechain 
c lactone 1996 Pathare, PM et 
al  
c sidechain 
Exchange NH2 for NH(CH2)12NH2 1996 Pathare, PM et al  
c sidechain Exchange NH2 for NH(CH2)12NH-
Biotin 1996 
Pathare, PM et 
al  
d sidechain 
Exchange NH2 for OH 1996 
Pathare, PM et 
al  
d sidechain 
Exchange NH2 for NH(CH2)12NH2 1996 Pathare, PM et al  
d sidechain Exchange NH2 for NH(CH2)12NH-
Biotin 1996 
Pathare, PM et 
al  
e sidechain 
Exchange NH2 for OH 
1991, 
1996 
Stabler, S et al  
Pathare, PM et 
al  
e sidechain 
Exchange NH2 for NH(CH2)12NH2 1996 Pathare, PM et al  
e sidechain Exchange NH2 for NH(CH2)12NH-
Biotin 1996 
Pathare, PM et 
al  
b sidechain Exchange NH2 for NH(CH2)12NH-p-
Iodohippurate 1997 
McLean, GR et 
al  






modification Modification Date Authors 
d sidechain Exchange NH2 for NH(CH2)12NH-p-
Iodohippurate 1997 
McLean, GR et 
al  
e sidechain Exchange NH2 for NH(CH2)12NH-p-
Iodohippurate 1997 
McLean, GR et 
al  
b sidechain Dimeric cobalamin linked by exchange 
of NH2 for NH(CH2)12NH2 in both 
monomers and then linked via an 
isophthaloyl moiety 
1997 M
cLean, GR et 
al  
d sidechain 
Dimeric cobalamin linked by exchange 
of NH2 for NH(CH2)12NH2 in both 
monomers and then linked via an 
isophthaloyl moiety 
1997 M
cLean, GR et 
al  
e sidechain 
Dimeric cobalamin linked by exchange 
of NH2 for NH(CH2)12NH2 in both 
monomers and then linked via an 
isophthaloyl moiety 
1997 M
cLean, GR et 
al  
b sidechain 
Dimeric cobalamin linked by exchange 
of NH2 for NH(CH2)12NH2 in both 
monomers and then linked via an 
isophthaloyl moiety with p-
iodobenzoate 
1997 M
cLean, GR et 
al  
d sidechain 
Dimeric cobalamin linked by exchange 
of NH2 for NH(CH2)12NH2 in both 
monomers and then linked via an 
isophthaloyl moiety with p-
iodobenzoate 
1997 M
cLean, GR et 
al  
e sidechain 
Dimeric cobalamin linked by exchange 
of NH2 for NH(CH2)12NH2 in both 
monomers and then linked via an 
isophthaloyl moiety with p-
iodobenzoate 
1997 M




3-aminopropyl linked Oregon Green, 
fluorescein, and naphthofluorescein 2001 Smeltzer, C et al  
b sidechain Exchange H for [pyridine-2-ylmethyl-
amino]-acetic acid [99mTc(OH2)3(CO)3] 2008 Waibel, R et al  
¶-O-ribose Exchange H for trans-1,4-
Diaminocyclohexane with Rhodamine 
6G or fluorescein
 
2009 Lee, M and Grissom, C  






modification Modification Date Authors 
&REDOWȕ
ligand 
C18 linked methotrexate, colchicine, 
dexamethasone, 
Tetramethylrhodamine, or fluorescein 
2014 Smith, W et al  
&REDOWȕ
ligand 
CH2CH2CH2COHN linked SulphoCy5, 
AlexaFluor700, Atto725, or DyLight800 2015 
Shell, T and 
Lawrence, D  
 
1.6.1 The need for new cobalamin analogues 
All of the potential cobalamin therapeutics listed in Table 1.6.2 have limitations. The 
sidechain e analogues are not specific to certain cell types and rely upon competition against 
intrinsic cobalamin to instigate a decrease in cell proliferation. The fluorophore conjugates 
hoping to target rapidly dividing cells have yet to be tested and are likely to photobleach 
during the proposed surgery. The most useful development is the observation that radioactive 
cobalamin analogues with no TCII recognition, accumulate in tumour cells by exploiting the 
potential HC uptake route, thereby increasing specificity to the tumours. However, in clinical 
trials it was shown to have low sensitivity and non-specific accumulation. 
Cobalamin analogues have great potential for therapeutic use not only in tumour 
identification but also in drug delivery. It is important to retain recognition by human 
transport proteins for targetting non-tumour highly proliferative cells, but the 99mTc studies 
show that only HC recognition is required for tumour targetting (Waibel et al. 2008). This is 
potentially exploitable as HC recognises cobalamin intermediates prior to complete lower 
loop assembly, whilst TCII requires the full DMB lower loop to be present (Nielsen et al. 
2012). Therefore, providing this uptake mechanism is legitimate, earlier intermediate 
analogues should be specifically internalised by tumour cells. Bacteria often have the end of 
the cobalamin biosynthesis pathway so they can complete coenzyme synthesis from earlier 
cobalamin intermediates. Humans do not have this ability to complete the synthesis of partial 
corrinoids, which suggests that earlier intermediate analogues can also be used to target 
bacterial infections, particularly those that cause cobalamin deficiency. 
An earlier cobalamin intermediate analogue cannot be modified on the lower loop as 
the loop is incomplete or not present. Sidechain modifications have mixed recognition, whilst 
FREDOWȕOLJDQGDQDORJXHVDUHOLJKWVHQVLWLYHDQGWKHFRQMXJDWHFRXOGEHH[FKDQJHGin vivo by 





the native enzymes for a methyl or adenosyl group. Ideally the conjugation should be directly 
on the corrin ring to limit the impediment of recognition. A ring modified corrin analogue 
could have a drug, a fluorophore or a radioactive moiety conjugated, but will not have any of 
the issues of light labile bonds or reduced recognition due to sidechain modifications. 
Macrocycle altered analogues could pave the way to a new generation of cobalamin 
therapeutics. 
1.7 The enigma of cobalamin and Mycobacterium tuberculosis 
M. tuberculosis is an obligate human pathogen. The World Health Organisation 
(WHO) cites tuberculosis (TB) as a major global health problem, alongside the Human 
Immunodeficiency Virus (HIV). TB is in fact the main cause of death in HIV positive patients. 
It is predicted that a third of the human population is latently infected with M. tuberculosis 
which accounts for the maintenance of TB in the human population despite a cocktail of drug 




in two stages of non-replicating persistence (NRP) (Boshoff and Barry 2005): NRP1, 
recognised by cessation of cell division with oxygen levels of 1 % saturation, and NRP2, 
which is a more comprehensive arrest of metabolism at oxygen levels of 0.06 % saturation 
(Boshoff and Barry 2005). M. tuberculosis is able to persist at 0.06 % oxygen without 
supplementation of external terminal electron acceptors, suggesting that an energised 
membrane is maintained without respiration; however, it is not known how this is achieved.  
M. tuberculosis has three cobalamin-dependent enzymes; MCM, MetH  and a 
ribonucleotide reductase (RNR), encoded by nrdZ (Gopinath, Venclovas, et al. 2013; 
Gopinath, Moosa, et al. 2013; Warner et al. 2007). None of the three cobalamin-dependent 
enzymes in M. tuberculosis appear to be essential (Gopinath, Moosa, et al. 2013). RNRs 
reduce ribonucleotide diphosphates (rNDPs) into deoxyribonucleoside diphosphates (dNDPs), 
which are then used to make deoxyribonucleoside triphosphates (dNTPs) and can be used in 
DNA synthesis, hence they are essential during cell replication (Gopinath, Moosa, et al. 2013; 
Dawes et al. 2003). There are broadly three classes of RNRs, I to III, and they each depend on 
different metal coenzymes; class I contain diiron-oxygen cluster, class II use adenosyl-
cobalamin, and class III have a 4Fe-4S iron-sulphur cluster and require SAM (Kolberg et al. 





2004). M. tuberculosis has both class I, which are oxygen dependent, and class II RNRs. The 
nrdZ gene is predicted to be a class II ribonucletide reductase and is completely oxygen 
independent (Dawes et al. 2003). In contrast to class I RNRs, the class II enzymes only have 
one subunit, as the cleavage of the (Co-C)-bond adenosyl-cobalamin generates the thiol 
radical instead of the second protein subunit present in class I RNRs (Kolberg et al. 2004; 
Gruber et al. 2011). In M. tuberculosis it is the nrdEF2 class I ribonucleotide reductase which 
is essential for growth, and the nrdZ is only induced in the dormancy response (Gopinath, 
Moosa, et al. 2013). It can be concluded that nrdZ requirement increases in low oxygen 
environments in the presence of adenosyl-cobalamin. It is here that M. tuberculosis has been 
postulated to become cobalamin-dependent during infection, due to the limited oxygen 
causing the other RNRs to be compromised (Gopinath, Moosa, et al. 2013). This makes the 
exit from dormancy a potential access point for a cobalamin linked therapeutic. 
The M. tuberculosis methionine synthases, MetE and MetH, both use 5-
methylterahydrofolate (N5-MeTHF) as the methyl donor when converting L-homocysteine 
into L-methionine (Figure 1.3.1). Unlike MetE, MetH requires methylcobalamin to function, 
and although the catalytic turnovers have not been calculated in M. tuberculosis, they are 
likely to show a similar benefit to cobalamin dependency as in E. coli (Gonzalez et al. 1992). 
MCM has no specific cobalamin independent enzyme to compensate its function in 
cobalamin deficient circumstances, although there is an alternative pathway (Figure 1.7.1). 
MCM is responsible for converting methylmalonyl-CoA to succinyl-CoA with an adenosyl-
cobalamin coenzyme in the final step of the methylmalonyl pathway. This pathway is one of 
the ways in which M. tuberculosis can remove propionate from the cell. Propionate 
accumulates as the three carbon terminal product of odd and branched chained fatty acids, 
branched amino acids and cholesterol catabolism.  Although propionate is a key precursor in 
lipid biosynthesis, it is toxic if accumulated. The methylcitrate cycle and the glyoxylate cycle 
can also stop propionate from accumulating. Interestingly, in M. tuberculosis  methylcitrate 
lyase (MCL) is not present and instead isocitrate lyase (ICL) from the glyoxylate cycle 
compensates for this methylcitrate cycle enzyme (underlined in red in Figure 1.7.1) (Savvi et 
al. 2008). This means that if ICL is compromised M. tuberculosis will become reliant on the 
methylmalonyl pathway and therefore cobalamin-dependent. Although the existence of these 
cobalamin-dependent enzymes is acknowledged, very little is understood about their 
regulation or their influence on viability and pathogenicity of M. tuberculosis (Warner et al. 
2007). 





 The genome of M. tuberculosis has been sequenced (Cole et al. 1998). It reveals that 
M. tuberculosis has all of the genes for the cobalamin biosynthesis pathway except for cobF, 
encoding the C1 deacetylase and methyltransferase, which has led to speculation about 
whether it can produce cobalamin de novo (Savvi et al. 2008). Curiously, Mycobacterium 
smegmatis, which is not a human pathogen but a soil bacterium, has all of the biosynthetic 
Figure 1.7.1: Predicted routes of propionate metabolism in M. tuberculosis. The ICL (isocitrate lyase) 
is underlined in red to highlight the reliance of both the methyl citrate and the glyoxylate pathways on 
this enzyme due to the loss of MCL (Methylcitrate lyase) in M. tuberculosis. Should ICL be knocked out 
M. tuberculosis propionate metabolism would become adenosyl-cobalmain (Ado-B12) dependent due to 
the reliance of MCM (boxed in orange) on this coenzyme. ACN: Aconitase, CIT: citrate synthase, FUM: 
Fumerase, ICD: Isocitrate dehydrogenase, MCD: Methylcitrate dehydratase, MCS: Methylcitrate 
synthase, MDH/MQO: Malate dehydrogenase/ Malate: quinine oxidoreductase, MEZ: Malic enzyme, 
MLS: Malate synthase, MMCE: Methylmalonyl-CoA epimerase, PCA: Pyruvate casrboxylase, PCC: 
Propionyl-CoA carboxylase, PCK: Pyruvate carboxykinase, PDHC: pyruvate dehydrogenase, PYK: 
Pyruvate kinase, SCS: Succinate synthase, SDH: Succinate dehydrogenase. This figure was reproduced 





genes, and does synthesise cobalamin whereas Mycobacterium leprae has only the 
biosynthesis genes to convert cobinamide into cobalamin (Cole et al. 2001; Szumowski et al. 
2013; Dawes et al. 2003). Both these organisms have homologues of MetH and MCM (Savvi 
et al. 2008; Young et al. 2015). M. leprae has undergone a severe genome reduction so it is 
not surprising that it has lost most of the biosynthetic genes, but by keeping the genes to allow 
the salvage of incomplete corrinoids, M. leprae is able to adapt to environmental conditions 
and to satisfy its cobalamin-dependent enzymes (Savvi et al. 2008).  
M. tuberculosis has never been shown to synthesise cobalamin de novo, although it 
could scavenge exogenous corrinoids, and it has known cobalamin-dependent enzymes that 
are not essential. It is therefore unknown to what extent cobalamin is needed in the lifecycle 
of M. tuberculosis.  
1.8 Cobalamin and Caenorhabditis elegans 
 C. elegans is a soil dwelling nematode worm which feeds on microbes, particularly on 
bacteria. They are an ideal model for humans in many research areas including, genomics, cell 
biology, neuroscience and aging, and have been shown to exhibit similar cobalamin 
deficiency phenotypes as humans (Altun and Hall 2009b; Froese and Gravel 2010; Bito et al. 
2013). C. elegans has both MetH and MCM, but very little is known about the cobalamin 
transport system (Bito et al. 2013). Like all non-monera, C. elegans must obtain cobalamin 
from its diet; therefore, it must have a transport protein from the gut to the pseudocoelom, 
however, one has not been identified. A study has been conducted showing that ribose linked 
dodecylamine derivatives of cobalamin inhibit nematode MCM and MetH, inducing a 
deficiency phenotype (Bito et al. 2014). These analogues have the same effect on mammalian 
cell lines but have not been tested in vivo in mammals (Bito et al. 2014). 
 C. elegans are predominantly hermaphrodites, although males do also occur (Altun 
and Hall 2009b). They have very simple bodies and a complete cell lineage has been 
established (Brenner 1974; Sulston et al. 1983). They are small (adults are around 1130 µm 
long), can easily be grown under lab conditions with a lifecycle of about 3 days at 20°C and 
are transparent throughout their lifecycle (Altun and Hall 2009b).  
 
 





1.9 Cobalamin, Lepidium sativum and Arabidopsis thaliana 
 A. thaliana is the most commonly used model organism for plants owing to its small 
stature and short lifecycle. Additionally, the whole genome of A. thaliana has been sequenced 
(Boyes et al. 2001). L. sativum, garden cress, is an easily obtainable plant which can be grown 
alongside A. thaliana to provide a comparison. Although no plants require or synthesise 
cobalamin, some have been shown to take it up, which offers a counterpoint to the organisms 
described above (Watanabe et al. 2013; Helliwell et al. 2011). 
1.10 The basis and aims of the investigations presented in this thesis 
Work into cobalamin analogue synthesis is not a new area of research. Initial usage 
was intended to be as a tumour detection mechanism, as studies dating back over 40 years 
have shown high accumulation of 57Co cobalamin in tumours (Waibel et al. 2008). From this 
start point the applications have diversified into proliferation inhibition (Mclean et al. 1997), 
tumour specific localisation (Waibel et al. 2008), and now specific drug/ cargo transport 
(Clardy et al. 2011). It is known that many forms of cancer cells, particularly solid malignant 
tumours, increase their requirement of cobalamin and, recently, M. tuberculosis infected cells 
have been implicated for the same reason (Waibel et al. 2008; Brown 2005; Gopinath, Moosa, 
et al. 2013). Most of the previously synthesised analogues target these compromised cells. 
However, these analogues revolve around modifications to the cobalt ion ligands, the 
peripheral sidechains, or to the nucleotide loop, all of which have various shortcomings 
(Section 1.6). This by no means implies that cobalamin analogues are limited in usage, in fact 
they have already been successfully applied in treatment (Herbert 1983; Corcino et al. 1971), 
but rather that the site of modification should ideally be directly on the corrin macrocycle. 
This will increase specificity and stability of modification without compromising recognition.  
The objectives of the investigations detailed forthwith are: 
1) To synthesise a corrin modified analogue of cobalamin. 
2) To attach a fluorophore or drug at this position  
3) To analyse the efficacy of these analogues in different organisms 
4) To identify corrinoid specificity and localisation in M. tuberculosis and C. elegans.  





There is much still unknown about cobalamin uptake, localisation and utilisation, but 
by designing fluorescent analogues that can be followed in vivo, the  journey and fate of 
cobalamin within these organisms can be studied in greater detail than formerly possible. A 
potential outcome of this research could be a corrin conjugated drug transportation 
mechanism which uses the cobalamin uptake pathway to enter the cell whereupon the drug 
takes effect in a Trojan horse-like subterfuge.  
  









Materials and Methods 
  






2.1 Materials  
2.1.1 Chemicals and equipment 
 Most of the chemicals were bought from Sigma Aldrich, Ltd. or Thermo Fisher 
6FLHQWLILF,QF7KRVHWKDWZHUHQRWDUHDVIROORZV,VRSURS\Oȕ-D-1-thiogalactopyranoside 
(IPTG) and ampicillin from Melford Laboratories, Ltd., VA044 from Wako Pure Chemical 
Industries, Ltd., chelating sepharose, buffer exchange and empty PD-10 columns from GE 
Healthcare Lifesciences, Amicon® 5 kDa centrifuge protein concentrators and LiChroprep® 
RP-18 from Merck Millipore, Merck KGaA, QIAprep® Spin Miniprep Kit, QIAquick® Gel 
Extraction Kit from QIAGEN GmbH, restriction enzymes from Promega, cloning strains 
from Novagen, tryptone, yeast extract and bacterial agar from Oxoid, Ltd., Middlebrook 7H9 
media and Bovine serum albumin from Becton, Dickinson and Company, Roche FastStart 
High Fidelity PCR system from Roche Diagnostics GmbH, 4-20 % Mini-PROTEAN® 
7*;SUHFDVWSRO\DFU\ODPLGHJHOV86$DQG%UDGIRUGUHDJHQWIURP%LR-Rad Laboratories, 
Inc., 4-20 % Novex TBE polyacrylamide gels (UK) were also purchased from Thermos Fisher 
Scientific, Inc., ATTO 1D dual mini slab gel tank from ATTO corporation, Ace 5 AQ column 
(2.1 x 150 mm) 5 µm particle size, 100 Å, from Advanced Chromatography Technologies 
Ltd.. 
2.1.2 Bacterial strains and plasmids 
 The bacterial strains were purchased from Novagen, Invitrogen or Promega. All the 
Mycobacterium tuberculosis strains were provided by H. Boshoff and C. Barry III, National 
Institutes of Health, MD, USA and originally sourced from . Plasmids which were previously 
constructed are listed alongside the name of the researcher who assembled them. 
2.1.2.1 Bacterial strains 
Table 2.1.2.1.1 Bacterial strains used 
Strains Genotype/ Phenotype Description Origin 
Escherichia coli 
JM109 
endA1 recA1 gyrA96, 











Strains Genotype/ Phenotype Description Origin 
BL21(DE3) pLysS 
F- ompT hsdSB (rB-, 
mB





 ompT hsdSB (rB-, 
mB
-) gal dcm (DE3)  Novagen 
Rosetta (DE3) 
F- ompT hsdSB(rB-, 
mB




Uracil auxotroph  mutant of 
E. coli B (Berkeley) (May 
et al. 2009) 
Dr J. Tullet 
OP50 BtuBF  
OP50 transformed with 
pET-BAD-btuBF, 
arabinose promoter 
Dr E. Deery 





hemBCD,sirC, cbiXS, cbiL. 




barkeri, and hemCD from 
Bacillus megaterium. 
Dr S. Frank 
with cbiXSL 
added by Dr S. 
Moore 
Bacillus megaterium 
B. meg CbiHHis 
Bacillus megaterium 
DSM509 (Moore and 
Warren 2012) 
B. megaterium DSM509 
transformed with PxylA-
CbiHHis. CbiH from B. 
megaterium. 
Dr S. Moore 
B. meg CbiFHis 
Bacillus megaterium 
DSM509 (Moore and 
Warren 2012) 
B. megaterium DSM509 
transformed with PxylA-
cbiFHis. cbiF from B. 
megaterium. 
Dr S. Moore 
B. meg CbiDHis 
Bacillus megaterium 
DSM509 (Moore and 
Warren 2012) 
B. megaterium DSM509 
transformed with PxylA-
cbiDHis. cbiD from B. 
megaterium. 
Dr S. Moore 
B. meg CbiGHis 
Bacillus megaterium 
DSM509 (Moore and 
Warren 2012) 
B. megaterium DSM509 
transformed with PxylA-
cbiGHis. cbiG from B. 
megaterium. 
Dr S. Moore 
B. meg CbiJHis 
Bacillus megaterium 
DSM509 (Moore and 
Warren 2012) 
B. megaterium DSM509 
transformed with PxylA-
cbiJHis. cbiJ from B. 
megaterium. 
Dr S. Moore 
Mycobacterium tuberculosis 






Strains Genotype/ Phenotype Description Origin 
WT H37Rv ATCC® 27294 Clinical isolate from 1934. Dr H. Boshoff 




deletion (Warner et al. 
2007). 




deletion (Warner et al. 
2007). 
 Dr H. Boshoff 
ǻPHW+ 
H37RvJO with ǻPHW+
deletion (Warner et al. 
2007). 
 Dr H. Boshoff 
 
2.1.2.2 Plasmids 
Table 2.1.2.2.1 Plasmids used 
Name Description Origin 
pET14b Over-expression N-terminal His-tag fusion protein 
vector with T7 promoter, AmpR. Novagen 
pET3a Over-expression vector with T7 promoter, AmpR. Novagen 
pLysS Vector with basal T7 lysozyme expression in Ȝ'(O\VRJHQLFKRVWWRVXSSUHVVWKH7SURPRWHU Novagen 
pETcoco-2 
A low copy plasmid maintained in a single copy 
state which can be switched to a medium copy 





Low copy plasmid with cobA, hemBCD,sirC, 
cbiXS, cbiL. hemB, sirC and cbiXSL from 
Methanothermus thermoautotrophicus, cobA from 
Methanosarcina barkeri, and hemCD from 
Bacillus megaterium. 
Dr S. Moore 
pET14b-cbiE 
PCR product of the cbiE gene from 
Methanothermus thermoautotrophicus inserted 
NdeI and SpeI into pET14b. 
Dr S. Moore 
pET14b-cbiT 
PCR product of the cbiT gene from 
Methanothermus thermoautotrophicus inserted 
NdeI and SpeI into pET14b. 
Dr S. Moore 
pET14b-cbiC 
PCR product of the cbiC gene from Salmonella 
enterica serovar typhimurium inserted NdeI and 
SpeI into pET14b. 
Dr S. Moore 
pET3a-
cobAIGJFMKLCEHis 
PCR product of Rhodobacter capsulatus SB1003 
for cobA, I, J, F, M, K, L and H, Brucella 
melitensis 16M for cobE, and Pseudomonas 
denitrificans for cobG inserted AseI or NdeI at the 
¶DQGSpe,DWWKH¶LQWRS(7D 
Dr E. Deery 






Name Description Origin 
pET14b-cobL 
PCR product of Rhodobacter capsulatus SB1003 
for cobL inserted Nde,DWWKH¶DQGSpe,DWWKH¶
into pET14b. 
Dr E. Deery 
pET14b-cobH 
PCR product of Rhodobacter capsulatus SB1003 
for cobH inserted Nde,DWWKH¶DQGSpe,DWWKH¶
into pET14b. 
Dr E. Deery 
pET14b-cobB 
PCR product of Rhodobacter capsulatus SB1003 
for cobB inserted Nde,DWWKH¶DQGSpe,DWWKH¶
into pET14b. 
Dr E. Deery 
pET14b-cobQ 
PCR product of Allochromatium vinosum DSM 
180 for cobQ (Alvin_2223) inserted Nde,DWWKH¶
and Spe,DWWKH¶LQWRS(7E 
This study 
pET14b-btuF PCR product of Escherichia coli for btuF inserted Nde,DWWKH¶DQGSpe,DWWKH¶LQWRS(7E Dr E. Deery 
pLysS-btuB PCR product of Escherichia coli for btuB inserted Nde,DWWKH¶DQd Spe,DWWKH¶LQWRS/\V6 Dr E. Deery 
pET14b-cobH(T85A) 
PCR product of Rhodobacter capsulatus SB1003 
for cobH with T85A mutant introduced, inserted 
Nde,DWWKH¶DQGSpe,DWWKH¶LQWRS(7E 
Dr. A Lawrence 
 
2.1.2.3 PCR of cobQ from Allochromatium vinosum 
Primers, obtained from Invitrogen Life Technologies by Mr J. Baker: 
Forward: CTACATATGACCGATTCAGCCCCCAC 
Reverse: CATACTAGTTCAGCGTGCCAGTTCGAG 
The restriction sites are underlined: NdeI in the forward primer, and SpeI in the reverse primer. 
2.1.3 Media and solutions for bacterial work 
Luria-Bertani (LB) broth: Tryptone 10 g 
    Yeast Extract 5 g 
    NaCl  5 g 
This was made up to 1 litre with distilled H2O and autoclaved. 
2YT broth:   Tryptone 16 g 
    Yeast Extract 10 g 






    NaCl  5 g 
This was made up to 1 litre with distilled H2O and autoclaved. 
Super optimal broth with catabolite repression (SOC) medium: 
    Tryptone 2 g 
    Yeast Extract 0.5 g 
    NaCl  10 mM (Final concentration) 
    KCl  2.5 mM (Final concentration) 
This was made up to 97.2 mL and autoclaved, and then the following were added: 
    Mg2+  20 mM (Final concentration)* 
    Glucose 0.36 % (Final concentration) 
*Mg2+ was made up of 2 g MgCl2˹6H2O and 2.5 g MgSO4˹7H2O made up to 10 mL with 
dH2O and filter sterilised. 
The two latter additions were filter sterilised before addition to the autoclaved solution. 
 
LB agar:   Bacterial agar 15 g 
This was added to 1 L LB broth, shown above. 
Fermenter medium:  YE  40 g 
    10x M9 salts 400 mL 
    Glucose 8 g 
    Glycerol 160 g 
    1M MgSO4 8 mL 
    0.1M CaCl2 4 mL  
This was made up to 4 L with distilled H2O. 






10x M9 salts   Na2HPO4 60 g 
    KH2PO4 30 g 
    NH4Cl  10 g 
    NaCl  5 g 
This was made up to a litre with distilled H2O and then autoclaved. 
7H9-ADC media  Middlebrook 7H9 9.4 g 
    Glycerol  0.2 % 
    Tween 80  0.05 % 
This was made up to 1800 mL with distilled H2O and filter sterilised. 
ADC   Bovine serum albumin 50 g 
    Glucose  20 g 
    NaCl   8.1 g 
This was made up to 1 L with distilled H2O and filter sterilised. 
The 1800 mL of 7H9 medium was made up to 2 L with 200 mL of the ADC and mixed 
thoroughly. The rest of the ADC was stored at 4 °C. 
 
6DXWRQ¶VPHGLD  KH2PO4  0.5 g 
    MgSO4˹7H2O  0.5 g 
    Citric acid  2.0 g 
   Ferric Ammonium Citrate 0.05 g 
    Glycerol  6 % 
    Asparagine  4 g 
    TWEEN80  0.05 % 






NaOH pellets were added until the medium was at pH 7. 
This was made up to 1 L with distilled H2O and filter sterilised. 
Calcium Chloride solution, 0.1 M: CaCl2˹H2O 2.94 g 
This was made up to 200 mL with distilled H2O. 
The calcium chloride solution with 15 % glycerol was made in the same way but with 30 mL 
of glycerol as well, and then made up to 200 mL with distilled H2O. 
,VRSURS\Oȕ-D-1-thiogalactopyranoside (IPTG), 1 M: 
    IPTG  2.383 g 
This was made up to 10 mL with distilled H2O and then filter sterilised. 
Arabinose, 2 % (w/v)  Arabinose 1 g 
This was made up to 50 mL with distilled H2O and filter sterilised. 
Xylose, 5 % (w/v)   Xylose  2.5 g 
This was made up to 50 mL with distilled H2O and then autoclaved. 
Glucose, 20 % (w/v)  Glucose 40 g 
This was made up to 200 mL with distilled H2O and then autoclaved. 
Ferric citrate, 1 M  Ferric citrate 2.5 g 
This was made up to 10 mL with distilled H2O, after slight heating to dissolve, and filter 
sterilised. 
Antibiotics: 
Table 2.1.3.1: The Antibiotics used for E. coli growth 
Antibiotics [Stock] [Working] 
Kanamycin 50 mg mL-1 in dH2O 30 µg mL-1 
Tetracycline 5 mg mL-1 in ethanol 10 µg mL-1 
Ampicillin 100 mg mL-1 in dH2O 100 µg mL-1 
Chloramphenicol 34 mg mL-1 in ethanol 34 µg mL-1 
Hygromycin B 50 mg mL-1  25 µg mL-1 
 






2.1.4 Media and solutions for DNA work 
TE Buffer  Tris-HCl, pH 8.0 10 mM 
   EDTA, pH 8.0  1 mM 
6x DNA Loading Buffer:  Bromophenol blue 0.25 % 
     Glycerol  50 % 
     TE Buffer  50 % 












2.1.5 Media and solutions for protein work 
2.1.5.1 Solutions for nickel ion affinity chromatography 
Charge buffer   NiSO4   100 mM 
High salt binding buffer Tris-HCl, pH 8.0 20 mM 
    NaCl   500 mM 
    Imidazole, pH 7.5 10 mM 
 
Figure 2.1.4.1: DNA 
Hyperladder. 5 µL of 
the Hyperladder I 
applied to 1 % (w/v) 
agarose gel. 






High salt wash buffer I: Tris-HCl, pH 8.0 20 mM 
    NaCl   500 mM 
    Imidazole, pH 7.5 50 mM 
High salt wash buffer II: Tris-HCl, pH 8.0 20 mM 
    NaCl   500 mM 
    Imidazole, pH 7.5 100 mM 
High salt elution buffer: Tris-HCl, pH 8.0 20 mM 
    NaCl   500 mM 
    Imidazole, pH 7.5 400 mM 
Low salt binding buffer Tris-HCl, pH 8.0 20 mM 
    NaCl   100 mM 
    Imidazole, pH 7.5 10 mM 
Low salt wash buffer I: Tris-HCl, pH 8.0 20 mM 
    NaCl   100 mM 
    Imidazole, pH 7.5 50 mM 
Low salt wash buffer II: Tris-HCl, pH 8.0 20 mM 
    NaCl   100 mM 
    Imidazole, pH 7.5 100 mM 
Low salt elution buffer: Tris-HCl, pH 8.0 20 mM 
    NaCl   100 mM 
    Imidazole, pH 7.5 400 mM 
Strip buffer:   Tris-HCl, pH 8.0 20 mM 
    NaCl   100 mM 






    EDTA, pH 8.0  100 mM 
2.1.5.2 Solutions for buffer exchange 
Exchange buffer:  Tris-HCl, pH 8.0 20 mM 
    NaCl   100 mM 
2.1.5.3 Solutions for cobalamin-agarose column chromatography 
Wash buffer I:   Tris-HCl, pH 8.0 20 mM 
Wash buffer II:  Tris-HCl, pH 8.0 20 mM 
    Cyanocobalamin 10 nM 
Wash buffer III:  Tris-HCl, pH 8.0 20 mM 
    Cyanocobalamin 100 nM 
Wash buffer IV:  Tris-HCl, pH 8.0 20 mM 
    Cyanocobalamin 1 µM 
Elution buffer:  Tris-HCl, pH 8.0 20 mM 
    Urea   8 M 
2.1.6 Media and solutions for cobalamin intermediate purification work 
2.1.6.1 Solutions for DEAE-Sephacel® column chromatography 
Wash buffer I:   Tris-HCl, pH 8.0 20 mM 
Wash buffer II:  Tris-HCl, pH 8.0 20 mM 
    NaCl   100 mM 
Wash buffer III:  Tris-HCl, pH 8.0 20 mM 
    NaCl   200 mM 
Elution buffer:  Tris-HCl, pH 8.0 20 mM 
    NaCl   600 mM 






2.1.6.2 Solutions for RP-18 column chromatography 
Wash buffer I:   Trifluoroacetic acid 0.1 % (v/v) 
Wash buffer II:  Methanol  5 %   
Wash buffer III:  Methanol  15 %     
Wash buffer IV:  Methanol  25 % 
Wash buffer V:  Methanol  50 % 
Wash buffer VI:  Methanol  100 % 
2.1.7 Solutions for protein acrylamide gel and MALDI 
2.1.7.1 Sodium dodecyl sulphate (SDS) gel 
2x sample buffer  500mM Tris-HCl, pH 6.8 2.5 mL 
    Glycerol   2 mL 
    10 % (w/v) SDS  4 mL 
    ȕ-mecaptoethanol  1 mL 
    Bromophenol blue  Two tips 
10x Running buffer  Tris-HCl   30 g L-1 
    Glycine   144 g L-1 
 
Coomassie blue stain  Trichloroacetic acid (100 %) 250 mL 
    Coomassie blue R250  0.6 g 
    SDS    0.1 g 
    Tris-HCl   0.25 g 
    Glycine   0.15 g 
This was made up to 500 mL with double distilled H2O. 



















Figure 2.1.7.1.2: Low 
range protein 
marker. 7 µL of the 
molecular mass marker 








Broad range protein 
marker. 7 µL of the 
molecular mass marker 
was applied to the SDS 
gel. 






2.1.7.2 SDS gel compositions 
Table 2.1.7.2.1: SDS gel compositions 
SDS gels 
Running gels 8 % 10 % 12.5 % 15 % Stacking gel 5 % 
dH2O (mL) 5.7 4.7 3.4 2.2 dH2O (mL) 3.4 
30 % Acrylamide 
(mL) 4 5 6.3 7.5 30 % Acrylamide (mL) 1.5 
1.5 M Tris-HCl, pH 
8.8 (mL) 3.8 3.8 3.8 3.8 
0.5M Tris-HCl, pH 6.8 
(mL) 1.9 
10 % SDS (mL) 1.5 1.5 1.5 1.5 10 % SDS (mL) 0.75 
10 % APS (mL) 0.15 0.15 0.15 0.15 10 % APS (mL) 0.075 
TEMED (mL) 0.01 0.01 0.01 0.01 TEMED (mL) 0.01 
 
2.1.7.3 MALDI solutions 
Gel stains 
5 % coomassie blue G-250 stock  
Coomassie blue G-250  0.5 g 
This was made up to 10 mL with double distilled H2O. 
Colloidal coomassie blue G-250 dye stock solution 
Ammonium sulphate   50 g 
Phosphoric acid 85 % (w/v)  6 mL 
5 % coomassie blue G-250 stock 10 mL 
This was made up to 500 mL with double distilled H2O. 
Colloidal coomassie blue G-250 dye working solution (prepared immediately before staining) 
Coomassie blue G-250 dye stock solution 40 mL 
Methanol    10 mL 
Gel fix   Acetic acid    10 % 
   Ethanol    40 % 
All made up in distilled H2O. 






Wash solution I: NH4HCO3: acetonitrile (1:1)  50 mM  
Wash solution II:  NH4HCO3    50 mM 
Swell solution I:  DTT      10 mM 
NH4HCO3    50 mM 
Swell solution II: NH4HCO3    50 mM 
Iodoacetimide    50 mM 
Digest solution: NH4HCO3    10 mM 
   Acetonitrile    10 % 
This digest solution was diluted 1 in 10 for the working solution. 
Trypsin solution Trypsin    20 µg 
This was all rehydrated in 200 µL of resuspension buffer. 
Extraction solutions Acetonitrile    50 % 
   Formic acid    5 % 
TA solution  0.1 % Trifluoroacetic acid 
100 % Acetonitrile 
These two were combined in a 2:1 ratio. 
Matrix solution 2,5-dihydroxybenzoic acid  1 mg 
This was diluted in 1 mL of TA solution. 
 
2.1.8 Solutions for gel filtration column (size exclusion) 
Buffer A, Sample buffer: Tris-HCl, pH 8.0  20 mM 
    NaCl    100 mM 







2.1.9 Solutions for HPLC-MS 
Elutant A:   Trifluoroacetic acid  0.1 % 
This was diluted in double distilled H2O and filtered. 
Elutant B:   Methanol   50 % 
This was diluted in double distilled H2O and filtered. 
2.1.10 Solutions for NMR 
Solution for the whole intermediate: D2O   100 % 
Solution for amide recognition: 10 mM Phosphate buffer pH 7 
     D2O   10 % 
2.1.11 Media for plant growth 
Murashige and Skoog salts (Sigma)   2.2 g L-1  
Phyto-agar      0.8 % (w/v) 
The pH was subsequently adjusted to 5.7 with 1 M KOH. 
 
2.1.12 Media for Caenorhabditis elegans growth 
NaCl͒      3 g 
 Agar͒      17 g 
Peptone͒     2.5 g   
H2O͒͒      975 mL 
This was autoclaved, and then the following sterile solutions were added: 
1 M potassium phosphate pH 6   25 mL 






1 M MgSO4͒     1 mL 
1 M CaCl2͒     1 mL 
 Cholesterol (5 mg mL-1 in ethanol)  1 mL 
 
2.2 Microbacterial methods 
2.2.1 Sterilisation 
 Every solution was sterilised for 15 minutes at 121 °C and 1 bar of pressure in the 
autoclave, apart from those that were temperature sensitive which were filter sterilised 
through a 0.21 µm filter. 
2.2.2 Storage of bacteria 
 Glycerol stocks were made for long-term storage of bacteria. Glycerol was added to an 
overnight bacterial culture to a final concentration of 15 % (v/v), except for the 
Mycobacterium tuberculosis stocks which were 20 % glycerol. The stocks were then stored at 
-80 °C. 
2.2.3 Using the bacterial stocks 
 The bacteria were streaked directly from the frozen stock on to LB agar plates with 
antibiotics where appropriate. The plates were then incubated overnight at 37 °C or 28 °C 
depending on the strain. M. tuberculosis stocks were added straight into liquid media to start 
the culture growing. 
2.2.4 Liquid cultures 
 Liquid cultures were inoculated with a single colony from an agar plate culture. The 
medium was supplemented with antibiotics where required. The cultures were rotated at 180 
rpm in baffled flasks at 37 °C, 28 °C or 25 °C, depending on the culture. 
2.2.5 Preparation of competent cells 
 Competent E. coli cells were prepared based on the method described by Sambrook et 
al, 1989 (Sambrook and Green 2001). To start with, 100 mL of LB medium was inoculated 






with a single colony and left to grow overnight at 37 °C at 180 rpm. The starter culture was 
grown to an optical density of between 0.4 and 0.6 at OD600. The cells were cooled on ice for 
10 minutes and pelleted at a rotation of 3,000 rpm at 4°C. The pellets were then resuspended 
in 20 mL of ice cold 0.1M CaCl2 and incubated on ice for 40 minutes. This was spun down at 
3000 rpm for 10 minutes at 4 °C. The pellet was resuspended in 2 mL of ice cold 0.1 M CaCl2 
with 15 % of glycerol (v/v). This cell solution was pipetted into sterile tubes in 25 µL aliquots, 
and frozen in the -80 °C freezer. 
2.2.6 Transformation of competent cells 
 The competent cells were defrosted on ice for 10 minutes. To this, 1 µL of plasmid 
DNA was added and gently flicked to mix it through. The mixture was incubated on ice for 15 
minutes, and then heat shocked by incubation in a 42 °C water bath for 50 seconds before 
being transferred on to ice for at least 2 minutes. To these cells, 250 µL of SOC medium was 
added.  The cells were then incubated at 37 °C for 20 minutes to 1 hour. After this the culture 
was spread over an LB agar plate containing the appropriate antibiotics and incubated at 
37 °C overnight. 
2.2.7 Production of recombinant proteins 
 To produce recombinant protein the E. coli strains BL21(DE3) pLysS or BL21(DE3) 
were transformed with a vector containing the gene of interest and plated on the appropriate 
LB agar. The recombinant strain was grown in LB or 2YT (see Section 2.1.3) at 37 °C, 28 °C 
or 25 °C with 180 rpm rotation. In the 37 °C cultures protein expression was induced with 0.4 
mM IPTG overnight at 19 °C. The 28 °C cultures were not induced, but grown overnight at 
28 °C except for the CbiG cultures which were incubated overnight at 25 °C. 
 The next day cells were centrifuged down at 4000 rpm for 15 minutes at 4 °C. The 
pellet was resuspended in 10 mL of the appropriate binding buffer (see Section 2.1.5.1) and 
then frozen at -20 °C until used for protein purification (see Section 2.5.1).  
 The precorrin-7 producing strain was overproduced in the fermenter using the medium 
described in Section 2.1.3, with a 50 mL starter culture. It was grown at 28 °C overnight at 
200 rpm, maintained at pH 7 using 2 M NH4OH and 2 M phosphoric acid, with 1 % (v/v) 
antifoam dripped in to prevent it from bubbling over. 
2.2.8 Sonication of bacteria 






 The harvested cells were defrosted and lysed by sonication using a Sonics Vibracell 
Ultrasonic processor. An output wattage between 20 and 30 was applied to the cell pellet for 
30 seconds followed by a 30 second rest which was repeated for a total of 6 minutes. The 
sonicated cells were centrifuged at 18,000 rpm for 20 minutes at 4 °C. 
2.3 Molecular biology methods 
2.3.1 PCR reactions 
 The PCR reactions were performed in an Eppendorf AG 22331 PCR machine, as set 
out below: 
Table 2.3.1.1: PCR reaction set up 
 Without DMSO With DMSO With DMSO 
ddH2O 34.5 µL 33.5 µL 32.5 µL 
10 x PCR buffer (Roche, containing 18 
mM MgCl2) 5 µL 5 µL 5 µL 
DMSO 0 µL 1 µL 2 µL 
2 mM dNTPs 5 µL 5 µL 5 µL 
0¶SULPHU 2 µL 2 µL 2 µL 
0¶SULPHU 2 µL 2 µL 2 µL 
DNA template 1 µL 1 µL 1 µL 
Taq polymerase 0.5 µL 0.5 µL 0.5 µL 
 
Table 2.3.1.2: PCR reaction methods 
Step Temperature Time Cycles Function Roche Taq 
1 96 °C 2 minutes 1 Initial denaturation of the 
chromosomal DNA 
2 96 °C 30 seconds 
35 
Denaturation of the amplified 
DNA 
3 55 °C 30 seconds Annealing of the primers 
4 72 °C 1 minute per 1,000 base pairs Elongation 
5 72 °C 5 minute 1 Final elongation 
Stop 4 °C Paused 
 
 Upon the completion of the PCR the reaction was run on an agarose gel by 
electrophoresis.  






2.3.2 Agarose gel electrophoresis 
 All agarose gel electrophoreses used 1 % (w/v) agarose gel concentration in TAE 
buffer with ethidium bromide (0.5 µg mL-1 final concentration). DNA loading buffer was 
added to the samples at 20 % of the total sample volume, and then loaded into the gel wells. 
The electrophoresis was run between 70-80 V for about 1 hour. 
 Once this was complete the gel was exposed to UV radiation (312 nm). The ethidium 
bromide, which absorbs this, is a fluorescent dye intercalated between the DNA base pairs. 
Therefore the emission at 590 nm was used to visualise the DNA, and a photograph was taken 
through a red filter. 
2.3.3 Extraction and purification of DNA 
 The band of interest was cut from the agarose gel using a scalpel blade. The extraction 
and purification of the DNA from the gel was performed using the microcentrifuge protocol 
from the Qiagen QIAquick® gel extraction kit. Purification of DNA from PCR samples was 
done using the same kit, but using the QIAquick® PCR purification method. 
2.3.4 Construction of plasmids 
 The vector and the insert were both digested with sticky end compatible enzymes, 
usually NdeI and SpeI. These fragments were incubated for 2 hours at room temperature with 
T4 DNA ligase (Promega) in the following manner: 
Insert      5 µL 
Vector      3 µL 
10x Rapid ligation buffer (Promega)  1 µL 
T4 DNA ligase (Promega)   1 µL (1 U per 10 µL) 
2.3.5 Amplification and checking of plasmids 
 The ligation mixture was used to transform E. coli JM109 (see Section 2.2.6) which 
was plated and incubated overnight on LB agar plates containing the appropriate antibiotics. 
A single colony was picked to inoculate 5 mL of LB, which was incubated overnight at 37 °C. 
This starter culture was spun at 3000 rpm and the DNA was purified from the pellet using 
Qiagen QIAprep® miniprep kit, miniprep purification protocol using a microcentrifuge. 






 The isolated plasmid DNA was digested again to confirm that the insert had ligated 
into the vector. The optimal buffer for the digestion was chosen using the information 
provided by Promega or New England Biolabs. The relevant enzymes were added to the 
plasmid DNA and incubated at the optimum temperature for the chosen enzymes, usually 
37 °C, for 2 hours. The digested plasmid was run by agarose gel electrophoresis and the 
results were compared to the theoretical migration and number of the digested fragments.  
Table 2.3.5.1: A typical digest protocol 
 Single digest Double digest 
ddH2O 3.5 µL 3 µL 
Restriction enzyme 1 0.5 µL 0.5 µL 
Restriction enzyme 2 - 0.5 µL 
10 x digest buffer 1 µL 1 µL 
Plasmid DNA 5 µL 5 µL 
 
 
2.3.6 Sequencing of the plasmids 
 Once the insert was confirmed to be present in the vector, the plasmid was sequenced 
(at Source Bioscience PLC) to make sure that no mutations were introduced in the gene 
amplification and ligation processes. 
 
2.4 Protein purification and analysis  
2.4.1 Immobilised metal ion chromatography 
 In all the IMAC purifications nickel was used as the immobilised ion for isolating the 
hexa-histidine tagged proteins from the supernatant of the sonicated bacterial pellet (see 
Section 2.2.8). The Ni2+ was loaded on to Chelating SepharoseTM Fast Flow resin whereupon 
the supernatant of the bacterial pellet after sonication was applied to the column. Proteins with 
exposed hexa-histidine tag will stick to the column whilst everything else flows through. The 
His-tagged protein is isolated by competitive elution with increasing concentrations of 
imidazole. Imidazole is a histidine mimic which displaces the hexa-histidine tagged protein 
from the nickel when in high enough concentrations, i.e. in elution buffer (see Section 2.1.5.1). 
All the proteins were purified at room temperature, but CbiH was purified anaerobically (at < 






2 ppm oxygen). The purification method in an empty PD-10 column is set out below in Table 
2.4.1.1. 
Table 2.4.1.1: IMAC purification method 
Step  Volume (mL) 
1 Chelating Sepharose
TM
 resin 3-5 
Distilled H2O 50 
2 0.1 M NiSO4 10 Binding buffer 50 
3 Supernatant ~40 
4 Binding buffer 50 
5 Wash buffer I 25 
6 Wash buffer II 25 
7 Elution buffer ~25 
8 Strip buffer 15 
9 dH2O 50 
 
 The elution buffer was applied to the column to wash off the hexa-histidine tagged 
protein so the flow through was collected in 2 mL fractions. In order to identify the fractions 
with the most concentrated protein Bradford reagent (Bio-Rad) was used, as set out below: 
 dH2O   10 µL 
 Bradford reagent 5 µL 
 Protein fraction 5 µL 
This gives an arbitrary measure of protein concentration as the drop turns from red to varying 
degrees of blue depending on protein concentration. In this way the most concentrated 
elutions could be identified for further use.  
The strip buffer contains EDTA which chelates the nickel ions and washes them off 
the resin, regenerating it for the next purification. All of the buffers were allowed to flow 
through according to gravity and were not pushed. 
2.4.2 Buffer exchange 
 The most concentrated elutions were combined and desalted on a PD-10 desalting 
column (GE healthcare) using the protocol provided, summarised in Table 2.4.2.1. 
 






Table 2.4.2.1: Buffer exchange protocol  
Step  Volume (mL) 
1 Exchange buffer 25 
2 Protein elution 2.5 
3 Exchange buffer 3.5 
4 dH2O 50 
 
 The 3.5 mL of the exchange buffer in step 3 was collected as it contained the protein.  
2.4.3 Protein concentration calculations 
Instead of performing a full Bradford protein assay and using the standard curve 
produced to find the concentration, the extinction coefficients of the proteins were used. The 
absorbance at 280 nm and the extinction coefficient was combined in the equation below to 
calculate the concentration of the protein. 
A280 İFO 
:KHUH$LVWKHDEVRUEDQFHDWQPİLVWKHH[WLQFWLRQFRHIILFient of the protein at 280 nm, 
c is the concentration and l is the path length. The cuvettes used were 1 cm deep, so the path 
length was invariably one. 
 The concentration could then be converted into mg mL-1 using the following equation: 
Protein concentration (mg mL-1) = Molecular mass (Da) x Concentration (M) 
2.4.4 Gel filtration 
 An Amersham Biosciences P-920 FPLC chromatography system was used for gel 
filtration purification. A superdexTM G200 column (GE Healthcare) was pre-equilibrated with 
1.2 column volumes of buffer. Concentrated purified protein (1-2 mL) was loaded onto the 
column. The protein was eluted at a flow rate of 0.5 mL min-1 into 1 mL fractions with real-
time detection of protein concentration at 280 nm to determine when the protein eluted. 
Fractions were further analysed by SDS-PAGE. 
2.4.5 Polyacrylamide gel electrophoresis 
 Single concentration polyacrylamide gels were made using the protocol described in 
Section 2.1.7.2. , but the 4-20 % gradient gels were from Bio-Rad (USA) and Thermo Fisher 






Scientific (UK). The polyacrylamide gels  were run according to the protocol set out in 
Laemmli, 1970 . The samples, taken from every flow through of each buffer during protein 
purification, the supernatant, pellet and the post-sonication total, were combined with SDS 
sample buffer in a 1:1 ratio and boiled in a water bath for 5 minutes to denature the proteins. 
Depending on protein concentration, 5-20 µL of the samples were loaded into each well, and 
7 µL of the protein marker was added to the first well to provide a guide to the relative 
molecular mass of the proteins. Electrophoresis was performed at a constant voltage of 200 V 
using an ATTO 1D dual mini slab gel tank, ATTO Corporation and a Bio-Rad Power Pac 300 
electrophoresis power supply, for around 90 minutes. Once this had run the gel was stained 
with coomassie blue stain for about 1 hour before sequential washing with dH2O. The de-
stained gel was then photographed. 
2.4.6 MALDI-TOF SDS-PAGE analysis 
 The MALDI (Matrix-assisted laser desorption/ionisation) samples were run on SDS-
PAGE and fixed for one hour before being transferred into colloidal coomassie stain. The 
bands of interest were excised using a clean scalpel, finely chopped into small cubes and 
transferred into a microcentrifuge tube. These gel pieces were then subjected to alkylation and 
reduction, before an overnight tryptic digest at 37 °C. The peptide fragments were extracted 
using an ultrasonic water bath and the supernatant was collected. The samples were mixed 1:1 
with a matrix solution (10 mg mL-1 2,5-dihydroxybenzoic acid in 2:1 0.1 % TFA/acetonitrile) 
and 1 µL of each sample was pipetted on to a MTP AnchorChip 384 plate.  A peptide 
calibration standard was used to calibrate the machine every four samples. The samples were 
analysed by a Bruker Ultrafile Xtreme MALDI TOF-TOF (time-of-flight) mass spectrometer. 
Data was collected using flexControl and sent, using BioTools to the in house MASCOT 
analysis suite. The peptide mass fingerprint was run against the Uniprot database. MS-MS of 
every sample was also performed and run against the same database. 
2.4.7 Crystallisation of CobH (T85A) 
 The hanging drop method of vapour diffusion was implemented for the crystallisation 
trials (McPherson 1976). Recombinantly produced CobH (T85A) was purified on a nickel 
affinity column using the hexa-histidine tag. The most concentrated elutions were buffer 
exchanged (Section 2.4.2) and concentrated to 1 mL using Amicon® 10 kDa centrifuge 
protein concentrators, which gave a concentration of 57.3 mg mL-1. This was purified on the 






FPLC (Section 2.4.4). The FPLC elutions were diluted from 31.5 mg mL-1 to 15.75 mg mL-1 
(diluted further to 7 mg L-1 for the optimised tray) in buffer comprised of 20 mM Tris pH 8 
containing 100 mM NaCl for the apo-protein, or with 1.3 mM of allyl-HBA (dissolved in 20 
mM Tris pH 8 containing 100 mM NaCl) for the holo-protein. The protein was diluted 1:1 
ZLWKWKHZHOOFRQGLWLRQRQDFRYHUVOLSWRJLYHDWRWDOYROXPHRIȝ/7KHFRYHUVOLSZDV
inverted, placed over the well condition and sealed with vacuum grease. The 24 well plates 
used in this hanging drop vapour diffusion method were incubated at 20 ºC and checked 
regularly for crystal formation. The initial screen used was the Molecular Dimension 
Structure Screen-01 (Jancarik and Kim 2000; Wooh et al. 2003). Any promising conditions 
were screened around with slight changes in well composition (see Appendix A.6 for an 
example). The crystals were picked up using a loop and dipped into the appropriate 
cryoprotectant solutions, as described by McFerrin and Snell (McFerrin and Snell 2002). The 
crystal data was collected at the Diamond Light Source synchrotron (Oxfordshire) by Prof. 
David Brown. The structure elucidation and refinement statistics are described in Chapter 3, 
3.4.3). 
 
2.5 Biochemical methods  
2.5.1 Anaerobic techniques 
 All anaerobic work was performed in a glove box (Belle Technologies) nitrogen 
environment containing less than 2 ppm oxygen. Liquids were degassed under argon prior to 
transferring into the glove box, and any chemicals were taken in to the glove box as powders 
and dissolved within, using degassed H2O, providing they did not need pH adjustment. Any 
resins, such as PD-10 columns, were taken into the glove box at least 24 hours prior to use, 
and equilibrated with 50 mL of anaerobic buffer. 
2.5.2 Preparation of cobalt-factor III 
 The vector pET-coco-2-cobA-hemB-hemC-hemD-sirC-cbiXs-cbiL was provided by Dr 
Simon Moore. It was modified from pET-coco-ABCDC, originally constructed by Dr 
Evelyne Deery and subsequently added to by Dr Stefanie Frank. These proteins were 
overproduced in E. coli and purified on a nickel affinity column. After transfer into the glove 
box and buffer exchange into 20 mM Tris pH 8 and 100 mM NaCl, these proteins were 






incubated with 4 mM ALA, 7.5 mM SAM, 750 nM NAD+ and 1 mM cobalt at 37 °C. To 
prevent precipitation of the proteins the cobalt was gradually titrated into the incubation every 
10-15 minutes to allow cobalt chelation to occur. Cobalt factor III was produced up to a 
concentration of 1 mM (5-10 mL) using this method. After completion, 1 mM DTT could be 
added to maintain the cobalt (II) oxidation state, and prevent oxidation to cobalt (III). 
2.5.3 Preparation of cobalt-precorrin 6b 
 The five glycerol stocks of Bascillus megaterium transformed individually with PxylA-
CbiHHis, PxylA-cbiFHis, PxylA-cbiDHis, PxylA-cbiGHis, and PxylA-cbiJHis were provided by Dr Simon 
Moore. All five cultures were grown in LB in the presence of tetracycline at 28°C, 150 rpm 
for 3-4 hours before induction with 5 % (w/v) xylose, 1 mM of ferric citrate was also added to 
the CbiH culture. These litres were then left overnight at 28°C except for CbiG which was 
grown at 25°C. All of the proteins were purified using nickel affinity chromatography, but 
only CbiH was purified anaerobically in the glove box. The other proteins were purified 
aerobically and buffer exchanged in the glove box. The proteins were combined and 
incubated with 1 mM cobalt-factor III, 2.8 mM SAM, 1.7 mM NADH, 56 nM Na Dithionite, 
5.56 mM DTT, NaOH, and 20 mM Tris pH 8, and incubated overnight in the dark at 37 °C. 
The reaction was monitored using a UV-vis spectrophotometer. 
2.5.4 Preparation of C5-allyl-cobalt-precorrin 7 
 The CbiE, T and C proteins were overexpressed in E. coli and purified by nickel 
affinity chromatography, then buffer exchanged in the glove box. The CbiE (436 µM) was 
incubated with allyl-SAM (400 µM), DTT (10 mM) and cobalt-precorrin 6 overnight in the 
dark at 37 °C. The next day the CbiC (40 µM) and CbiT (57 µM) were added to the 
incubation with SAM (1 mM) and again incubated overnight in the dark at 37 °C. The product 
was analysed using HPLC-MS (see Section 2.5.13). 
2.5.5 Preparation of precorrin-7 
 The vector pET3a-cobA-cobI-cob G-cob J-cob F-cob M-cob K-cob LC-cob EHis was 
provided by Dr Evelyne Deery. A 4 L BioSTAT® A plus fermenter (Sartorius AG) was used 
to grow E. coli transformed with this plasmid which overproduced precorrin-7 for 24 hours at 
28 °C. The pH and temperature were kept constant at 7 and 28 °C respectively, using the 
Sartorius BioPAT® MFCS/DA software. The cells were harvested and lysed using a B series 
cabinet model cell disrupter (Constant systems). This was spun again at 18,000 rpm. The 






supernatants were acidified with 0.3 % (v/v) TFA and heated to 70 °C for 30 minutes to 
remove as many proteins from the solution as possible. This was spun at 4,000 rpm until the 
supernatant was clear. It was then diluted 1:1 with acetonitrile and spun again at 4,000 rpm 
before being applied to an anion exchange column (see Section 2.5.11) followed by further 
purification on a C18 column (see Section 2.5.12). The product was run on the HPLLC-MS to 
confirm its mass (see Section 2.5.13). 
2.5.6 Preparation of C5-allyl HBA 
 CobL and CobH were overproduced in E. coli and purified on a nickel affinity column 
using the hexa-histidine tag. The allyl-SAM was synthesised chemically as described by 
Wang et al. 2011, and run on a DOWEX-50W X4-200® resin to separate the R and the 
desired S isomers using HCl as the elutant. This was then added to the in vitro protein assay 
composed of precorrin-7 (60 µM), cobL (6 µM), cobH (30 µM) and allyl-SAM (170 µM) 
performed in exchange buffer. This was incubated at 28 °C, 160 rpm, overnight in the dark. 
To purify, the assay was heated to 65 °C, then spun at 4,000 rpm in a benchtop centrifuge, and 
the resulting supernatant was applied to an anion exchange column (see Section 2.5.11). 
2.5.7 Preparation of C5-allyl HBAH 
This assay contained C5-allylHBA (30 µM), CobB (2 µM), CobQ (5 µM), adenosine 
triphosphate pH 7 (8 mM), L-Glutamine (8 mM), and MgCl2 (20 mM) performed in exchange 
buffer. This was incubated at 28 °C, with 160 rpm rotation, overnight in the dark. To purify, 
the assay was heated to 80 °C, then spun at 4,000 rpm, acidified with 0.3 % trifluoroacetic 
acid (TFA) and then spun again. The supernatant was applied to an RP18 column (see Section 
2.5.12). 
2.5.8 Preparation of C5-Fluorophore Cobyric acid 
 The C5-allyl group was modified through a thiol-ene coupling reaction with 
cysteamine. A solution of C5-allyl-+%$+ȝ0ZDVLQFXEDWHGDW& in acetate buffer 
(pH 4.0, 0.25 M) containing cysteamine (100 mM) and VA-044 (20 mM) in the dark for 15 
mins. The product was purified over RP18 and analysed by HPLC-MS (see Section 2.5.10). 
 Cobalt insertion was achieved through incubation of the desired metal-free corrinoid 
ȝ0ZLWK&R&O2 (10 mM) in ammonium hydroxide (0.2 M) at 80 °C under an anaerobic 
N2 atmosphere. The reaction was followed UV-visible spectroscopy until deemed complete (~ 






60 mins) after which it was quenched with KCN and the product purified over RP18 (see 
Section 2.5.12). 
The fluorophore succinimidyl ester (BODIPY® TR-X, Oregon green® 514, or 
fluorescein) (0.5 mg) was added to C5-thioamide- cyano cobyric acid (0.1 mg) and N, N-
DIPEA (10 µL) in DMSO (0.5 mL). The reaction was shaken at room temperature for 2 hours 
in the dark. The solvent was removed in vacuo and the compound was purified by semi-
preparative HPLC (see Section 2.5.13). 
2.5.9 Preparation of ribose Fluorophore cobalamin 
 The ribose-¶-hydroxyl group of commercial cyano-cobalamin (Sigma) was activated 
with CDI and coupled with 1, 2-diaminoethane as described previously (McEwan et al. 1999). 
The alkyl derivative was added to either the succinimidyl ester of Oregon Green® 514 or 
BODIPY® TR-X with 2 equivalents of N, N-DIPEA in DMSO. The reaction was stirred for 
16 hours in the dark at room temperature. The product was precipitated with acetone and 
collected by filtration. Fluorescent derivatives were dissolved in 50 % acetonitrile and 
purified by semi-preparative HPLC (see Section 2.5.13). 
2.5.10 Ultraviolet-visible (UV-vis) spectrophotometry 
 UV-vis spectra were recorded on a Varian Cary 50 Bio UV-vis spectrophotometer 
over a range of 200-800 nm, usually 280-650 nm. For UV-vis data obtained in tandem with 
mass spectra please see Section 2.5.13. 
2.5.11 Anion-exchange chromatography 
 An empty PD-10 column had 5 mL of diethylaminoethyl sepharose (DEAE-
Sephacel®) (Sigma) poured into it, and washed with 25 mL of wash buffer I. The solution 
containing the intermediate was then loaded onto the column. The column was washed with 
buffers containing increasing concentrations of NaCl (100-600 mM) whereupon the coloured 
elution fractions were collected (Section 2.1.6). 
2.5.12 RP-18 chromatography 
 LiChroprep® RP-18 (Merck) was routinely used for bench-top preparative reverse 
phase chromatography. The LiChroprep® was mixed with hexane before 2 mL of the slurry 
was applied to the PD-10 column (in the fume cupboard). The hexane was removed by 






continuous washing with methanol. Once the column was in methanol, 50 mL of 0.1 % (v/v) 
TFA was used to wash the column. TFA was then added to the tetrapyrrole solution at 0.1 % 
(v/v) in order to acidify it. This was applied to the column and washed with 0.1 % (v/v) TFA. 
The column was then washed with increasing concentrations of methanol until the 
tetrapyrrole eluted (usually ~50 %). The elutions were dried down on a vacuum centrifuge 
and resuspended in dH2O for HPLC-MS analysis. 
 For intermediates with six amide groups this was done at neutral pH in order to 
encourage the more hydrophyllic intermediates to be retained during mobile phase, but 
otherwise the process was the same.  
2.5.13 Reversed phase HPLC-MS analysis 
 Every intermediate produced was run on the HPLC-MS, and the SAM-analogues and 
fluorophore analogues were purified by preparative HPLC prior to use. Depending on the 
concentration of the sample between 10-100 µL was loaded onto the Ace 5 AQ column (2.1 x 
150 mm, 5 µm, 100 Å, from Advanced Chromatography Technologies). The column was 
connected to an Agilent 1100 series HPLC coupled to a micrOTOF-Q (Bruker) mass 
spectrometer, equipped with an online UV-vis diode array and fluorescence detectors. Every 
protocol run was at a 0.2 mL min-1 flow rate using 0.1 % (v/v) TFA (solvent A) and 100 % 
acetonitrile (solvent B), with the column kept at 25 °C. The three methods used are shown in 
Figure 2.5.13.1. 
 
































Figure 2.5.13.1: The LC timetable of solvent composition. Three 
LC methods were used during HPLC analysis, all using the same 
solvents. Solvent A is 0.1 % (v/v) TFA and solvent B is 100 % 
acetonitrile. All the methods were designed by Dr Andrew 
Lawrence. 






The electrospray ionisation mass spectrometry (ESI-MS) data was obtained on a 
Bruker micrOTOF II-MS using positive mode electrospray ionisation. The results were 
correlated to the UV-vis spectra acquired after the LC, using diode array and UV detection, 
over a 200-800 nm range. 
 Semi-preparative HPLC was performed on an Agilent 1000 series HPLC using a CS 
6,/&FROXPQPP[PPȝP&KDUOWRQ6FLHQWLILFDWDIORZUDWHRImL min-1 
running the gradients described above. Elutants were identified by the UV spectra. 
2.5.14 NMR analysis 
 NMR experiments were performed using a 600 MHz (1H) Bruker Avance III 
spectrometer with a 5 mm QCI-F cryoprobe. 1H Chemical shift referencing was based on the 
position of the water resonance, 13C referencing used 1H/13C gyromagentic ratios to define 
indirect carrier position and all data were obtained at 25 °C (Wishart and Case 2001).  
2.5.15 Allyl-SAM synthesis and DOWEX-50W X4-200 ® purification  
 First a 1:1 ratio of formic: acetic acid was cooled in an ice bath, 600 µL of this was 
used in the reaction mixture outlined below: 
  SAH   5 mg 
  Allyl Bromide  44 µL (40 equivalents) 
  AgClO4  6 mg (2 equivalents) 
This was stirred for 2.5 hours at room temperature and then the following were added: 
  Allyl Bromide  44 µL (40 equivalents) 
  AgClO4  6 mg (2 equivalents) 
This was stirred for a further 2.5 hours at room temperature. The reaction mixture was then 
centrifuged to remove the AgClO4 and other precipitants. The supernatant was diluted with 3 
mL of ddH2O. To extract the residual allyl bromide 5 mL of diethyl ether was added to the 
mixture and the top layer was removed. This was repeated 3 times. The remaining solution 
was dried in a vacuum centrifuge and resuspended in 500 µL of 1:1 formic: acetic acid. 






The DOWEX-50W X4-200® column was prepared with ddH2O and then the allyl-
SAM mixture was applied. This was washed with two column volumes of increasing 
concentrations of HCl (0.1 M, 1 M, 2.5 M, and 5 M). The R isomer washed off the column at 
2.5 M HCl whilst the desired S isomer purified at 5 M HCl. The aliquots were dried on the 
vacuum centrifuge and resuspended in ddH2O before running on the HPLC-MS (see Section 
2.5.13). 
2.6 Methods of experiments conducted in vivo 
2.6.1 Bioassay plates 
 Quantitative S. enterica AR3612 bioassay plates were performed as explained in 
Chapter 3 (pg96) and as described previously (Raux et al. 1996). 
2.6.2 Imaging in Escherichia coli 
 BL21 (DE3) E. coli was transformed with pLysS-btuB whilst OP50 E. coli was 
transformed with pET-BAD-btuBF. Both were grown in a 4 mL LB culture after inoculation 
with 16 µL of starter culture. This was grown with 1 µM of C5-fluorophore-cobyric acid 
overnight with induction. One mL of culture was spun down and washed three times with 
fresh LB to remove external fluorophore. Next, 5 µL of this culture was dried on to a 1 % 
(w/v) LB-agarose pad and imaged on an Olympus IX81 widefield microscope with PlanApo 
150 x OTIRFM-SP 1.49 numerical aperture lens mounted on ASI stage (Applied Scientific), 
and illuminated using LED light sources (Cairn Research Ltd) with appropriate filters (YFP 
and mCherry, Chroma). The samples were visualised using a Princeton ProEM 1024 back-
thinned EMCCD camera (Princeton Instruments) on Metamorph software (Molecular 
Devices). Each 3D-maximum projection of volume data was calculated from 13 z-plane 
LPDJHVHDFKȝPDSDUW 
2.6.3 Extraction of cobalamin from Lepidium sativum using P-Per 
 Lepidium sativum seeds were sterilised by washing with 70 % ethanol three times then 
rinsed five times with sterile water. The seeds were placed on the agar (see Section 2.1.11) 
containing different concentrations of cobalamin, and grown for one week in sunlight at room 
temperature. The cotyledons of the cress were collected and washed 5 times with water.  The 
residual water was removed by pipette, after centrifugation. The P-Per was prepared as 
instructed in the enclosed manual (Thermo Fisher): 283 µL reagent A, 2.9 µL of reagent B, 






and 214 µL of reagent C. A little sand was added to the cotyledons along with 100 µL of the 
P-Per. The cotyledons were ground using a hand held pellet pestle (Sigma Aldrich) for 2 
minutes. The suspension was vortexed and then centrifuged for 3 minutes at 15,000 rpm 
rotation. The lower aqueous phase was collected and applied to the bioassay plate (see Section 
2.6.1). 
2.6.4 Imaging in Plants 
 Both A. thaliana and L. sativum seeds were sterilised by washing with 70 % ethanol 
three times then rinsed five times with sterile water. The seeds were then placed on the agar 
(see Section 2.1.11) with 0.5 µM Oregon green linked to either the ribose of cobalamin or to 
the C5 of cobyric acid, and grown at room temperature in the dark for five days. Whole 
cotyledons or sectioned cress were placed directly on the glass slide with water. The samples 
were imaged with a Leica TCS SP2 laser scanning confocal microscope (Leica Microsystems, 
Germany) with AOBS (Acoust-Optical Beam Splitter) detected using PMTs (photomultiplier 
tubes). Both the 40 x and 63 x HCX PL APO oil lenses, numerical aperture 1.25 and 1.4 
respectively, were used. Samples were excited at 514 nm from an Argon±Krypton-mixed gas 
laser and images were acquired in the green/yellow region of the light spectrum (525±590 
nm). The software used to image was LCS (Leica Confocal Software) and the images were 
processed using Leica Lite confocal software and FIJI (Schindelin et al. 2012). 
2.6.5 Imaging in Caenorhabditis elegans 
The OP50 pET-BAD-btuBF were grown in the same way as Section 2.6.2 with 
BODIPY® TR-X as the fluorophore in the analogues. The following day the cells were 
pelleted and resuspended in 1 mL of fresh LB, then pelleted again and so on until the cells had 
been resuspended three times in fresh LB. The final pellet was resuspended in 1 mL of fresh 
LB and 200 µL of the OP50 culture was pipetted on to the centre of NGM agar plates. These 
plates were left to dry in a sterile culture hood for 4 hours and then stored at 4 °C until used 
(see Section 2.1.12). Three forth larval stage (L4) C. elegans were transferred to the seeded 
plates and left to grow at 20 °C for four days before imaging. Almost all of the nematodes 
reported in these investigations are at L4, the stage just before adult. This is because adults are 
hard to image as the middle of the worm is obstructed by eggs. In contrast, the somatic 
structures of the nematode have formed by mid-L4 stage but eggs within the uterus have not 
formed, which make this the perfect stage for imaging. 






For each slide, 3-5 L4 stage C. elegans were mounted in M9 + 0.2 % levamisole on a 
2 % agarose pad and imaged within 30 min at the University of Bristol on a Leica SP8X 
AOBS confocal laser scanning microscope attached to a Leica DMi8 inverted epifluorescence 
PLFURVFRSHZLWKµ$GDSWLYH)RFXV&RQWURO¶7KHVDPSOHZDVH[FLWHGZLWKDZKLWH light laser at 
594 nm and detected between 599-712 nm using a hybrid gated detector for the fluorophore, 
and excited with a 405 nm diode, with images acquired between 410-505 nm for the gut 
granule autofluorescence. All images were taken using a 20 x numerical aperture 0.75 dry 
lens. Again the images were processed using Leica Lite confocal software and FIJI . 
The persistence of the fluorescence in the C. elegans was investigated by transferring 
L3 nematodes, previously grown on BODIPY® TR-X analogue containing OP50, on to plates 
with unfortified OP50 and imaging after 22 hours. The imaging was done on a Leica DM R 
fluorescence microscope using 515-560 nm (N2-1) excitation and 590 nm emission filters for 
the BODIPY® TR-X fluorescence and 456-490 nm (I3) excitation and 515 nm emission 
filters for autofluorescence. The images were obtained using a Photometrics Cool Snap HQ 
camera with a 20 x HC PL Fluotar lens, numerical aperture 0.5. The software used was 
Micro-manager (Edelstein et al. 2014). 
2.6.6 Imaging in Mycobacterium tuberculosis 
 The ǻPHW( strain of M. tuberculosis was grown in 150 µL in a 96 well plate with 1 
µM of the BODIPY® TR-X fluorophore analogues added to the media. Two samples of each 
analogue were grown, one for 24 hours and the other for 48, until the cells were at a predicted 
optical density of 0.6 at 65QP7KHFRQGLWLRQVZHUHUHSHDWHGIRUERWK+DQG6DXWRQ¶V
media. To image, each sample was spun down (15,000 rpm rotation) and washed three times 
LQ6DXWRQ¶VPHGLXP'URSVRI/Zere pipetted directly onto the slide and imaged live on 
a Leica SP5 using 594 nm excitation and imaging between 600-700 nm, in a CAT-III (BSL-3) 
laboratory at the NIH (Bethesda, MD, USA). The images were processed using Leica Lite 
confocal software and FIJI (Schindelin et al. 2012). 
2.7 Other Mycobacterium tuberculosis methods 
2.7.1 Cobalamin-agarose column 
 Every strain used (H37Rv (WT), H37RvJO (H37Rv), and ǻEDF$H37RvJO (ǻEDF$) 
was grown in 3 x 450 mL for five days in 7H9 medium until an optical density of 0.6. The 






cultures were then spun down at 3500 rpm for 10 minutes and the pellets were resuspended in 
7H9 before being transferred into microcentrifuge tubes containing small beads. These were 
then cooled on dry ice and bead beaten at 7000 for 45 seconds. This was repeated 5 times with 
cooling between each beating. The samples were centrifuged for a minute at 15,000 rpm and 
the supernatant was filtered through 0.22 µm filters into clean microcentrifuge tubes. 
 The supernatant was removed from CAT-III (BSL-3) and applied to the ~2 mL 
cobalamin-agarose column, synthesised as described in Bioconjugate technologies 
(Hermanson 2013), which had been pre-equilibrated with 20 mM Tris pH 8. This was washed 
with buffers containing increasing concentrations of cobalamin (10 nM to 1 µM) and then 
washed with 8 M urea to strip any remaining proteins off the column, before washing again 
with 50 mL 20 mM Tris pH 8. Every flow through was collected and, after buffer exchanging 
the urea elution into 20 mM Tris pH 8, all the samples were concentrated using 10 kDa 
3LHUFH3URWHLQ&RQFHQWUDWRUFHQWULIXJHFRQFHQWUDWRU7KHUPR)LVKHU6FLHQWLILFWR/
from 50 mL. The samples were then run on 4-20 % SDS-PAGE (see Section 2.4.5) and 
analysed by MALDI-TOF (see Section 2.4.6). 
2.7.2 Corrinoid supplemented growth 
 Three strains were used: H37Rv (WT), H37RvJO (H37Rv), and ǻEDF$H37RvJO 
(ǻEDF$). Each strain was grown with five different concentrations of corrinoid: 0 µM, 100 
nM, 500 nM, 1 µM, and 10 µM. The cultures were grown for five days in 7H9 medium until 
an optical density of 0.6 at 650 nm. The cultures were then spun down at 3,500 rpm for 10 
minutes and the pellets were resuspended in 1 mL of 7H9 before being transferred into a 
microcentrifuge tube. These were spun for 30 seconds at 15000 rpm and washed three times 
with 7H9. The pellet was resuspended in 1 mL of H2O and transferred into a microcentrifuge 
containing small beads. These were then cooled on dry ice and bead beaten at 7,000 for 45 
seconds, repeated 5 times. The samples were centrifuged for a minute at 15,000 rpm and the 
supernatant was filtered through 0.22 µm filters into clean microcentrifuge tubes. These 
samples were then plated on AR3612 S. enterica bioassay plates and subsequently analysed. 
2.7.3 RNA sequencing 
 Five strains were used: H37Rv (WT), H37RvJO (H37Rv), ǻEDF$H37RvJO (ǻEDF$), 
ǻPHW(H37RvJO (ǻPHW(), and ǻPHW+H37RvJO (ǻPHW+). All RNA sequencing cultures were 
set up with and without 1 µM of corrinoid added to the 7H9 media except for ǻPHW( which 






was set up in three cultures: + corrinoid + 2 mM L-methionine, + corrinoid - 2 mM L-
methionine, and - corrinoid + 2 mM L-methionine. The samples were subcultured five times, 
maintaining an optical density under 0.2 at 650 nm, and grown at 37 °C at 200 rpm. After 5 
subcultures the cells were harvested and TRIzol® (Thermo Fisher Scientific) was rapidly 
added to the pellet. Once resuspended, all the samples were transferred to 0.2 µm bead 
containing microcentrifuge tubes (about one fifth of a 1 mL tube). The samples were cooled 
on dry ice and then bead beaten at 7,000 for 45 seconds at a time for at least three minutes. 
They were then spun down at 15,000 rpm for 40 seconds and the supernatant was transferred 
to a clean microcentrifuge tube. The RNA was then extracted using Quick-51$0LQL3UHS
Plus (Zymo research) RNA purification protocol. The purified RNA samples were sent to the 
microarray services at the NIH (Bethesda, MD, USA) to be analysed. Samples containing the 
corrinoid were compared to those without, and with ǻPHW( the sample with corrinoid was 
compared to the sample with corrinoid and methionine, as well as the sample with just 
methionine. 
2.7.4 ǻPHW( rescue  
In a 24 well plate, six different cobalamin intermediates were added to a 1 µM 
concentration in 500 µL of 7H9 media. Three strains were tested: H37RvJO (H37Rv), ǻPHW( 
H37RvJO (ǻPHW(), ǻPHW+ H37RvJO (ǻPHW+). These were diluted in the well so a predicted 
OD650 of 0.6 would be reached on the fifth day. Each well was mixed every day by pipetting, 
and a photograph was taken. The plate, set up as shown in Table 2.7.4.1, was grown at 37 °C 
with 100 rpm rotation for one week. 
Table 2.7.4.1: Set up of the ǻPHW( rescue experiment 
 






The blank denotes that no corrinoid was added to the media and wells containing X were 
filled with 1 mL of ddH2O to prevent the plate from drying out. 
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The aim of the research discussed in this chapter was to determine whether it is 
possible to attach a reporter group directly onto the corrin macrocycle of cobalamin, and to 
assess whether such an analogue would remain biologically active. There are three main ways 
in which to approach such a construction: chemically, biologically (enzymatically), and a 
combination of the two. The total chemical synthesis of cobalamin is difficult as it involves 
around 70 steps with very low yield (Eschenmoser 1988). The complete de novo biological 
synthesis of cobalamin involves about 30 enzymatic steps, many different cofactors and 
roughly 25 molecules of ATP (Deery et al. 2012; Galperin and Grishin 2000; Heldt et al. 
2005). The hybrid method of synthesis is relatively new. It uses recombinantly expressed 
cobalamin biosynthesis enzymes to produce an intermediate, which can then be chemically 
converted into cobalamin. The primary advantage of the hybrid technique in analogue 
synthesis is that the intermediate can be chemically modified and then fed back into the 
biological synthesis system by incubating in vitro with subsequent native pathway enzymes. 
If these analogues are recognised by the native enzymes it gives a good indication that they 
will also be accepted by the cobalamin uptake system in vivo. 
The analogues synthesis detailed in this chapter utilises the hybrid synthesis route. 
This can be broken down into three sections: overproduction and extraction of the required 
intermediate from cell culture, modification of the intermediate and progression of 
biosynthesis by native biosynthesis enzymes in vitro, and chemical extension and further 
modification of the introduced appendage (Figure 3.0.1). It is ideal for the position of 
modification to be on the corrin ring because it is less likely to be cleaved in vivo and specific 
modification is possible. Previous modification to cobalamins have involved alkylation of the 
central cobalt ion, esterification of the ribose on the lower nucleotide loop, or modification of 
one of the amidated side chains (Clardy et al. 2011)$Q\FREDOWFRRUGLQDWHGȕOLJDQGLVDWULVN
of being exchanged to a methyl or adenosyl group in vivo. It is also undesirable to modify the 
side chains off the macrocycle as they are implicated in uptake and transport (Clardy et al. 
2011). Additionally, the side chains are very similar and therefore, hard to specifically modify, 
often resulting in preparative HPLC purification to attain the desired product, which is very 
time consuming. The nucleotide loop itself can be modified, but this could affect base on/ off 
configuration which is important in some binding conformations, and some organisms 
exchange the lower loop altogether (Fedosov et al. 2007; Helliwell et al. 2016; Yi et al. 2012). 
With all this considered, a direct modification of the corrin ring is preferable. The chosen site 





of modification is the C5 position in between rings A and B, the recipient of the final SAM 
mediated methylation. Therefore, the alternative group on the C5 will not interfere with any 
modifications on the corrin ring as they have already taken place. As the intermediates to be 
used for C5 modification have completed corrin macrocycles this tends to make them more 
stable. Additionally, the C5 position methyl group is in the plane of the ring unlike the b and c 
sidechains which flank it on either side, therefore a small new chemical group will also be in 
the plane of the ring which will decrease the likelihood of it hindering sidechain recognition.  
There are two pre-C5 methylation intermediates which can be used because there are 
broadly two different pathways for cobalamin synthesis: The Early Insertion (or anaerobic) 
pathway; and The Late Insertion (or aerobic) pathway, so called in reference to the timing of 
cobalt insertion (see Figure 3.0.2). Both pathways were investigated for their potential in 
constructing cobalamin analogues. The main advantage of the Early insertion pathway is that 
the intermediates already contain cobalt, whereas the Late insertion pathway intermediates do 
not, and are therefore, stable in aerobic environments. The required intermediate from the 
Early insertion pathway is cobalt-precorrin 7, whilst the Late insertion pathway equivalent is 
precorrin-7. These are the intermediates which were incubated with their respective C5 
methyltransferases and a SAM analogue, allyl-SAM, in an attempt to modify the C5 position. 
Figure 3.0.1: The abridged late insertion pathway from precorrin-7 until the BODIPY® TR-X C5 
analogue. Uroporphorinogen (8UR¶JHQ) III is the modified tetrapyrrole precursor, Av denotes that CobQ 
is from Allochromatium vinosum unlike all the other proteins which are from R. capsulatus. The 
enzymes and chemicals are in blue whilst the cofactors are in black. The modifications which have taken 
place during the reaction are highlighted in red. 





An allyl group was chosen as the transfer group because it is small and yet easily modifiable 
at a later stage. This increases the chances of the methyltransferase enzymes attaching it to the 
C5 position whilst limiting the detrimental effects the presence of this group may have on 
binding and recognition.  
Precorrin-7 is not a natural intermediate of the Late insertion pathway. Normally, 
precorrin-6 is methylated at C5, C15 and decarboxylated at C12 by CobL, to form precorrin-8. 
However, a recent paper discovered that CobL is a fused protein, and that the C-terminus of 
CobL (CobLC) can function independently to methylate C15 and decarboxylate C12 (Deery et 
al. 2013). CobLC can therefore, be incubated with precorrin-6 to produce a new intermediate, 
precorrin-7, which is unmethylated at C5. Hence, precorrin-7 can be used to synthesise the C5 
analogues.  
The lack of the cobalt ion in the Late insertion pathway intermediates means that it 
will have to be inserted into the corrin macrocycle after the C5 modification. Previous 
unpublished data from the Warren group showed that CobNST, the cobalt chelation complex, 
is inefficient in in vitro assays, so chemical insertion of cobalt is preferable, even though 
much of the substrate is lost in the reaction due to the harsh conditions.  In the Late insertion 
pathway in vivo cobalt chelation occurs after the first amidase reaction. However, as the 
cobalt will be inserted chemically there is no reason not to do this later, after the final 
amidations. This may serve to stabilise the corrin macrocycle and increase the yield of the 
chemical cobalt insertion reaction. CobQ, the final amidation enzyme, usually requires the 
presence of cobalt and the adenosylation of the upper ligand. However, Allochromatium 
vinosum, a halotolerant purple sulphur reducing bacteria, has been proposed to make metal 
free cobalamin, so called hydrogenobalamin (Toohey 1965). It follows that the CobQ from A. 
vinosum should not require a cobaltous intermediate, so this was used instead of the R. 
capsulatus homologue. 
Once the sidechains have been modified and the cobalt inserted, the allyl group can be 
extended to a thioamine. This will leave a terminal primary amine which will react with 
activated N-hydroxysuccinimidyl ester groups commonly found on fluorophores, to produce a 
fluorescent C5-cobyric acid analogue. 
The aims set out for this chapter were: 





1. To investigate the Early and Late insertion cobalamin biosynthesis pathways to 
determine which was better suited for analogue synthesis. 
2. To synthesise a C5 modified analogue. 
3. To attach a fluorophore to the C5 position. 
4. To test the recognition of the C5 fluorophore analogue in S. enterica. 
  
 
Figure 3.0.2: The two cobalamin biosynthesis pathways. The late insertion is shown on the right in red 
and early on the left in green.  The intermediates of both pathways where they converge are shown in 
black. This Figure is taken from 'U'HHU\¶VUHVHDUFKSRVWHU 






3.2 Synthesis of allyl-SAM 
 An allyl group was chosen as the transfer group because it is small enough to limit any 
interference with the native enzymes, but easily extendable with a thioamine, to produce a 
primary amine which can subsequently react with many compounds, like fluorophores. The 
synthesis of allyl-SAM is shown in Figure 3.2.1, A (Chapter 2.5.15). The product is an 
enantiomeric mix of R and S isomers which were separated during purification on DOWEX-
50W X4-200® cation exchange column. This separation is possibly due to shielding of 
cations in the R-isomer which prevent it from binding as tightly as the S-isomer. Only the S-
isomer is biologically active. The mass of the allyl-SAM was confirmed by HPLC MS (see 
Figure 3.2.1, B and C).  
 
 
Figure 3.2.1: The synthesis of allyl-SAM and HPLC-MS confirmation. A: The analogue was sythesised 
using allyl bromide as the allyl donator and silver perchlorate as the catalyst. The reaction was conducted in an 
acetic acid/ formic acid mixture at room temperature (see Chapter 2, 2.5.15) and then purified on a DOWEX-
50W X4-200® column followed by confirmation on the HPLC-MS. B: The HPLC trace shows two peaks 
corresponding to the two entioisomers, R and S respectively, prior to DOWEX-50W X4-200® purification. C: 
The later HPLC peak at 6.3 minutes is the S isomer which shows an absorbance at 257 nm with the expected 
425.1639 m/z. 
3.3 Early insertion (anaerobic) pathway 
The Early insertion or anaerobic pathway, as the names suggests, inserts cobalt into 
the macrocycle at a very early stage in the synthesis of cobalamin. It is sometimes referred to 
as the oxygen independent pathway, as the ring contraction mechanism does not require 









Schroeder et al. 2009). Partly as a result of early cobalt insertion, intermediates isolated from 
this pathway are very oxygen sensitive. Consequently work on the early insertion pathway has 
to be conducted in anaerobic glove boxes at <2 ppm oxygen (Moore, Biedendieck, et al. 
2013).  
3.3.1 Producing the substrate for modification: Cobalt precorrin-6b 
 The C5 position was chosen as the point of modification on the cobalamin macrocycle. 
The methylation of the C5 position is one of the two last methylation reactions on the 
macrocycle and, in the early insertion pathway. Cobalt precorrin-7 is the intermediate used as 
the substrate in the C5 methylation reaction. However, cobalt precorrin-7 is very unstable, 
therefore, the more stable intermediate one step before cobalt precorrin-7, cobalt precorrin-6b, 
was isolated. This was produced in two stages: synthesis of cobalt factor-III, and conversion 
of this into cobalt precorrin-6b. Cobalt precorrin-6b can subsequently be converted into cobalt 
precorrin-7 in vitro (Figure 3.3.1.1). 
The plasmid pETcoco-2-cobA, hemB, hemC, hemD, sirC, cbiXS, cbiL (see Chapter 2, 
2.1.2.2) was over expressed in E. coli to produce the enzymes for the conversion of 
aminolevulinic acid (ALA) to cobalt factor-III. The enzymes were purified aerobically on the 
bench using a nickel affinity column and then buffer exchanged in the glove box into 20 mM 
Tris pH 8, 100 mM NaCl. The proteins were incubated with 4 mM ALA, 7.5 mM SAM, 750 
nM NAD+. After 30 minutes at 37 °C, 1 mL of 10 mM CoCl2˹6H2O was added dropwise, 
with constant stirring. The reaction mixture was left overnight at 37 °C. During this time the 
three Hem proteins convert ALA into uroporphorinogen-,,,XUR¶JHQ,,,, the modified 
tetrapyrrole progenitor (Lobo et al. 2009)&RE$VXEVHTXHQWO\PHWK\ODWHVXUR¶JHQ,,,DW
positions C2 and C7 to make precorrin-2. SirC oxidises the corrin ring using NAD+ as a 
cofactor, to generate sirohydrochlorin (factor-II), the substrate for the cobalt chelatase CbiX. 
Figure 3.3.1.1: The strategy for synthesising C5-allyl analogues using Early insertion pathway 
intermediates. Cobalt-Factor-III was isolated from cultures recombinantly exressing the first seven enzymes. it 
was subsequnetly incubated in vitro  with CbiH, F, G, D, and J to produce Cobalt-precorrin-6B. CbiE allylates 
the C5 position using the synthesised allyl-SAM as the donor. CbiT methylates the C15 position using SAM as 
the methyl donor and decarboxylates C12, after which CbiC migrates the methyl group from C11 to C12.  





CbiL methylates the C20 position to produce the last uncontracted ring intermediate, cobalt 
factor-III (Kadish et al. 2003). The cobalt factor-III was purified on an anion exchange 
column and eluted in 20 mM Tris pH 8 containing 600 mM NaCl. Cobalt factor-III is a green 
pigment and these distinctive, coloured fractions were collected. 
The cobalt factor-III was converted into cobalt precorrin-6b using the enzymes of the 
anaerobic pathway from Bacillus megaterium, as the pathway had recently been elucidated 
using this suite of enzymes (Moore and Warren 2012). From cobalt factor-III there are 5 
enzyme reactions to cobalt precorrin-6b. These reactions were performed in one in vitro 
incubation with CbiH, F, G, D, and J, together with 2.8 mM SAM, 1.7 mM NADH. CbiH was 
purified in the glove box, but the other enzymes were purified aerobically on the bench using 
a nickel affinity column. All of the enzymes were buffer exchanged in the glove box into 20 
mM Tris pH 8 containing 400 mM NaCl. The incubation was set up at 37 °C overnight in the 
presence of the reducing agents sodium dithionite and DTT. The colour change resulting from 
the extrusion of the C20 carbon catalysed by CbiH can be followed by UV-vis 
spectrophotometry (Appendix A.3). 
There were a couple of issues with this assay: The 4Fe-4S centre that is found in CbiH 
makes it difficult to overproduce and purify in great quantities as it is unstable, and the protein 
is prone to proteolytic cleavage (see Appendix A.2). This meant that it had to be purified just 
before it was added to the assay. The bigger issue was CbiF, which gave a low yield when 
purified from frozen pellets. However, freshly grown CbiF purified in good yields (see 
Appendix A.3).  
3.3.2 Specifically modifying the C5 position 
 The native enzyme that modifies the C5 position in B. megatarium is CbiET, a fusion 
of CbiE and CbiT. CbiET is responsible for methylation of C5, C15 and decarboxylation of 
C12. However, this is not useful for specific modification of C5 only. Therefore, the unfused 
CbiE and CbiT from Methanothermobacter thermautotrophicus were used. CbiE is the 
protein responsible for the methylation of C5 and CbiT for the methylation of C15 and 
decarboxylation of C12 (Moore, Lawrence, et al. 2013). The proposed mechanism of C5 
modification involves the allyl-SAM analogue together with the CbiE methyltransferase to 
allow the transfer of an allyl group instead of a methyl one (Figure 3.3.1.1). 
Methyltransferases have previously been shown to work with SAM analogues (Wang et al. 
2011).  





CbiE, T, and C were all overproduced in E. coli and purified by nickel affinity column 
in the glovebox. Cobalt precorrin-6b was incubated with 400 µM allyl-SAM and CbiE 
overnight. The following morning 1 mM SAM was added, to flood the reaction with SAM, 
along with CbiT and CbiC to try to produce C5-allyl cobyrinic acid.  
The incubation of allyl-SAM and CbiE was attempted many times, potentially 
producing C5-allyl cobalt precorrin-7. However, due to the instability of C5-allyl cobalt 
precorrin-7 the production of intermediate was not confirmed by HPLC-MS. Subsequent 
incubations with CbiT and CbiC resulted in the production of extremely low yields of a 
different corrinoid (Figures 3.3.2.1). The compound detected is a corrinoid as it expresses a 
corrin-like UV absorbance (Figure 3.3.2.1) with a characteristic peak around 350 nm and two 
around 490/ 510 nm. However, it is not C5-allyl cobyrinic acid, which has a mass of 963.3 
m/z, as it has a mass of 923.3 m/z. This corresponds to the mass of cobalt precorrin-7 where 
the C12 position is decarboxylated and the C15 position is methylated. 
The failure to produce C5-allyl cobyrinic acid, combined with the temperamental 
nature of all the assays, led to the conclusion that the Early insertion pathway, despite the 
benefits of cobalt containing intermediates, is not the best pathway for analogue synthesis. 
Therefore, the late insertion pathway was investigated for synthesis potential. 
 
 
Figure 3.3.2.1: HPLC-MS data for the synthesis of C5-Allyl-Cobyric acid using the Early insertion 
pathway. A: The HPLC trace for the C5-allyl cobyrinic acid reaction at 450 nm. There are many peaks and the 
sample is not clean so an extracted ion chromatogram (EIC) was taken, shown below, using the mass of the 
predicted C5-allyl cobyrinic acid. However, there are no mass peaks corresponding to the theoretical mass of the 
C5-allyl cobyrinic acid. B shows the UV spectrum at 21.2 minutes and the corresponding mass spectra. Although 
the mass of C5-allyl cobyrinic acid, 963.3 m/z, is not clear in the mass spectra, the characteristic cobalamin UV 
peaks at 352 nm is present and the 494 nm peak is close to the 510/530 nm peaks. The shift to 488 nm may be 
caused by   DTT so this compound is likely to be a corrinoid. However, the m/z of 923.3 corresponds to cobalt 
precorrin-7 where C5 is unmodified (inset). 
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3.4 Late insertion (aerobic) pathway 
 The late insertion pathway was elucidated in the early 1990s in Pseudomonas 
denitrificans (Blanche et al. 1995) and the naming of the enzymes is therefore specific for this 
organism. This pathway was characterised before the Early insertion pathway was elucidated. 
The Late insertion pathway incorporates the cobalt ion after the first amidase reaction, into 
HBAD. Therefore, the cobalt has to be inserted after the C5 modification has taken place. 
Two significant benefits of the late insertion pathway are that the proteins are a lot easier to 
work with recombinantly in E. coli, and the later intermediates are oxygen stable, so they can 
be manipulated on the bench instead of in an anaerobic chamber. 
3.4.1 Making the substrate: Precorrin-7 
 The key intermediate for modification at the C5 position in the late insertion pathway 
is precorrin-7. This intermediate can be synthesised recombinantly in vivo in E. coli through 
the expression of CobA, I, G, J, M, F, K, LC, (Figure 3.4.1.1, A, inset) and harvested from the 
bacterial pellet. The proteins were coproduced with CobE which binds precorrin-7 in the E. 
coil. After growth, the precorrin-7 was purified from the lysed cells by binding it to a 
diethylaminoethyl (DEAE-Sephacel®) column followed by a C18 column, as detailed in 
Chapter 2, 2.5.5 (Figure 3.4.1.1). The plasmid containing all of the necessary genes was 
provided by Dr Evelyne Deery.  
 
 
Figure 3.4.1.1: The HPLC and MS data of purified precorrin-7 and the plasmid used to make it. A: The 
UV trace of precorrin-7 at 400 nm. Both peaks represent precorrin-7, but only the first (13.2 minutes) mass 
spectra data is shown (B). The mass, 867.4134 m/z is exactly what was expected. The large plasmid containing 
all the genes to recombinantly produce precorrin-7 is shown inset in A. CobLc indicates it is just the C-terminus 
that is present, whilst CobEHis indicates that the protein has a hexahistidine tag, which is used to purify the 
precorrin-7 bound to CobE on a nickel affinity column. AmpR encodes ampicillin resistance and ori shows the 












3.4.2 The synthesis of C5-allyl-HBA 
 The strategy for ananlogue synthesis using the Late insertion pathway intermediates 
and enzymes is shown in Figure 3.4.2.1. The synthesis of C5-allyl-HBA firstly requires the 
transformation of precorrin-7 into C5-allyl-precorrin-8 by incubating precorrin-7 with allyl-
SAM and CobL. C5-allyl-precorrin-8 is then incubated with CobH to generate C5-allyl-HBA.  
C5-allyl-precorrin-8 less is stable than C5-allyl-HBA, so CobL and H were incubated together. 
This reaction has a clear colour change (Figure 3.4.2.2) caused by the shift in the macrocycle 
double bond conjugation instigated by CobH. The T85A mutant of CobH was found to give 
higher yields of C5-allyl-HBA than the wild type enzyme. This increase in activity likely 
reflects an improved ability of the substrate to be accommodated within the active site. To 
demonstrate this clearer, the T85A mutant was crystallised in the presence and absence of its 
product. 
 
Figure 3.4.2.1: The strategy for synthesising C5-allyl analogues using Late insertion pathway 
intermediates. The purified precorrin-7 can be incubated with CobL and allyl-SAM to specifically modify the 
C5 position, alongside incubation with CobH to migrate the C11 methyl group to C12. The a, b, c, d, e, and g 
sidechains are amidated by CobB and CobQ (from A. vinosum) in another in vitro incubation to produce C5-




Figure 3.4.2.2: C5-allyl- HBA HPLC-MS data and the colour change from precorrin-7. A: The colour 
change which occurs during the incubation of CobL and CobH from precorrin-7 (left) and C5-allyl- HBA (right). 
B: The UV trave aat 328 nm showing two peaks for C5-allyl-HBA. Both peaks have the expected mass of C5-
allyl-HBA, 907.4 m/z. The UV spectra have changed from 391 nm to have maxima at 328 nm and either side of 
500 nm, characteristic of cobalt-less corrins. 
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3.4.3 The crystal structure of CobH (T85A) with C5-allyl-HBA 
 A crystal structure of the T85A CobH mutant will not only give insight into the 
reasons this mutation is more efficient for work with analogues, but the co-crystal will 
confirm the structure of the C5-allyl-HBA analogue too. In order to form crystals of the R. 
capsulatus CobH (T85A) mutant it was overproduced in E. coli BL21 (DE3) with a hexa-
histidine tag and purified on a nickel affinity column as described in Chapter 2, 2.4.1. The 
most concentrated elutions were pooled and concentrated further using a 15 mL protein 
concentrator (Millipore) to 1 mL of 57.3 mg mL-1. This millilitre was further purified on the 
FPLC (fast protein liquid chromatography) machine using a size exclusion column to remove 
any aggregates. The most concentrated elution from the FPLC was 31.5 mg mL-1, or 1.3 mM 
of protein. In an earlier crystallisation trial 14 mg mL-1 of protein was used, so this elution 
was diluted to 15.75 mL-1 either in buffer (20 mM Tris pH 8 containing 100 mM NaCl) for 
the apo-protein or with 1.3 mM of allyl-HBA for the holo-protein. This gives a 1:1 ratio of 
CobH (T85A): allyl-HBA concentration. Both of these were used in the hanging drop vapour 
diffusion experiments on siliconised cover slips (Hampton research) in 24-well XRL plates 
(Molecular Dimensions Ltd.), as described in Chapter 2.5.6, with two drops per condition: 
one apo-protein, one holo-protein. Structure screen 1TM (Molecular Dimensions Ltd.) was 
used to identify conditions that either produced crystals or crystalline precipitant. These trays 
were incubated aerobically at 20 °C and checked regularly for crystal growth. 
The condition from structure screen 1 which produced the best crystals consisted of 
0.1 M sodium cacodylate pH 6.5, 18 % w/v of polyethylene glycol (PEG) 8000 with 0.2 M 
calcium acetate hydrate as the salt. This condition was optimised by changing either the 
concentration of calcium acetate hydrate and PEG 8000, or adding volatile compounds to the 
well (Appendix A.4). The concentration of the protein was halved to 7 mg mL-1. These 
optimisation trays were also incubated aerobically at 20 °C. The condition in the custom 
screen which yielded the best crystals was 20 % PEG 8000, 0.2 M calcium acetate hydrate, 
0.1 M sodium cacodylate pH 6.5 with 20 % methanol in the well. An arm was isolated from 
the apo-crystal (Figure 3.4.3.1, A) and the whole co-crystal was taken for diffraction (Figure 
3.4.3.1, B). This was achieved by scooping the crystal up on a loop, dipping it into cryo-
protectant and flash freezing in liquid nitrogen. The initial hit screen was checked again and a 
diffraction quality crystal was found in condition 3: 0.2 M ammonium sulphate, 0.1 M sodium 
acetate, 25 % PEG 4000. This was also picked and frozen in its own cryo-protectant. The 
cryo-protectant was the same as the well condition, minus the methanol in the case of the 





optimised condition, with 20 % glycerol added (McFerrin and Snell 2002). This serves to 







 All of the data were collected at Diamond Light Source (Oxfordshire, UK) in 
collaboration with Prof. David Brown (University of Kent/ Argenta, Charles River) on the 
IO4-1 beamline using an Pilatus 2M (289x254 mm2) detector. The data was auto-integrated 
and scaled using the Xia2 package  using XDS (X-ray data software) and XSCALE (3dii) at 
the beamline (Winter and Waterman 2012). The apo-crystal diffracted to 1.2 Å and the co-
crystal diffracted to 1.6 Å. They both belonged to space group C 1 2 1 which is the same as 
the published structure of R. capsulatus CobH co-crystallised with HBA (PDB 4AU1) (Deery 
et al. 2012). This crystal was solved in the Warren Lab (Deery et al. 2012). The parameters of 
the collected data were similar to the published data (Table 3.4.3.2, apo-crystal data in 
Appendix A.5). As there is only one amino acid substitution between this solved wild-type 
CobH and the T85A mutant, instead of molecular replacement, the initial model was 
generated by refining the dataset in Refmac5 against 4FDV (Murshudov et al. 1997). This 
model was further refined using Refmac5 in the CCP4i suite and manual model improvement 
was performed in Coot to produce the final model (Murshudov et al. 1997; Winn et al. 2011; 






Figure 3.4.3.1: CobH (T85A) crystals. A: The apo-protein, the arm of which 
was broken off (circled) for diffraction. B: A few of the co-crystals which 
formed, some of these were frozen to be taken for diffraction. 






Table 3.4.3.2: Comparison of the mutant-allyl-HBA co-crystal data collected to the 
previously published wild type-HBA 
 
 The data used in Table 3.4.3.2 for the wild type crystal complex are a combination of 
the data published in the paper and online in the protein database (PDB) (Deery et al. 2012). 
The final refinement statistics are shown in Table 3.4.3.3. 
 
Table 3.4.3.3: The final refinement statistics of the mutant-allyl-HBA co-crystal data  
 Final 
R factor 0.1723 
R free 0.2384 
Rms Bond Length (Å) 0.0304 
Rms Bond Angle (°) 2.7310 
Single wavelength anomalous dispersion/diffraction (SAD) 
 
Co-crystal CobH (T85A) allyl-
HBA 
Co-crystal CobH HBA 
(4FDV) 
Wavelength (Å) 0.92819 0.97630 
High resolution limit 1.57 (7.02 - 1.57) 1.68 
Low resolution limit 48.38 (48.38 - 1.61) 34.7 
Completeness 98.8 (91.6 - 99.7) 97.4 
Multiplicity 3.3 (3.4 - 3.2)  4.1 (redundancy)  
I/sigma 6.3 (12.6 - 1.3) 16.9 (6.6) 
Rmerge 0.237 (0.249 - 0.899) 0.059 
Anomalous completeness 85.8 (87.3 - 81.9)  
Anomalous multiplicity 1.5 (1.9 - 1.7)  
Unit cell dimensions: a (Å) 71.230 70.250 
b (Å) 66.630 66.030 
c (Å) 48.920 48.480 
Į 90.000 90.000 
ȕ 99.030 98.980 
Ȗ 90.000 90.000 
Spacegroup C 1 2 1 C 1 2 1 
Sfcheck twinning score 2.13 Data does not appear twinned 
 





The Ramachandran plot for this data is shown in Figure 3.4.3.4 and Table 3.4.3.5. 
Ramachandran plots show the distribution of the residues in the solved crystal structure 
against the theoretically favoured regions. Only one residue, glycine 161, lies outside the 












Table 3.4.3.5: The Ramachandran Plot data  
Residues Number Percentage (%) 
In preferred regions 195 97.99 
In allowed regions 3 1.51 
Outliers 1 0.50 
Figure 3.4.3.4: The Ramachandran plot of the final co-crystal model.  
Of all the residues 98 % are in preferred regions, 1.5 % are in allowed 
regions and 0.5 %, one residue GLY 161 is an outlier shown in the red 
triangle on the plot. This high level of residues in the preferred regions 
validates the model of the CobH (T85A) protein which validates the 
structure if the ligand bound, thereby confirming the structure of allyl-
HBA. Plot was generated in Coot (Emsley et al. 2010). 





The high number of residues in preferred regions validates the final model of CobH 
(T85A) and confirms the structure of allyl-HBA. T85A CobH is a dimer, as is wild type 
CobH, and two molecules of allyl-HBA are bound within the dimer (Figure 3.4.3.6). The 
active site pocket is located around the dimer interface and is composed of residues from both 
of the CobH monomers in the complex (Figure 3.4.3.6, A). The resulting substrate binding 
pocket is very tight and there is very little space in the vicinity of the C5 position (Figure 
3.4.3.6, B). The reason the T85A mutant was more efficient than the wild type CobH when 
synthesising C5-allyl-HBA is likely to be due to there being more space in the active site 
around the C5 position. The T85A CobH structure shows that allyl group is bent acutely 
round in order to fit into the binding pocket, even though the substitution of alanine for 
threonine has already increased the space available (Figure 3.4.3.7). In all the Figures with 




FLgure 3.4.3.6: Allyl-HBA in the binding cleft of CobH(T85A).The close fitting dimer 
of CobH (T85A) can been seen in A, inset, with one dimer predominantly in blue and the 
other in green. B is a zoomed in image of the black box in A showing the cramped 










Figure 3.4.3.7: The binding pocket of wildtype CobH (PDB:4FDV) and CobH (T85A) complexed with 
the natural product, HBA, or analogue, C5-allyl-HBA. A and B show the wild type CobH, whilst C and D 
are CobH (T85A), as labelled on the figure. The mesh represents the protein surface at the THR85 or ALA85 
residue. As seen in B, the THR85 mesh clashes with the allyl group (black), modelled in using PyMol 
(Delano 2002), however it does not in the T85A mutant, D. The wild type CobH is coloured with carbon in 
orange, nitrogen in blue and oxygen in red. CobH (T85A) has carbon in yellow, nitrogen in blue and oxygen 
in red. HBA shows carbons in grey, nitrogen in blue and oxygen in red, with the C5 carbon and methyl group 
in cyan. In C5-allyl-HBA carbon is cyan, nitrogen is blue and oxygen is red, with the allyl group in black. 
 The threonine residue in wild type CobH is shown in the structure in panels A and B 
(Figure 3.4.3.7), PDB reference 4FDV. The mesh which indicates the predicted surface of this 
residue shows a clash with the allyl group whereas the alanine 85 mutation (Figure 3.4.3.7, C 
and D) allows the allyl group to fit. The contortion of the allyl group suggests it would fit 
better if given more space and further mutations will be necessary if transferring a larger 
group to the C5 position.  
The presence of the allyl group at the C5 position confirms the structure of the C5-
allyl-HBA (Figure 3.4.3.8), the first of the novel cobalamin analogues. 
A B 
C D 















3.4.4 Amidation of the sidechains 
There are two amidases which amidate all of the propionate and acetate sidechains of 
the corrin, except for sidechain f. The first reaction, catalysed by CobB, uses glutamine as the 
amide donor to amidate sidechains a and c (Chapter 2, 2.5.7). These are the first two of the six 
amidations that occur around the macrocycle. This reaction also requires ATP, 8 mM, and 
magnesium chloride, 20 mM, and was incubated overnight at 37 °C. 
The reaction progressed efficiently to form C5-allyl-HBA-a,c-diamide (C5-allyl-
HBAD) (HPLC-MS data Figure 3.4.4.1). The other four amidation reactions are catalysed by 
CobQ which, in R. capsulatus, requires cobalt insertion, reduction of the metal ion and 
adenosylation before it will amidate the sidechains. To avoid cobalt insertion at this stage the 
CobQ from A. vinosum was used as it has no requirement for cobalt or the adenosyl upper 
ligand, even though there is hardly any sequence discrepancy between the two CobQs 
(Appendix A.9).  
The reaction assay was set up much like the CobB reaction, and the A. vinosum CobQ 
amidated the b, d, e and g sidechains, producing a completely new intermediate (even 
excluding the allyl group) C5-allyl-HBA-a,b,c,d,e,g-hexamide (C5-allyl-HBAH)  (Figure 
3.4.4.1). The structure of this intermediate was confirmed by NMR (Figure 3.4.4.1 with 
HPLC-MS data) (Additional data in Appendix A.11). Subsequent modifications to C5-allyl-
 Figure 3.4.3.8: The structure of C5-allyl-HBA. This was 
confirmed by X-ray diffraction in the CobH (T85A) protein crystal. 
Carbon is shown in cyan, nitrogen in blue and oxygen in red. 









Figure 3.4.4.1: HPLC-MS data for C5-allyl-HBAD and C5-allyl-HBAH as well as C5-allyl HBAH NMR 
data. A: Top top panel shows C5-allyl HBAD trace with the corresponding UV absorbance and MS. The mass is 
the expected value of 907.4.  C5-allyl HBAH is on the lower panel and elutes earlier than C5-allyl HBAD. 
Again, the mass was the expected 901.5. This sample of C5-allyl HBAH was also run on the NMR (B), 











3.4.5 Extending the linker and cobalt insertion  
To extend the allyl group a thiol-ene reaction was implemented (Figure 3.4.5.1) with 
cysteamine as the donor molecule and VA044 (chemical name 2,2'-Azobis[2-(2-imidazolin-2-
yl)propane]dihydrochloride) as the radical initiator. This left the C5 group with a terminal 
amine which reacts with succinimidyl ester groups on commercial fluorophores (Wang et al. 
2011) (Chapter 2, 2.5.8).  
 The extension of the allyl group gave rise to C5-thioamine-HBAH (HPLC-MS data in 
Figure 3.4.5.2). This intermediate analogue was then used in the cobalt insertion reaction. The 
chemical insertion method was used. The intermediate was incubated with cobalt chloride 
 
Figure 3.4.4.2: Strategy for chemical modifications to C5-allyl-HBAH for fluorophore attachment. The 
allyl can be extended using cysteamine to give a primary amine at the C5 moiety. The cobalt can then be inserted 
into the macrocycle and a fluorophore, in this instance BODIPY-TR-X succinimidyl ester can be attached. 
Figure 3.4.5.1: The thiol-ene reaction mechanism used to extend the allyl group at C5. The 
attachment of cysteamine to the C5 allyl results in a terminal primary amine which can be exploited for 
further modifications. VA044 is the radical initiator used to form the thiol radical. 





hexahydrate and ammonium hydroxide, and then stirred for 1.5 hours at 80 °C in the dark in 
an anaerobic glove box at < 2 ppm oxygen (Moore, Biedendieck, et al. 2013; Kräutler 2006) 




Figure 3.4.5.2: HPLC-MS data for C5-thioamine-HBAH 
and C5-thioamine-cobyric acid as well as C5-thioamine-
cobyric acid NMR data. A: Top panel shows C5-
thioamine-HBAH trace with corresponding UV and mass 
spectra. The m/z is one more than the expected 977.5. The 
bottom panel of A is C5-thioamine-cobyric acid with the 
UV and mass spectra. It is important to note the shift of 
maxima from 328 nm to 352 nm. This is caused by the 
incorporation of cobalt into the macrocycle. The NMR data 
in B confirms the structure of this new analogue C5-
thioamine-cobyric acid, in particular the extension of the 
allyl group at C5 and the incorporation of cobalt. 
3.4.6 Attaching the fluorophore 
Once the allyl group had been extended to a primary amine and the cobalt inserted, the 
C5-thioamine-cobyric acid was ready for fluorophore conjugation. It is also possible to attach 
the lower loop at this stage but this was not done as many cobalt containing intermediates of 
cobalamin are recognised by the uptake proteins of different organisms regardless of the 
presence of the lower loop (Nielsen et al. 2012; Fedosov et al. 2007; Lildballe et al. 2012). 
The fluorophore conjugate cobyric acid analogues can be traced in vivo upon uptake, and the 










fluorescein (Figure 3.4.6.1 A,  HPLC-MS data in Appendix A.15), but this photobleached 
quickly (see Chapter 4, 4.3 E. coli) so BODIPY® TR-X  and Oregon green® 514 nm cobyric 
acid analogues were also synthesised (Figure 3.4.6.1 B) as they are known to be more photo-
stable (Hinkeldey et al. 2008). 
The C5-fluorescein cobyric acid was tested for recognition in vivo on a bioassay plate. 
This was done by dotting the analogue on a S. enterica AR3612 bioassay plate (Figure  
3.4.6.2) (Raux et al. 1996). This S. enterica has both cysG and metE genes deleted. The metE 
gene encodes the cobalamin independent methionine synthase protein, so the deletion of metE 
means S. enterica relies on the cobalamin dependent metH for methionine synthesis making 
the growth dependent on cobalamin (or exogenous methionine). The cysG gene encodes the 
HQ]\PHUHVSRQVLEOHIRUWKHFRQYHUVLRQRIXUR¶JHQ,,,WRSUHFRUULQ-2, the first committed step 
 
Figure 3.4.6.1: Strategy for the attachment of the fluorophore. A shows the formation of the peptide 
bond linking the fluorescein to the cobyric acid analogue to synthesise a fluorescent analogue. B contains 
the two other cobyric acid analogues: Oregon-green on the left and BODIPY on the right. They were 
both synthesised in the same way as shown in panel A. 





in cobalamin biosynthesis (Figure 1.2.1.1), deletion of this means S. enterica cannot produce 
its own cobalamin. The first cobalamin intermediate that the S. enterica cobalamin transport 
proteins can take up is cobyric acid, which it can convert to cobalamin. Therefore, S. enterica 
AR3612 is dependent on cobalamin intermediates from cobyric acid onwards for growth 
(Raux et al. 1996). If the S. enterica in the agar grows around the dot of the analogue then it 
can not only take the analogue up, but can convert it into an active cofactor for MetH, the 
cobalamin dependent methionine synthase. The reason S. enterica is in the agar is because it 










The samples were dotted on to the plate in 10 µL drops, and incubated overnight at 
37 °C. Figure 3.4.6.2 shows that the fluorescein analogue is taken up by S. enterica and 
facilitates its growth. The lower left spot is the C5-allyl cobyric acid which supports growth 
more effectively than the C5 fluorescein equivalent. The 1 µM cobalamin standard is the 
lower right spot. There is a clear decrease in either recognition of the C5 analogues or 
utilisation in vivo compared to the cobalamin standard, which is less concentrated than any of 
the analogues and yet induces a larger area of growth. 
3.5 Discussion 
The specific modification of the C5 position using a combination of an allyl-SAM 
analogue and the C5 methyltransferase enzyme works well, resulting in the synthesis of C5 
analogues of cobyric acid. However, the Early insertion pathway was not viable. The 
Figure 3.4.6.2: S. enterica bioassay plate 
grown with analogue intermediates S. 
enterica bioassay plate showing the growth 
induced by the presence of C5-fluorescein 



















substrate intermediate, cobalt precorrin-6b, was difficult to synthesise and there is no proof 
that C5-allyl analogues were made. The HPLC-MS data shows that a un-allylated cobalt 
precorrin-7 was synthesised. This intermediate has the C12 position decarboxylated, a 
reaction catalysed by CbiT which also methylates the C15 position. Therefore, this 
intermediate is likely to have the C5 position undecorated. This indicates that the CbiE 
protein may not be active in the incubation, or unable to use allyl-SAM as a donor molecule. 
This was not the only issue with using the Early insertion pathway to synthesise analogues. 
The main issue was the instability of the intermediates used and produced. This meant that 
analysis and confirmation of the products on the aerobically run HPLC-MS was impossible. 
Due to these problems the Late insertion pathway was investigated. 
In the Late insertion pathway the recent discovery that the C15 methylated, C12 
decarboxylated intermediate precorrin-7 could be overproduced revolutionised this research 
(Deery et al. 2012). The C5 position could now be specifically targeted for allylation by CobL 
and allyl-SAM. The following methyl migration reaction, catalysed by CobH, was improved 
by the T85A mutation. This mutation was shown in the crystal structure to increase the space 
within the binding pocket around the C5 position, thereby allowing the allyl group to fit easier. 
The allyl group was highly bent to fit into the enlarged active site, which means that this 
reaction can be improved further by expanding the active site. The crystal structure also 
confirmed the presence of the allyl group on the C5-allyl-HBA. The amidation reactions 
catalysed by CobB and CobQAv worked efficiently to produce C5-allyl-HBAH. The structure 
of this was confirmed by NMR which showed clear peaks corresponding to the six amides 
and the allyl group. The allyl was extended using cysteamine to give a terminal amine which 
can react with many chemicals. Cobalt was chemically inserted into the macrocycle of this 
thioamine analogue. The one drawback of using this pathway was this need for subsequent 
cobalt insertion as there is a significant loss of material, but this also meant that the (cobalt-
less) intermediates produced were much more stable than those of the Early insertion pathway.  
The fluorophores were attached to the thioamine linker to complete the cobyric acid 
analogue synthesis. This reaction and the cobalt insertion reaction resulted in multiple 
products and the desired analogue had to be purified by preparative HPLC. The biological 
activity of these analogues was confirmed on bioassay plates containing a cobyric acid 
dependent strain of S. enterica. The C5-fluorescein cobyric acid analogue supported the 
growth of S. enterica. This proved that the analogue was recognised by the S. enterica 





cobalamin uptake proteins, and converted into functional methyl-cobalamin cofactors in vivo, 
which were subsequently used by MetH to produce methionine.  
These fluorescent analogues can be used to image the uptake and localisation of 
FRE\ULFDFLGLQEDFWHULDDQGLQKLJKHURUJDQLVPVDVZHOO&REDOWȕOLJDQGIOXRURSKRUH
conjugates of cobalamin have been imaged in human cells, but C5 analogues have never been 
made before (Shell and Lawrence 2015). These C5 analogues allow investigations into the 
earlier intermediates of the pathway as well as cobalamin. In the next chapter these analogues 
are imaged in various organisms, something that has never been done before. 
 








recognition of cobalamin 
analogues in a variety of 
organisms 
  






Cobalamin is an essential vitamin for many organisms, such as humans, but higher 
plants and fungi do not require it (Croft et al. 2005; Moore and Warren 2012; Helliwell et al. 
2011). However there is evidence that plants, for example lettuce and soya beans, can absorb 
exogenous cobalamin (Watanabe et al. 2013). There is thus a need to confirm cobalamin 
uptake as opposed to bacterial contamination and hence L. sativum (garden cress) and A. 
thaliana were included in the investigations. Although L. sativum is not a standard model 
organism for plants, it is small and easily cultivatable in the lab alongside A. thaliana. 
Parasitic worms such as D. latum can cause cobalamin deficiency in the host organism 
due to the parasite stealing cobalamin from the host (Allen 2008). A recent paper has shown 
that C. elegans, a nematode worm, displays a cobalamin deficiency phenotype when grown in 
the absence of cobalamin which causes loss of fertility, extended life cycle and a reduced 
lifespan (Bito et al. 2013). However, little is known about cobalamin uptake and distribution, 
and a C. elegans cobalamin transport protein has not yet been identified. Other model 
organisms, such as zebrafish, have cobalamin binding proteins which display similar binding 
affinities to the human transport proteins TCII, IF and HC for cobalamin recognition (Greibe, 
Fedosov, and Nexo 2012). It is likely that C. elegans will behave in a comparable way as 
bioinformatic analyses suggest that 60-80 % of human genes have orthologues in C. elegans 
(Kaletta and Hengartner 2006). C. elegans have two cobalamin-dependent enzymes: MetH 
and MCM, and are easy to nurture in the lab on agar plates with E. coli as their food source, 
but they can also eat other microorganisms (Bito et al. 2013; Corsi et al. 2016).  
The lifecycle of C. elegans at 22 °C is around 3 days long (Figure 4.0.1), with the first 
eggs laid around 60 hours after the nematodes hatch. These eggs can obstruct the internal 
detail around the vulva when imaging the nematodes. Therefore, L4 stage nematodes were 
used for the imaging investigations, as the somatic structures of the nematode have formed 
but eggs within the uterus have not.  
The occurrence of a cobalamin deficiency phenotype, the homology with humans and 
the ease of culturing and imaging all make C. elegans an optimal laboratory model for 
animals, specifically humans. In addition, cobalamin metabolism related human homologue 
gene mutants in C. elegans are available which can provide insight into cobalamin related 
diseases arising in humans (Froese and Gravel 2010). 





Of all the uptake systems associated with cobalamin absorption, the E. coli cobalamin 
uptake mechanism has been the best studied in terms of molecular detail (Figure 4.0.2). This 
system allows for the uptake of both complete cobalamin molecules as well as the salvage of 
incomplete corrinoids such as cobinamide (K. Kadish et al. 2003). The outer membrane 
protein, BtuB, has a cobalamin riboswitch upstream of the gene which stops gene expression 
in the presence of cobalamin, limiting the cellular concentrations of corrinoids (Gallo et al. 
2008). E. coli can convert cobinamide into cobalamin, but it cannot convert cobyric acid into 
cobinamide (Figure 4.0.2) even though it can scavenge it (Raux et al. 1996). S. enterica has 
similar cobalamin uptake proteins to E. coli, and can synthesise cobalamin de novo so it can 
complete the cofactor synthesis from any scavenged intermediates (Kanehisa and Goto 2000; 
Kanehisa et al. 2016). 
 
 
Figure 4.0.1: The lifecycle of C. elegans at 22°C. The lifecycle is about 3 days from egg to adult at 
22 °C, illustrating how quickly C. elegans grows. Most of the animals imaged in the results presented in 
this chapter are L4 stage molts because they are fully developed but without any eggs. This allows for 
clearer imaging of internal structures. Reproduced with permission from WormAtlas (Altun and Hall 
2009b). 






The aims set out for this chapter were: 
1. To compare the molecular recognition/ interference of the fluorophore analogues on 
the uptake mechanism in S. enterica. 
2. To compare the uptake of C5 cobyric acid analogues to the ribose linked cobalamin 
analogues in E. coli and C. elegans. 
3. To ascertain where the corrinoid analogues localise in C. elegans. 
4. To examine C5 cobyric acid analogue and ribose linked cobalamin analogue uptake in 







Figure 4.0.2: The cobalamin uptake system and biosynthesis pathway enzymes in E. coli. A: BtuB 
recognises corrinoids on the extracellular surface and transports them into to periplasm via a TonB 
mechanism. BtuF then binds the periplasmic corrinoids and forms a complex with BtuCD on the inner 
membrane. This initiates the release of the corrinoid from BtuF and allows BtuCD to transport it to the 
cytoplasm.  Reproduced with permission from (Kräutler and Puffer 2012). B: The boxes in green highlight 
the genes present in E. coli. It has all the enzymes necessary to convert cobinamide into various 
cobalamins, starting with BtuR, the enzyme responsible for adenosylating cobinamide, but has none of the 
earlier biosynthesis enzymes. 






4.2 Chemical synthesis of ribose linked cobalamin analogues  
Having made a number of cobalamin analogues, the natural next step was to 
investigate how, or if, these compounds are taken up in different biological systems. The 
organisms listed above may not take up C5-cobyric acid intermediate analogue; therefore 
cobalamin ribose analogues were made in the same way as previously reported (Lee and 
Grissom 2009; Pathare et al. 1996). These ribose linked cobalamin analogues have been 
shown to bind to cobalamin transport proteins, and allow a comparison between cobyric acid 
and cobalamin analogue uptake (Clardy et al. 2011). 
4.2.1 Chemical synthesis of BODIPY® TR-X ribose linked cobalamin  
 The chemical synthesis of ribose linked cobalamin analogues was performed as 
previously reported (Lee and Grissom 2009; Pathare et al. 1996). Firstly CDI (1,1-carbonyl 
diimidazole) coupling of 1,2-Diaminoethane on commercial vitamin B12 (Sigma) formed a 
SULPDU\DPLQHRQWKH¶K\GUR[\ORIWKHULERVH7KHDWWDFKPHQWRIWKHIOXRURSKRUHWRWKH
primary amine is the same reaction as for the C5 analogues (Figure 4.2.1.1). The resulting 
product was dried in a vacuum centrifuge and resuspended in water before HPLC purification.  
 
Figure 4.2.1.1: The chemical synthesis of BODIPY® TR-X ribose linked cobalamin. The experiment was 
repeated with Oregon green® 514 as well. 





 The mass was confirmed by HPLC-MS (Figure 4.2.1.2). The recognition of ribose 
linked cobalamin analogues by IF, HC  and TCII, the human uptake proteins, has been 
confirmed in previous studies (McEwan et al. 1999; Clardy et al. 2011). 
 
4.2.2 Chemical synthesis of Oregon green® 514 ribose linked cobalamin 
 The Oregon green® 514 ribose linked cobalamin (Figure 4.2.2.1, A)  was synthesised 
in the same way as the BODIPY® TR-X analogue, but using Oregon green® 514 instead of 
BODIPY® TR-X as the fluorophore conjugate (Figure 4.2.1.1). The resulting product was 
 
Figure 4.2.1.2: HPLC-MS of BODIPY TR-X® ribose linked cobalamin (BOB12). This 
sample was run before purification using preperative HPLC. Panel A is the absorbance 
exhibited by the analogue at 355 nm. The m/z and the UV absorbance correlate exactly with the 
predicted mass of the BODIPY cobalamin analogue, and the absorbance peaks of cobalamin 
(~355 nm) and BODIPY (~588 nm) are present. 
B 
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dried in a vacuum centrifuge and resuspended in water before HPLC purification, and the 
mass was confirmed by HPLC-MS (Figure 4.2.2.1). 
 
Figure 4.2.2.1: The structure of ribose linked Oregon green® 514nm cobalamin (OGB12) and the 
HPLC-MS data. This sample was run after purification using preparative HPLC. Panel A shows the 
absorbance exhibited by the analogue at 355 nm, with the structure of OGB12 inset. The m/z and the UV 
absorbance also correlate exactly with the predicted mass of OGB12 and the absorbance peaks of 











4.3 Recognition and uptake of C5-cobyric acid and ribose linked cobalamin 
analogues in Salmonella enterica 
 The BODIPY® TR-X and Oregon green® 514 cobyric acid analogues and the 
equivalent ribose linked analogues were tested for uptake into S. enterica via the cobalamin 
uptake system. This was done by applying the analogues on to S. enterica containing bioassay 
plate. This S. enterica (AR3612) has both cysG and metE deleted. The metE gene encodes the 
cobalamin independent methionine synthase, so the deletion of metE means S. enterica relies 
on the cobalamin-dependent MetH protein for methionine synthesis, making the growth of the 
S. enterica dependent on cobalamin. The cysG gene is responsible for the conversion of 
XUR¶JHQ,,,WRSUHFRUULQ-2, the first committed step in cobalamin biosynthesis (Chapter 1, 
Figure 1.2.1.1), so S. enterica cannot produce its own cobalamin. The first cobalamin 
intermediate that the S. enterica can take up is cobyric acid, which it can convert to cobalamin, 
therefore the S. enterica AR3612 is dependent on cobalamin intermediates from cobyric acid 
onwards for growth (Raux et al. 1996).  
Each analogue was dotted in 10 µL drops of 5 µM on to the bioassay plate along with 
a 50 nM reference dot of cobalamin (Figure 4.3.1, A). Dots of 10 nM, 50 nM, 100 nM and 1 
µM of cobalamin were placed on another plate. This is the standards plate (Figure 4.3.1, B) 
which is incubated alongside the analogues plate, and is then used to calculate a standard 
curve of the diameter of growth against the concentration of corrinoid provided (Graph 4.3.2). 
The equation of the line is used to calculate the concentration of analogue taken up compared 
to cobalamin. In this equation, x is substituted for the diameter of growth measured and thus y, 
the concentration of analogue, 
can be solved. The 
concentration is normalised to 
the 1 µM reference point on 
the plate. Figure 4.3.1 shows 
that the analogues are 
recognised by S. enterica, but 




Figure 4.3.1: The S. enterica bioassay plate of all the Oregon 
green® 514 and BODIPY® TR-X fluorophore intermediates and 
the cobalamin standards. A: The analogues were dropped at a 5 µM 
concentration, with a reference dot of 50 nM cobalamin. B: The 
cobalamin reference plate which is used to calculate the concentration 
of cobalamin equivalent to the growth facilitated by the analogues by 
measuring the diameter of growth and plotting this against 










The diameter of the whole plate and the diameter of growth with the analogues were 
measured. The diameter of growth was divided by the diameter of the plate to give the size of 
growth in relation to the plate. This was regarded as x and substituted into the equation of the 
line shown in Graph 4.3.2. The equation was solved to give y, the concentration in nM. The 
50 nM cobalamin reference drop was divided by the calculated concentration of the 50 nM 
standard, and the calculated concentrations of the analogues was normalised to this. 
 All of the analogues were 5 µM, 100 times more concentrated than the reference drop, 
but yielded growth spots which represented significantly less concentrated solutions.  
However, it is evident that the analogues are taken up and can be used to synthesise functional 
cobalamin cofactors to support the growth of cobalamin-dependent S. enterica.  
Both of the BODIPY® TR-X analogues facilitate less growth than their Oregon 
green® 514 equivalents and the ribose-linked analogues support more growth than their 
cobyric acid counterparts. This is evident in the diameter of S. enterica rings of growth each 
analogue can induce when the same volume and concentrations are dropped on the bioassay 
plate. Table 4.3.4 shows that the Oregon green® 514 ribose cobalamin supports the S. 
enterica growth equivalent to 180 nM of cobalamin whereas C5- Oregon green® 514 cobyric 
acid is only equivalent to around 37 nM of cobalamin. BODIPY® TR-X ribose cobalamin is 
comparable to around 13 nM cobalamin which is about a third of the C5- Oregon green® 514 
Graph 4.3.2: Relation between cobalamin concentration and diameter of growth on the S. enterica 
bioassay plate. The standard curve generated from measuring the diameter of growth of each standard 
in relation to the diameter of the plate, then plotted against the concentration of cobalamin dotted on to 
the plate. This was used to calculate the concentration of cobalamin equivalent to the growth facilitated 


































cobyric acid, but the C5-BODIPY ® TR-X cobyric acid equates to around 5 nM of cobalamin. 
The discrepancy between the cobyric acid analogues and the cobalamin analogues is likely to 
be because the cobyric acid intermediate must be converted into a functional cofactor before 
growth can occur. The difference between the two fluorophores may be caused by the 
fluorophore itself interfering with either the cofactor synthesis or binding to the cobalamin-
dependent enzymes.  
Table 4.3.4: The concentrations of the C5 analogues calculated using Graph 4.3.2 
4.4 Construction of Escherichia coli overproducing the outer membrane protein 
of the cobalamin transport system  
 Without the btuB plasmid (Figure 4.4.1) in the E. coli cells the analogues are not taken 
up in sufficient concentrations to produce detectable fluorescence (data not shown). This is 
due to a nonsense mutation in the btuB gene in BL21(DE3) which causes early termination of 
translation (Figure 4.4.1). Therefore, to ensure maximum uptake of the corrinoids and 
overcome the riboswitch regulation, E. coli were transformed with pLysS-btuB. These BL21 







Pixels Pix/plate Concentration (nM) 
Normalised 
(nM) 
C5- Oregon green® 514 cobyric 
acid 346 0.14 40.49 37.33 
C5-BODIPY ® TR-X cobyric 
acid 189 0.08 5.17 4.77 
Oregon green® 514 ribose 
cobalamin 466 0.19 195.15 179.93 
BODIPY® TR-X ribose 
cobalamin 268 0.11 14.57 13.43 
50 nM Cobalamin ref 365 0.15 51.94 47.89 
Whole plate 2496 







Figure 4.4.1: The pLysS plasmid containing the E. coli btuB gene and the amino acid alignment of BtuB in 
BL21 (DE3) and JM109. A: On the pLysS plasmid containing the btuB gene (orange) the T7 promoter and 
terminator are in white whilst the chloramphenicol resistance gene, CmR is in green. There is a His tag present at 
the start of the gene which is not on the plasmid map. The T7 lysozyme hydrolyses the T7 RNA polymerase 
SURGXFHGE\WKHDFWLYLW\RIWKHZHDN751$SRO\PHUDVHSURPRWHUĭVKRZQLQZKLWHDERYe the lysozyme, 
but it is still leaky enough to transcribe and translate the T7 RNA polymerase. B: There is a missense mutation at 
position 162 in the BtuB from BL21 (DE3), but the most detrimental mutation is the nonsense mutation at 
position 58, resulting in an early termination instead of glutamine. Therefore, BL21 (DE3) does not have a native 
functional BtuB. 
4.5 Imaging of uptake of C5-cobyric acid and ribose linked cobalamin analogues 
in Escherichia coli 
To test whether the analogues were recognised by native cobalamin transport systems 
they were incubated with BL21 (DE3) E. coli transformed with pLysS-btuB. This was grown 
in 4 mLs of LB (Luria-Broth, Chapter 2, 2.2.2) with 34 µg mL-1 of chloramphenicol and 
either 6 µM of the C5-fluorescein cobyric acid or 1 µM of one of the Oregon green® 514 
analogues. The cultures were induced with 2 mM of IPTG and left overnight at 37 °C in a 
shaking incubator before imaging. 
The next day the cells were pelleted, and resuspended in LB to wash off any of the 
analogue attached to the surface of the cells. This process was repeated three times. The cells 
were mounted on LB-agarose pads and imaged on an Olympus IX81 widefield microscope 
mounted on ASI stage (Applied Scientific) (see Chapter 2, 2.6.2) using PlanApo 100 x 
OTIRFM-SP 1.49 numerical aperture lens giving a total magnification of 160 x with the 
camera. The GFP filter (488±10 nm excitation/ 530±15 nm emission) was used for the C5-
fluorescein cobyric acid containing cells and the YFP filter (500±10 nm excitation/ 535±15 
nm emission) was used for the Oregon green® 514 analogues. Although this is not the 
maxima for Oregon green® 514, which is excited at 514 nm and emits at 530 nm, it was the 
closest filter available but it means the fluorescence is diminished compared to what it would 
have been if excited at 514 nm. 





  The C5-fluorescein cobyric acid can be seen localising to the cells but the fluorophore 
photobleached quickly (Figure 4.5.1, C). This is why the concentration of the C5-fluorescein 
cobyric acid added to the E. coli culture is six times more than that of Oregon green® 514: to 
allow the camera to image the fluorescence before it bleached completely. No DIC image was 
taken of the cells grown with C5-fluorescein cobyric acid, so there is no overlay, but the 




Figure 4.5.1: Cobalamin ribose linked Oregon green® 514 and C5- Oregon green® 514 cobyric acid and 
C5-fluorescein cobyric acid, internalised by BL21 (DE3) expressing BtuB. All three of the analogues are 
internalised by BL21 (DE3) expressing BtuB which proves that they are all recognised by BtuB and the 
subsequent cobalamin transport proteins, BtuFCD.  Some of the cells are very long indicating stress possibly 
caused by overexpression of BtuB in the membrane. 
BODIPY® TR-X and Oregon green® 514 fluorophores have been shown to be more 
photo-stable and this was observed in the cells grown in the presence of Oregon green® 514 
(Hinkeldey et al. 2008). The Oregon green® 514 analogues were both taken up by E. coli 
(Figure 4.5.1, A and B) but it appears that the C5-cobyric acid analogue is not taken up as 
well in comparison to the cobalamin ribose analogue.   
4.6 Imaging of uptake of C5-cobyric acid and ribose linked cobalamin BODIPY® 
TR-X analogues in Escherichia coli OP50  
 OP50 is the E. coli strain used to feed C.elegans. Due to the broad auto-fluorescence 
around blue/violet spectrum in the nematodes, the BODIPY® TR-X analogues were used as 
the excitation and emission wavelengths avoid any overlap with the autofluorescence. OP50, 
are a uracil requiring mutant of the Berkley strain and have been the food source for C. 
elegans since Sydney Brenner proposed C. elegans as a model organism in the 1970s 
(Brenner 1974; May et al. 2009). As these E. coli are the route by which the fluorescent 
analogues were introduced to C. elegans the cells needed to contain as much fluorophore-
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analogue as possible. To do this, both BtuB and BtuF, which is the E. coli periplasmic 
cobalamin binding protein, were overexpressed in these cells using a pET-BAD vector 
(Figure 4.6.1, A).  
The OP50 was transformed with the pET-BAD btuB btuF plasmid. It was grown for 4 
hours and then induced with 2 % (w/v) L-arabinose. The BODIPY® TR-X analogues and 
controls were added to a final concentration of 1 µM at the same time as the arabinose. Eight 
cultures of OP50 were grown, all with pET-BAD btuB btuF but four were uninduced and four 
were induced. Four different supplements were provided to the two different induction 
backgrounds: the first had BODIPY® TR-X ribose linked cobalamin, the second just 
BODIPY® TR-X, the third had C5- BODIPY® TR-X cobyric acid, and the forth got nothing. 
These were left overnight in the dark at 28 °C in a shaking incubator. The next day the cells 
were pelleted (Figure 4.6.1, B) and resuspended 3 times with LB to wash off any exogenous 
BODIPY® TR-X analogues stuck to the outer cell membrane. These cells were resuspended 
in LB and imaged in the same way as the C5-fluorescein cobyric acid and the two Oregon 
green® 514 analogues. 
 
 
Figure 4.6.1: The pET-BAD plasmid containing the E. coli btuBF genes and the colour of the OP50 pellets 
after three washes with LB. A: The btuBF genes (orange and yellow respectively) in this plasmid are under a 
BAD promoter inducible by L-arabinose (light blue). The BAD promoter was used instead of the T7 promoter 
because it is weaker, resulting in less protein production so the cell membrane should be less stressed. AmpR 
encodes ampicillin resistance. B: The pellet of cells incubated with BODIPY TR-X ribose cobalamin and 
induced have an intense dark blue colour from the BODIPY TR-X, but the equivalent uninduced cell pellet is 
cream, as if there was no supplementation in the media. Therefore, induction is necessary to obtain a high level 
of analogue in the cells for ease of imaging. Cells grown in the presence of BODIPY TR-X alone showed no 
difference between the induced and uninduced backgrounds, and the slight blue seen in the pellets is likely due 










 Figure 4.6.1, B shows the colour of the different pellets after washing the external 
fluorophore analogues off. The blank cultures with nothing added are a normal cream colour, 
the two supplemented with BODIPY® TR-X alone both show the same blue tinge regardless 
of whether the transporters are present or not, this is probably due to the hydrophobic 
BODIPY® TR-X sticking in the bacterial membrane. In contrast, the BODIPY® TR-X ribose 
cobalamin pellet is dark blue in the OP50 which were induced, but a similar cream colour to 
the blanks without induction. The native copies of BtuB and BtuF are present in the OP50 
proteasome so there should be some BODIPY® TR-X ribose cobalamin inside these cells. 
The C5- BODIPY® TR-X cobyric acid cultures looked like the BODIPY® TR-X ribose 
cobalamin (data not shown). 
 The fluorescence microscopy images show that the C5-BODIPY® TR-X cobyric acid 
is taken up into the OP50 when the transport proteins are overproduced (Figure 4.6.2, A). The 
ribose linked BODIPY® TR-X cobalamin is also taken up in the same conditions (Figure 
4.6.2, B). As there is no difference between the cobalamin analogue and the C5-cobyric acid 
analogue this suggests that the position of the fluorophores does not impede uptake or 
recognition. It also proves that E. coli cobalamin uptake proteins can scavenge cobyric acid 
even though they cannot use it (Raux et al. 1996). However, in the un-induced cultures 
(Figure 4.6.2, D and E), neither of the corrinoid analogues were taken up well, with only a 
small percentage of cells fluorescing enough to be visualised. The cultures which were 
supplied with only the BODIPY® TR-X fluorophore showed little difference between 
induced and un-induced backgrounds (Figure 4.6.2, C and F). The slight fluorescence seen in 
the BODIPY® TR-X samples is likely to be due to it sticking in the membrane, or reacting 
with outer membrane proteins, and not washing off.  
 The three induced backgrounds shown in Figure 4.6.2: C5- BODIPY® TR-X cobyric 
acid; BODIPY® TR-X ribose and BODIPY® TR-X fluorophore only were the three used as 









































































































   
 
 
Figure 4.6.2: Cobalamin ribose linked BODIPY® TR-X and C5- BODIPY® TR-X cobyric acid internalised by OP50 E. coli expressing 
btuB and btuF. A: OP50 pET-BAD-btuB btuF incubated with C5- BODIPY® TR-X cobyric acid. B is OP50 pET-BAD-btuB btuF incubated with 
BODIPY® TR-X ribose cobalamin. C is OP50 pET-BAD-btuB btuF incubated with BODIPY® TR-X. The lower panels are the uninduced 
cultures. D is C5- BODIPY® TR-X cobyric acid, E is BODIPY® TR-X ribose cobalamin and F is BODIPY® TR-X. 





4.7 Recognition and localisation of C5- BODIPY® TR-X cobyric acid and BODIPY® TR-X 
ribose cobalamin in Caenorhabditis elegans 
OP50 E. coli saturated with the BODIPY® TR-X analogues were used to seed 
nematode growth medium (NGM) plates (Chapter 2, 2.2.2). The OP50 was transformed with 
pET-BAD-btuBF and grown in 5 mL cultures with 1 µM of BODIPY® TR-X analogue added 
to the media. The plasmid was induced with L-arabinose and incubated overnight at 28 °C in 
the dark. The following day the cells were pelleted and resuspended in 1 mL of fresh LB, then 
pelleted again and so on until the cells had been resuspended three times in fresh LB. The 
final pellet was resuspended in 1 mL of fresh LB and 200 µL of the OP50 culture was 
pipetted on to the centre of NGM agar plates. These plates were left to dry in a sterile culture 
hood for 4 hours and then stored at 4 °C until used. Three L4 nematodes of the N2 Bristol 
strain of C. elegans were transferred on to plates seeded with OP50 grown with either C5- 
BODIPY® TR-X cobyric acid, BODIPY® TR-X ribose cobyric acid, or BODIPY® TR-X 
only. These plates were left for four days at 20 °C and the L4 C. elegans were imaged on a 
confocal microscope. The microscope used in this experiment was the Leica SP8 (Chapter 2, 
2.6.5) at Bristol University. The gut autofluorescence of C. elegans, excitation 405 nm, 
emission 410-505 nm, was used to orientate the nematode (Coburn et al. 2013). All of the 
images were taken using a 20 x lens at 1 x zoom for the whole nematode, and 2.5 x zoom for 
the more detailed images. They were 1024 x 1024 pixels and then further zoomed to 500 x 
500 pixels in the 2.5 x zoomed images shown below.  
The BODIPY® TR-X ribose cobalamin (Figure 4.7.1) fluorescence is localised to 
discrete spots in the head, vulva and tail regions. These rings of fluorescence are not in the 
intestine which suggests that the analogues have been taken up and specifically transported 
into these fluorescent regions. The C5- BODIPY® TR-X cobyric acid did not show much 
fluorescence, only a scant glow at the end of the intestine (Figure 4.7.2). The same is true of 
the BODIPY® TR-X on its own, although this can be seen in the intestinal granules near the 
head (Figure 4.7.3). This proves that the C. elegans cobalamin uptake protein from the 
intestine to the pseudocoelem (discussion Figure 4.9.1) cannot scavenge a cobyric acid 
intermediate. In Figure 4.7.4 these fluorescent areas were expanded in all three conditions to 
show a direct comparison. These six cells to which the BODIPY® TR-X ribose cobalamin 
associates are thought to be the coelomocytes. There is a pair in the head, tail and vulva 
regions. The coelomocytes 3 and 4 in panel A clearly show a ring like structure consisting of 
many smaller spherical compartments. What these compartments correspond to is unknown. 




























Figure 4.7.1: C. elegans given OP50 transformed with pET-
BAD-btuB btuF provided with BODIPY® TR-X ribose 
cobalamin at 1 x zoom. The autofluorescence is shown in cyan 
and the BODIPY® TR-X ribose cobalamin analogue is shown in 
red. The red fluorescence localises to discrete cells in three areas 
behind the head, tail and near the vulva. 
Figure 4.7.2: C. elegans given OP50 transformed with pET-
BAD-btuB btuF provided with C5- BODIPY® TR-X cobyric 
acid at 1 x zoom. The autofluorescence is shown in cyan and the 
BODIPY® TR-X ribose cobalamin analogue is shown in red. 
The red fluorescence is only present at the top of the gut where 
there is a high concentration of E.coli, but nowhere in the C. 
elegans. Therefore is appears that the C. elegans cobalamin 
uptake machinery does not recognise cobyric acid. 


























Figure 4.7.3: C. elegans given OP50 transformed with pET-
BAD-btuB btuF provided with BODIPY® TR-X only at 1 x 
zoom. The autofluorescence is shown in cyan and the 
BODIPY® TR-X ribose cobalamin analogue is shown in red. 
There is no fluorescence for BODIPY® TR-X so the uptake 
seen in figure 4.7.1 is due to the presence of cobalamin. 





4.7.1 Investigating the persistence of the BODIPY® TR-X cobalamin analogue in 
Caenorhabditis elegans coelomocytes 
In order to test how persistent the fluorescence is in the coelomocytes, nematodes 
grown on BODIPY® TR-X ribose cobalamin were transferred to unsupplemented OP50 
plates and imaged at intervals. There is very little time for the L4 nematodes to grow on the 
Figure 4.7.4: C. elegans fed with OP50 containing either BODIPY® TR-X ribose linked cobalamin, 
C5- BODIPY® TR-X cobyric acid, or BODIPY® TR-X zoomed in on the coelomocytes. Panel A 
shows the BODIPY® TR-X ribose linked cobalamin taken up into the coelomocytes (labelled 1 to 6) 
from the gut into discrete structures within the coelomocytes, what these compartments are is unknown. 
Panel B is C5- BODIPY® TR-X cobyric acid and C is BODIPY® TR-X on its own. Neither of these 
conditions shows any internal BODIPY® TR-X fluorescence proving that the C. elegans cobalamin 
uptake machinery does not recognise cobyric acid. The three panels from left to right show the head, 
vulva and tail regions respectively. These are all zoomed in regions of the nematodes shown in Figures 
4.7.1-3, but some of the images have been rotated. The autofluorescence of the gut granules is shown in 
cyan and the BODIPY® TR-X fluorescence in red.  
 





control plates before they mature into adults and become harder to image, therefore L3 worms 
were also transferred. However, after 22 hours even they were adults, which is evident in 
Figure 4.7.1.1. These images were taken on a Leica DM R fluorescence microscope using 
515-560 nm (N2-1) excitation and 590 nm emission filters for the BODIPY® TR-X 
fluorescence, and 456-490 nm (I3) excitation and 515 nm emission filters for 
autofluorescence. 
 The BODIPY® TR-X fluorescence is still present in all six coelomocytes. These are 
fluorescence microscope images so there is no z dimension to take an image stack and 
condense them together to get a clearer image like the confocal. This also means that the 
intensity of the signal is reduced to that of one image and less detail is apparent when 
compared to Figure 4.7.4. However it is evident that the fluorescence in the coelomocytes is 
still present. In Figure 4.7.1.1 eggs can be seen both inside and outside the nematode where 
they were laid prior to being picked for imaging. No fluorescence is observed in these eggs. 
 
Figure 4.7.1.1: Persistence of fluorescence in the coelomocytes. A: The head of worm 1 after being fed un-
supplemented OP50 E. coli for 22 hours, shows the coelomocytes, circled in white, at the side of the head are 
still fluorescing, so the analogues have not been hydrolysed. The vulva coelomocytes are harder to see due to 
the presence of the ova, but there is some fluorescence seen in the overlay which corresponds to the 
coelomocytes. The pair of coelomocytes in the tail are visible too, but could be slightly diminished in 
intensity. It is hard to draw any conclusions about the depletion in fluorescence as the images are a single 
image and not a projection through z as the previous images have been. The red of the coelomocytes are not 
associated with the intestine autofluorescence and do not co-localise. The two fluorescences overlays are 
shown in white, but the coelomocytes only appear red where the BODIPY TR-X® fluorophore is present and 
are therefore not caused by autofluorescence of the gut. These images were taken at 20 x zoom with 300 ms 
exposure. 





4.8 Investigating C5-Oregon green® 514 cobyric acid and ribose linked cobalamin analogue 
uptake in Lepidium sativum and Arabidopsis thaliana  
 In light of suggestions that plants can be cobalamin enriched by fertilising with 
cobalamin containing manure, the uptake of cobalamin into L. sativum, garden cress, was 
tested as part of an outreach programme at a local school arranged by the Warren Lab 
(Watanabe et al. 2013). This work was collated by Dr. Evelyne Deery.  
4.8.1 Cobalamin enrichment in Lepidium sativum 
 The garden cress seeds were sterilised in 10 % (v/v) bleach for 20 minutes, then spun 
and the bleach was pipetted off. The seeds were further washed in 70 % (v/v) ethanol-water, 
and spun before removing the liquid. This ethanol wash was repeated three times. The seeds 
were placed on Murashige and Skoog media containing increasing concentrations of 
cobalamin and grown for one week. Four conditions were used: no cobalamin, 0.1 mg L-1, 1 
mg L-1, and 10 mg L-1$IWHURQHZHHN¶VJURZWKWKHFRW\OHGRQVRIWZRSODQWVZHUHWDNHQ
from each condition and washed 5 times with water. Once the water was removed, P-Per 
(Thermo Fisher) was added to the leaves along with sand, and the mixture was ground for 2 
minutes. This was centrifuged for 3 minutes at 15000 rpm and the lower aqueous phase was 
removed as the sample. The samples were applied to the bioassay plate in 10 µL drops 










Figure 4.8.1.1:  Bioassay plate of 
extracts from the cress grown 
with different concentrations of 
cobalamin supplement. The cress 
appears to take up the cobalamin in 
a concentration dependent manner 
as the concentration of cobalamin 
supplement increases. 









Weight after the wash 
and spin (mg) 




in (pg mg-1) 
0 23 0 0 
0.1 36 0.8 3.3 
1 27 1.125 30.9 
10 23 1.75 712.5 
The diameter of growth on the bioassay plate was used to determine the concentration 
of cobalamin in each extract. This was calculated using a cobalamin standard curve in the 
same way as the S. entrica plates in Section 4.3. The concentration was converted into 
picogrammes and the uptake of cobalamin was calculated per milligramme of cress. 
Cobalamin uptake into the cotyledons increased in a concentration dependent manner with 
increased cobalamin in the media. A 10 fold increase from 0.1 mg mL-1 to 1 mg mL-1 resulted 
in a near-equivalent increase of 3.3 pg mg-1 to 30. 9 pg mg-1 in the cotyledons. However, the 
10 mg mL-1 sample contained around 20 times the cobalamin in the cotyledons compared to 
the 1 mg mL-1 sample. The results were plotted on the Graph 4.8.1.3 on log-log scales which 
gives a straight line of best-fit. This reiterates that the concentration of cobalamin in the 
cotyledons is proportional to the cobalamin added in the medium.  
 
Graph 4.8.1.3:  Graph plotting the cobalamin content of the L. sativum cotyledons against the 
concentration of cobalamin provided in the media. The graph shows that the concentration of 
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4.8.2 Uptake of Oregon green® 514 analogues in Lepium sativum and Arabidopsis thaliana 
The previous experiment shows that cobalamin is taken into the cotyledons. To 
confirm this, and to see if it is accumulated anywhere else in the plant, L. sativum was grown 
with Oregon green® 514 ribose cobalamin and then imaged. The greatest issue with imaging 
plants is the chlorophyll autofluorescence (Figure 4.8.2.1). Oregon green® 514 is excited at 
QPDQGHPLWVDWQPVHH&KDSWHU7KLVLVLQWKHµGDUNUHJLRQ¶RIFKORURSK\OO
fluorescence which allows the Oregon green® 514 to be imaged without too much bleed 
through from the chlorophyll.   
 The seeds of the plants were sterilised in 10 % (v/v) domestic bleach for 20 minutes. 
The bleach was removed with three 70 % ethanol washes followed by the same in distilled 
water. These were placed on Murashige and Skoog media (Chapter 2, 2.2.2) supplemented 
with 0.5 µM of either the Oregon green® 514 ribose linked cobalamin or cobalamin and dried 
around a flame. The glass pots used for the L. sativum were placed in the dark at room 
temperature for 5 days. A. thaliana requires vernalisation so after the seeds were washed and 
placed on the agar, the A. thaliana petri dishes were wrapped in aluminium foil and left in the 
fridge for at least 4 days. They were then exposed to a bright light for 30 minutes to 









On the fifth day of growth the plants were harvested and imaged using Leica TCS SP2 
confocal microscope (see Chapter 2, 2.6.4). The excitation was at 514 nm and emission was 
detected between 525±590 nm. The A. thaliana were imaged as whole plants but the L. 
Figure 4.8.2.1: The absorption and emission spectra of 
chlorophyll. This graph was reproduced with permission from 
Leiper 2010. 





sativum were sectioned at the root, hypocotyl and cotyledon to increase light penetration. No 
part of the A. thaliana plants took up Oregon green® 514 ribose linked cobalamin (data not 
shown). However, L. sativum did (Figure 4.4.2.2, A and C). The Oregon green® 514 ribose 
linked cobalamin is localising to the vacuoles of the cotyledons (Figure 4.4.2.2, C) which 
cannot be seen in the L. sativum when provided with cobalamin only (Figure 4.4.2.2, D). The 
roots did not show any difference in fluorescence between the Oregon green® 514 ribose 
linked cobalamin and the cobalamin sample (Figure 4.8.2.2, A and C). This shows that the 
cobalamin analogue is deposited in the cotyledons and not in any other part of the seedlings. 
The C5-Oregon green® 514 cobyric acid analogue also appears to be taken up into the 
cotyledons (Figure 4.8.2.2, E). However, these images were taken on a different microscope 
(Chapter 2, 2.6.4) with slightly different parameters and should be repeated to confirm that the 
fluorescence is present in the vacuoles and is not due to bacterial contamination. 
 
Figure 4.8.2.2: Confocal microscope images of Oregon green® 514 linked analogue uptake in L. sativum 
cotyledon and root. All of the images shown are in L. sativum. From left to right: The first column has 
cobalamin added to the media, the second has Oregon green 514® ribose linked cobalamin and the last column 
has C5-Oregon green 514® cobyric acid. There is no great difference between the Oregon green® 514 B12 and 
the B12 in the root tip but there is a noticeable difference in the cotyledons. The Oregon green® 514 cobalamin 
fluorescence is clearly localising in the vacuoles of the cotyledons (D) and is not present in the cobalamin 
(vitamin B12) sample (C).  The cotyledons of the seedlings given C5-Oregon green 514® cobyric acid (E) show 
some fluorescence (green) which is within the ring of chloroplast fluorescence (red) which suggests it is also 
localising to the vacuoles of the cotyledons. However, this experiment was conducted on a different microscope 
and needs to be repeated. 
  






 The research reported in this chapter shows that fluorescent analogues of cobalamin 
can be taken up into a range of organisms. Analysis of the cobalamin-dependent S. enterica 
AR3612 bioassay plates demonstrate that the strain can be rescued by the C5 and ribose 
analogues, therefore coenzyme synthesis can be completed so as to facilitate growth on a 
bioassay plate (Figure 4.3.1). However, this growth is poor compared to the cobalamin 
standard which indicates that the presence of the fluorophore is causing a disruption to the 
natural cobalamin metabolism in vivo. There is a possibility that the linker joining the 
corrinoid to the fluorophore can be hydrolysed in vivo but the difference in efficacy between 
the two fluorophore analogues suggest that it is the fluorophore which has caused the varied 
reduction in growth. This infers that the fluorophore is still present on the analogue and has 
not been cleaved. 
E. coli also shows clear uptake and localisation to the cells (Figure 4.5.1 and 4.6.2) of 
all the analogues, regardless of which fluorophore is used or where it is conjugated. This 
confirms that E. coli can recognise cobyric acid and that the position of the fluorophore on the 
corrin ring does not halt uptake. 
In C. elegans, which requires cobalamin, the ribose linked cobalamin analogues 
localised to six distinct cells thought to be the coelomocytes. The function of the 
coelomocytes has not been fully defined but they are thought to be involved in endocytosis 
and coupled with lysosomal degradation (Treusch et al. 2004; Fares and Grant 2002). The 
coelomocytes are not essential as the C. elegans still reproduce after toxin ablation of them all 
(Fares and Greenwald 2001). There is no known cobalamin related reason for the BODIPY® 
TR-X ribose cobalamin to localise to here, but little is known about cobalamin storage and 
transport in C. elegans, and it could be that this is where cobalamin is sequestered until 
required. Alternatively, after the initial uptake of the analogue, the next transport protein 
recognition could be blocked by the presence of the BODIPY® TR-X on the ribose so the 
analogue remains in the pseudocoelom until the coelomocytes endocytose it on the basis it is 
an unnatural substance to the C. elegans. Although the fluorescence in the coelomocytes is 
not affected within 22 hours, it gives no insight into the state of the cobalamin analogue: the 
BODIPY® TR-X may have been cleaved off. Also it is unclear whether the vesicles 
containing the BODIPY® TR-X ribose linked cobalamin within the coelomocyte are 
lysosomes or storage vesicles. In either case, the initial intestinal lumen to pseudocoelom 





(Figure 4.9.1) transporter recognises the BODIPY® TR-X ribose cobalamin analogue. This 
experiment also proves that C. elegans cannot recognise cobyric acid. C. elegans have no 
cobalamin biosynthesis genes and cannot complete cofactor synthesis from earlier 
intermediates. It is therefore unlikely that the uptake proteins will recognise any early 
intermediates of cobalamin synthesis.  
 
Figure 4.9.1: Sections through C. elegans.                                                   
A. Posterior body region. Body wall (outer tube) is separated from the inner tube 
(alimentary system, gonad) by a pseudocoelom.  
B. Section through anterior head. The narrow space between the pharynx and the 
surrounding tissues anterior to the NR (Nerve Ring) can be considered an accessory 
pseudocoelom because the main pseudocoelom is sealed off at the NR level.  
C. Section through the middle of head.  
D. Section through posterior head.  
E. Section through posterior body.  Dorsal nerve cord (DNC); ventral nerve cord (VNC).  
F. Section through tail, rectum area. 
 
The BODIPY TR-X® ribose linked cobalamin analogue must be taken up from the intestine 
into the pseudocoelemic cavity through a cobalamin-dependent transport protein which is 
currently unidentified. 
This figure was reproduced with permission from WormAtlas ©(Altun and Hall 2009b)           
 





Even though plants do not require cobalamin, L. sativum showed uptake of the 
cobalamin in the cotyledons in a concentration dependent manner. Oregon green 514® 
cobalamin analogues were also taken up into the cotyledons where it was stored. This 
transport and storage of cobalamin in plants could be exploited to produce plants with a 
higher nutritional value. 
The lack of uptake in the A. thaliana compared to the L. sativum suggests that, 
although plants do not require cobalamin and are therefore unlikely to have specific uptake 
mechanisms, there appears to be different uptake processes for cobalamin. These are not 
likely to be cobalamin specific but may regulate macromolecule traffic in some plants.  
 















  Little is known about the relationship between M. tuberculosis and cobalamin. It was 
only relatively recently that the cobalamin membrane transporter, BacA, was identified 
(Gopinath, Venclovas, et al. 2013). Bioinformatics analyses has shown that M. tuberculosis 
has cobalamin biosynthetic enzyme candidates for almost the whole pathway (Rodionov et al. 
2003). However, it is still not known whether M. tuberculosis is a facultative scavenger of 
cobalamin, if it can synthesise cobalamin de novo, or scavenge earlier intermediates and 
complete cofactor synthesis. The genome of M. tuberculosis encodes for three cobalamin-
dependent enzymes: MetH, RNR-II, and MCM, none of which appear to be essential (Table 
5.0.1) (see Chapter 1, Section 1.7) (Gopinath, Moosa, et al. 2013).  
Table 5.0.1: Cobalamin dependent enzymes of M. tuberculosis and their independent 
alternatives 
Protein Gene Cobalamin independent 
alternative 
Methionine synthase metH metE 
Ribonucleotide reductase 
class II nrdZ 
Ribonucleotide reductase 
class I 
Methyl malonyl coenzymeA 
mutase 
mutAB Methylcitrate pathway 
 
It has been reported that the expression of the adenosyl-cobalamin requiring RNR-II, 
encoded by nrdZ, is upregulated during dormancy (Gopinath, Moosa, et al. 2013; Boshoff and 
Barry 2005). However, it is not known whether this is for chromosomal integrity upkeep or 
DNA repair upon exit from non-replicating persistence 2 (NRP2) dormancy. NRP2 is the 
second stage of dormancy where oxygen levels are at about 0.06 % saturation. Exit of this 
VWDJHLVWHUPHG³GLVHDVHUHDFWLYDWLRQ´:KHQM. tuberculosis is replicating in a low oxygen 
environment it is reliant on RNR-II enzymes for the production of dNTPs. This upregulation 
of the adenosyl-cobalamin dependent RNR-II is potentially exploitable as a means of 
shepherding cobalamin conjugated drugs into M. tuberculosis either at the reactivation point 
or even during dormancy. 
In order to understand better the relationship between M. tuberculosis and cobalamin 
there is a need to study the roles of these enzymes and their effect on M. tuberculosis. 




The aims set out for this chapter were: 
1. To determine if cobalamin analogues, cobalamin itself or intermediates of cobalamin 
biosynthesis are exogenously taken up by M. tuberculosis. 
2. To ascertain which form of cobalamin M. tuberculosis makes, and if it can synthesise 
it from an earlier intermediate. 
3. To investigate if corrinoids regulate genes via the cobalamin riboswitch. 















5.2 Cobalamin and other Corrinoid uptake in Mycobacterium tuberculosis 
5.2.1 Cobalamin and Cobinamide uptake 
 The aims of this experiment are two-fold: The first data required is the confirmation 
that cobalamin can be exogenously taken up in detectable quantities, and to ascertain whether 
Figure 5.0.2: Immunological lifecycle of tuberculosis infection in humans. The period of 
latency during the immunological equilibrium is where the low levels of oxygen can occur. Exit 
of this phase into the reactivation stage is thought to be the point at which nrdZ will be most 
active, providing a route of access for cobalamin conjugated drugs. This figure was reproduced 
with permission from The immunological life cycle of tuberculosis by Ernst 2012. 




the BacA cobalamin transporter is also responsible for transport of earlier intermediates as 
well. For this three different strains of M. tuberculosis were chosen to test for uptake (referred 
to by the underlined lettering): Wild type (WT) ATCC 2729Y M. tuberculosis (clinically 
isolated in 1934), H37Rv ATCC M. tuberculosis (clinically isolated in 1998), and ǻEDF$, a 
bacA deletion of H37Rv. These strains were incubated with 0 nM, 100 nM, 500 nM, 1 µM, 
and 10 µM of either cobalamin or cobinamide for five days at 37 ºC in 50 mL cultures. After 
this the cultures were spun, washed with fresh 7H9 growth media, lysed, spun again and 10 
µL of the supernatant was plated on S. enterica AR3612 containing minimal media plates 
(Chapter 2, 2.6.1 and Chapter 3, 3.4.6) (Raux et al. 1996). The three M. tuberculosis strain 
samples, with the same concentration of exogenous corrinoid, were plated on the same 
bioassay plate with an extra 50 nM reference drop of commercial cobalamin or cobinamide 
where appropriate. Dots of 10 nM, 50 nM, 100 nM and 1 µM of the relevant commercial 
corrinoid were dropped on another plate. These plates were then incubated overnight at 37 ºC 
to allow the S. enterica to grow. 
 The standards plate was used to calculate a standard curve of the diameter of growth 
against the concentration of corrinoid provided (as peformed in Chapter 4, Section 4.3). The 
concentration of the corrinoids detected for each culture in the three different strains were 
normalised to the 50 nM reference point on each plate, and compared once the repeats were 
averaged (Graphs 5.2.1.1 and 5.2.1.2). 
The ǻEDF$strain shows severe impairment of cobalamin transport (Graph 5.2.1.1.). 
The uptake is between 3 and 5 times worse in ǻEDF$ apart from the culture provided with 10 
µM of cobalamin were it is closer to 10 times poorer. This could indicate that there is another 
mode of uptake, perhaps promiscuous transport or diffusion, but its efficiency is limited to 
just over 20 µM of cobalamin over 5 days.  
In contrast, the uptake of cobinamide (Graph 5.2.1.2) is lower across all three strains 
when fortified with 10 µM of cobinamide but equivalent at lower supplement concentrations 
compared to the cobalamin uptake. The adverse effects of the bacA deletion are less 
pronounced in all the cultures which imply that there is another uptake mechanism for 
cobinamide, independent of BacA. However, the loss of BacA does hamper cobinamide 
uptake more in the 10 µM supplemented culture. This increase in impairment is also true in 
the cobalamin sample and could indicate that the alternative route of uptake, postulated 
previously, is negatively regulated by the concentration of corrinoid in the cell. Overall, the 
concentration of cobalamin taken up in the 10 µM culture of the ǻEDF$strain is less than that 




of cobinamide which suggests that either there is a preference for cobinamide over cobalamin 
or that the negative feedback is more sensitive to cobalamin levels (please note that Graphs 
5.2.1. 1 and 5.2.1.2 are on different scales). All three of the tested M. tuberculosis strains can 
take up cobalamin and cobinamide in a concentration dependent manner.  
There are no previous reports concerning cobinamide uptake into M. tuberculosis, but 
this experiment clearly demonstrates that both cobalamin and cobinamide can be exogenously 
taken up into M. tuberculosis in a concentration dependent manner. It also shows that BacA 
may not be the sole route of cobalamin transport, as both cobalamin and cobinamide are taken 
up in the ǻEDF$ strain. This could indicate the presence of an unknown corrinoid transport 
module in M. tuberculosis. 
Graph 5.2.1.1: The concentration of corrinoid detected in three different strains of M. tuberculosis 
when provided with increasing concentrations of cobalamin in culture. The uptake increases in a 
concentration dependent manner across all three strains even though the cobalamin uptake in ǻEDF$ is 10 
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5.2.2 Pseudo-cobalamin 
 Pseudo-cobalamin is a naturally occurring analogue of cobalamin. Instead of a DMB 
as the lower axial ligand it has adenine (Figure 5.2.2.1) (Fieber et al. 2002). This difference 
results in a 500 times lower binding affinity for human IF compared to cobalamin. IF is one of 
the human cobalamin transport proteins responsible for ferrying cobalamin from the 
duodenum to the blood  and it is this reduction in binding affinity that is thought to contribute 
to pseudo-cobalamin lack of function in humans (Nielsen et al. 2012; Taga et al. 2008). TCII 
and HC, two other human cobalamin transport proteins, do not have such a drastically low 
binding affinity for pseudo (Greibe, Fedosov, and Nexo 2012). In fact some bacteria, e.g. 
Synechococcus species and Lactobacillus reuteri, synthesise pseudo-cobalamin instead of 
cobalamin, whilst, more commonly, others can recognise pseudo-cobalamin and then swap 
the lower loop to the DMB version so cobalamin can be used as a cofactor e.g. Pavlova 
lutherii, Chlamydomonas reinhardtii,  S. enterica and Dehalococcoides mccartyi (Helliwell et 
al. 2016; Santos et al. 2007; Yi et al. 2012).   
Graph 5.2.1.2: The concentration of corrinoid detected in three different strains of M. tuberculosis 
when provided with increasing concentrations of cobinamide in culture. The uptake increases in a 
concentration dependent manner across all three strains the same as with cobalamin, but the loss of BacA 
has less impact, perhaps due to the cobinamide uptake being uniformly worse across all strains. 
Interestingly, in both cases ǻEDF$ corrinoid uptake is most hindered when supplied with 10 µM of 































Concentration of cobinamide provided (nM)
Cobinamide uptake in three strains when given different 
concentrations of exogenous cobinamide
H37Rv cobinamide WT cobinamide BacA cobinamide




This experiment establishes whether or not pseudo-cobalamin can be taken up in M. 
tuberculosis. The investigation was set up in the same way as the cobalamin and cobinamide, 












Graph 5.2.2.2 shows that pseudo-cobalamin can be taken up by all three strains of M. 
tuberculosis, and in a concentration dependent fashion in the WT and ǻEDF$ strains. This can 
be seen by the increase in the concentration of corrinoid detected when 1 µM and 10 µM of 
pseudo-cobalamin is in the media. In the WT strain there is a 3 to 4 fold increase each time 
the concentration of exogenous cobalamin doubles, whereas in ǻEDF$ it only increases by 
50 %. It is impossible to know if the H37Rv strain increases uptake of pseudo-cobalamin in a 
concentration dependent manner as only the 10 µM culture extract enabled the S. enterica 
AR3612 to grow, and this may be due to contamination rather than uptake.  
The decrease in concentration of corrinoid detected in the 10 µM culture of ǻEDF$ is 
about 12 times lower than WT or H37Rv strains, equivalent to the decrease seen in the 
cobalamin experiment. This suggests that BacA recognises the lower ligands of corrinoids, 
especially as its absence had less effect on the transport of cobinamide which has no lower 
loop. However, the concentration of pseudo-cobalamin detected in the ǻEDF$ strain with 10 
µM exogenously added is about the same, around 50 nM, as the concentration detected in the 
equivalent cobinamide sample. This suggests that the possible BacA independent cobalamin 
Figure 5.2.2.1: The chemical 
structure of pseudo-cobalamin. 
The X denotes CN; Adenosyl or 
other upper axial ligands. The 
adenine, which differentiates it 
from cobalamin, is in the red 
circle.  




uptake route recognises pseudo-cobalamin as well as cobinamide, meaning that pseudo-
cobalamin is taken up via both the BacA and the non-BacA mechanisms. If this alternative 
route is negatively regulated, it is only done so by cobalamin and not by either pseudo-
cobalamin or cobinamide. A graph comparing all three corrinoid uptake in all strains is in 
Appendix C.2. 
 
5.3 Fluorescent Corrinoid uptake and detection in Mycobacterium tuberculosis  
In Chapter 3 two broadly different type of corrinoid analogue were synthesised: the 
ribose linked cobalamin analogues and the C5 linked cobyric acid analogues. A number of 
different fluorophores can be attached at these sites but for the purposes of this experiment the 
BODIPY® TR-X  fluorophore analogues were used as they contrast with M. tuberculosis 
autofluorescence (detectable in the cyan range: excitation 405 nm; emission, 475 nm) better 
than the other fluorophore analogues made (Patiño et al. 2008).  Both the C5 and ribose linked 
BODIPY® TR-X analogues were incubated with M. tuberculosis to ensure that they were still 
taken with the fluorophore attached. In this way the uptake can be visualised. 
Graph 5.2.2.2: The concentration of corrinoid detected in three different strains of M. tuberculosis 
when provided with the increasing concentrations of pseudo-cobalamin in culture. The uptake 
increases in a concentration dependent manner across all three strains the same as with cobalamin, but the 
loss of BacA has less impact, perhaps due to the cobinamide uptake being uniformly worse across all 
strains. Interestingly, in both cases ǻEDF$ corrinoid uptake is most hindered when supplied with 10 µM 
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 The H37Rv strain and the ǻPHW( strain (a deletion in H37Rv) were incubated with 1 
µM of both BODIPY® TR-X corrinoid analogues for 24 hours at 37 °C and then imaged. In 
the H37Rv sample the fluorescence shown in the middle of Figure 5.3.1 has a clear outline 
which marries up to the DIC. Although the correlation of the fluorescence with the DIC was 
good, the brightness of the fluorescence had to be artificially increased so much that 
unspecific background fluorescence artefacts became visible (Figure 5.3.1).   
 
The cobalamin-dependent ǻPHW( VWUDLQZDVJURZQLQ6DXWRQ¶VGHILQHGPHGLXP
(Chapter 2, 2.1.3) which is a minimal media used in this instance to limit potential 
contamination with endogenous cobalamin. In addition to the change in media, a 48 hour 
incubation was included as well as a 24 hour one. Apart from these alterations the ǻPHW( 
cultures were set up in the same way as the H37Rv experiment. The 24 and 48 hour 
incubations were both imaged at the same time (Figure 5.3.2). 
These changes succeeded in improving the uptake of the analogues into M. 
tuberculosis. This was particularly true of the C5-BODIPY® TR-X cobyric acid. Panel A 
(Figure 5.3.2) shows the C5-BODIPY® TR-X cobyric acid after 24 hours of incubation. The 
fluorescence clearly associates with the cells seen in the DIC. Panel B shows the ribose linked 
BODIPY® TR-X cobalamin after 48 hours of incubation. The fluorescence again matches the 
DIC well, although the fluorescence again had to be increased artificially, resulting in some 
background interference. After 24 hours the cobalamin analogue sample showed no detectable 
fluorescence (data not shown) whereas the C5 linked BODIPY® TR-X cobyric acid samples 
showed good correlation in both the 24 hour (Panel A, Figure 5.3.2) and 48 hour incubations 
(data not shown). This adds to the previous observation that earlier intermediates in the 
Figure 5.3.1: H37Rv incubated with cobalamin ribose linked BODIPY® TR-X. H37Rv incubated 
with ribose linked BODIPY® TR-X-cobalamin for 24 hours at 37°C 100rpm. Although the localisation 
of the fluorescence is clearly to the M. tuberculosis cell cluster, due to the increased fluorescence 
intensity needed to see this, there is a high level of background fluorescence. 




cobalamin biosynthesis pathway are more readily taken up than cobalamin. In both cases the 
analogue does localise to the M. tuberculosis, and the cultures of ǻPHW( continue to grow on 
analogue supplementation alone. Therefore, the M. tuberculosis can finish the lower loop 
formation, attach the upper ligand and then use tKHµFRPSOHWHG¶DQDORJXHDVDFRIDFWRU for the 
methionine synthase MetH. 
 
5.4 What is the earliest intermediate to rescue ǻPHW(and which cobalamin does 
Mycobacterium tuberculosis make? 
5.4.1 ǻPHW( rescue  
 The two previous sections have shown that cobinamide can be taken up by M. 
tuberculosis and that a cobyric acid analogue can be used to compensate the corrinoid 
dependent ǻPHW( strain for a lack of cobalamin. Is it possible for earlier intermediates to do 
the same? To investigate this, a number of intermediates were made and studied for rescue.  
Figure 5.3.2: ǻPHW( incubated with cobalamin ribose linked BODIPY® TR-X or C5- BODIPY® 
TR-X cobyric acid. Panel A: ǻPHW( incubated with C5 -linked BODIPY-cobyric acid for 24 hours at 
37°C 100rpm. The localisation of the fluorescence is clearly to the M. tuberculosis cell cluster and there 
is no background. Panel B is also ǻPHW( but incubated for 48 hours with ribose linked BODIPY. There is 
an improvement in uptake from the H37Rv 24 hour incubation but there is still some background noise.  
These results show that the C5 linked BODIPY cobyric acid is more readily taken up by the M. 
tuberculosis even though it has had half the incubation time or the ribose linked analogue which implies 








The intermediates used were precorrin-7, HBAD, HBAH, and cobyric acid. A final 
concentration of 1 µM of each intermediate was added to the 500 µL 7H9 media into which M. 
tuberculosis was added so an optical density of 0.6 would be reached on the fifth day (M. 
tuberculosis has a 17 hour doubling time at 37 ºC). Three strains of M. tuberculosis used 
were: ǻPHW(, ǻPHW+, and H37Rv.  
The experiment was conducted in a 24-well plate at 37 °C, revolving at 100 rpm. This 
was photographed every day. A blank, in which no intermediate was added, served as a 
negative control, and cobalamin was used as the positive control. Figure 5.4.1.1 is a 
photograph of the plate on the 7th day of incubation. The H37Rv and ǻPHW+ wells are all 
growing regardless of the presence or absence of any intermediate. However, there is no 
growth in precorrin-7, HBAD, HBAH or the blank wells with ǻPHW(. The slight growth 
observed in these wells is due to the original inoculum. The cobalamin and cobyric acid 
supplemented wells both support ǻPetE growth. 
 




Figure 5.4.1.1: ǻPHW( rescue attempt with different cobalamin biosynthesis intermediates. One week 
growth in 500 µL cultures with different intermediates. Precorrin-7 is the intermediate before the last 
methylation at C5. HBAD is the product of the first amidase, CobB, and HBAH is a very rare naturally occurring 
intermediate which has bypassed the cobalt insertion and become a fully amidated cobalt less equivalent of 
cobyric acid (Toohey 1965). Cobyric acid is the fully amidated, cobalt inserted intermediate, whilst the blank has 
no intermediate added, and cobalamin is the commercial cyano-cobalamin.
 
 




5.4.2 Which cobalamin does Mycobacterium tuberculosis make? 
 The previous sections of this chapter have shown that M. tuberculosis can recognise 
cobyric acid, cobalamin and pseudo-cobalamin. Both cobalamin and pseudo-cobalamin are 
potential final products for corrinoid biosynthesis, but it is unknown which M. tuberculosis 
makes. To find out, 1.35 L of ǻPHW( was grown for 5 days with 1 µM of dicyano-cobinamide 
in the 7H9 media. The culture was spun, lysed and the supernatant extracted. This supernatant 
was applied to a nickel affinity column with the His-tagged E. coli periplasmic binding 
protein BtuF preloaded. After a sequence of washes the BtuF bound compounds were eluted 
in 8 M urea which was then passed down a reverse phase C18 column to remove the urea, and 
eluted in 50 % methanol. This was concentrated on a vacuum centrifuge, left in the light to 
remove the upper ligand, and run on the HPLC-MS.   
 Figure 5.4.2.1 shows that the mass detected was 664.8 m/z and has absorption maxima 
at 350 nm and 526 nm. This is the expected mass of cobalamin with no upper ligand and the 
UV trace corresponds to that of cobalamin as well. Therefore M. tuberculosis makes 
cobalamin and not pseudo-cobalamin. The sample was also checked for residual cobinamide 
(Appendix C.3) but none was found.  
 
Figure 5.4.2.1: HPLC and MS data for the ǻPHW( grown with cobinamide sample. A: the absorbance at 328 
nm; B: the extracted ion chromatogram (EIC) of cobalamin in both the singly and doubly charged states, 1329.5 
m/z and 665.2 m/z respectively. C: the mass spectrometry data for the peak at 17.5 minutes (the peak of the EIC) 
showing the mass of cobalamin in C2, and the corresponding UV absorbance for this mass peak in C1. This is 









5.5 Corrinoid RNA Regulation 
There are two predicted cobalamin riboswitches in M. tuberculosis: one before metE 
and one prior to ppe2 (Vitreschak et al. 2003).The metE gene encodes the cobalamin 
independent methionine synthase mentioned previously, whilst the ppe2 gene encodes a 
predicted seven transmembrane domain cobalt transporter (Gopinath, Moosa, et al. 2013).  
This, combined with the evidence that suggests nrdZ, the cobalamin-dependent ribonucleotide 
reductase, is upregulated in hypoxic conditions induced during granuloma development, all 
indicate some cobalamin mediated/linked RNA regulation in M. tuberculosis (Boshoff and 
Barry 2005).  
5.5.1 Cobalamin 
In order to ascertain the effect of cobalamin on the RNA landscape of M. tuberculosis 
1 PM of cobalamin was incubated with different strains and subcultured four times, never 
exceeding an optical density of 0.2 at 650 nm. RNA sequencing data was taken and compared 
to the non-supplemented cultures which were grown alongside the fortified strains. Five 
strains were used in these experiments: WT, H37Rv, ǻEDF$, ǻPHW(, and ǻPHW+. As 
established earlier in the chapter, ǻPHW( does not grow without supplementation with 
cobalamin which means that the RNA sequencing cannot be performed by comparing a 
culture with added exogenous cobalamin to one without, as the one without will not grow. To 
circumvent this issue three cultures of ǻPHW( were set up: with 1 PM cobalamin, with 2 mM 
methionine, and with both 1 PM cobalamin and 2 mM methionine. By providing methionine 
the need for a functional methionine synthase is eradicated, but in order to compare the RNA 
profiles impartially the third culture which has been given both supplements must be 
compared to the other two cultures separately.  
 During the course of the experiment the ǻPHW+ culture with cobalamin struggled to 
grow more and more the further it was subcultured. The ǻPHW+ strain relies upon MetE for 
methionine synthesis, one of the genes proposed to have a cobalamin riboswitch preceding it. 
If the cobalamin riboswitch downregulates metE in the presence of cobalamin, as is predicted, 
then as the levels of metE RNA from the starter culture fall with subsequent subculturing and 
ǻPHW+ strain continues to proliferate there will be fewer metE transcripts to translate into 
protein, leaving the ǻPHW+ cells with no methionine synthase. This decrease in active 




methionine synthase will result in reduced methionine production which will limit protein 
production, leading to a slower growth rate and potentially cell death (Ron 1975). Fortunately 
the ǻPHW+cultures with cobalamin survived long enough to extract sufficient RNA for 
quantification by sequencing technology. 
5.5.2 Cobinamide 
 The experiment was also conducted using cobinamide instead of cobalamin. There 
were two reasons for this: to confirm that cobinamide could support the growth of ǻPHW(, and 
to investigate whether cobinamide could bind to the cobalamin riboswitch. Figure 5.5.2.1 
shows that cobinamide does facilitate ǻPHW(growth. Cobinamide can bind to the cobalamin 
riboswitch as the ǻPHW+ cultures showed that cultures provided with cobinamide diminished 
in the same way they did with cobalamin indicating that cobinamide can also stop 







 The RNA sequencing data presented in Table 5.5.2.3 combines both the cobalamin 
and cobinamide results. Differences in RNA levels of over ±1 were considered to be 
significant particularly if it is so across all of the strains. Increases in RNA levels compared to 
the control cultures of +1 and over are highlighted in green and decreases of -1 and under are 
in red, non-significant results are paler hues thereof. There were no high impact effects of 
either cobalamin or cobinamide on the RNA levels overall. Significant results relating to 
known cobalamin related genes or genes implicated in other experiments are summarised in 
Table 5.5.2.3.There were some that had markedly different regulation in the presence of 
cobalamin or cobinamide, for example mutB (Rv1493), the large subunit of the MCM was 
upregulated in all the strains in the presence of cobinamide compared to the control, but not 
with cobalamin. Oddly neither corrinoid had any significant effect on mutA (Rv1492) even 
though the two genes are next to each other in the M. tuberculosis genome. The metE gene 
Figure 5.5.2.1: ǻPHW( cultures grown with 
cobinamide and/ or methionine. ǻPHW( 
cultures grown at 37°C at 100 rpm 
supplemented with (from left to right) 1 µM 
cobinamide; 1 µM cobinamide and 2 mM 
methionine; and 2 mM methionine.
 




levels are increased in the WT, H37Rv and ǻPHW+ strains with cobalamin, and cobinamide 
has the same effect in both the WT and H37Rv, compared to their respective control cultures. 
In the ǻEDF$ strain on the other hand, cobinamide significantly decreases the level of metE. 
As this is the ǻEDF$ strain the internal concentration of the corrinoid should be lower than 
those with the transporter and yet this is the only strain in which metE transcripts decrease 
compared to the control. The metH gene transcription is not affected by the corrinoids in any 
strain. In contrast, the gene encoding ketol acid reductoisomerase, ilvC, is downregulated 
compared to the control in all strains in the presence of either corrinoid, but it is involved in 
amino acid synthesis and has no obvious link to cobalamin metabolism in any way.  The 
cobQ1gene is the only cobalamin biosynthesis gene upregulated in the cobinamide cultures 
compared to the control cultures. None of the other biosynthesis genes are significantly up or 
downregulated in either corrinoid cultures (Appendix C.5). M. tuberculosis has two cobQ 
genes, the one in question is Rv0255c which is the longer of the two, and the other Rv3713. 
There is no great similarity between the two in amino acid sequence (Figure 5.5.2.2) or DNA 
(Appendix C.4), and there is no known reason as to why there are two. 
The other cobalamin riboswitch regulated gene, ppe2, is upregulated compared to the 
control in both experiments, but more uniformly in the cobinamide cultures. Both the ǻEDF$ 
cultures show a diluted response compared to the other strains. 
Figure 5.5.2.2: The amino acid alignment of the two CobQs from M. tuberculosis. There is no known 





























































































































































































































































The gene identity is the number assigned to the gene within the M. tuberculosis 
genome whereas the gene name is how it is referred to commonly; it is usually based on the 
function of the protein. To provide a comparison with metE, metH is also shown in the table. 
The values shown in the table are the Q values comparing RNA levels with supplementation 
to cultures without supplementation. The more red the colour of the box, the lower the RNA 
level compared to the unsupplemented culture, and the more green the box is, the higher the 
RNA level is compared to the unsupplemented cultures. 
5.6 Cobalamin binding proteins 
 There are three known cobalamin-dependent enzymes and one known cobalamin 
transporter  but there may be more cobalamin binding proteins (Gopinath, Moosa, et al. 2013; 
Gopinath, Venclovas, et al. 2013). In order to investigate this at the protein level a cobalamin 
resin was synthesised by linking cobalamin to agarose beads via the ribose (Figure 5.6.1). 
This was then packed into a column.  
 The viability of the column was checked by purifying BtuF from E. coli. BtuF was 
overexpressed in E. coli and the supernatant of the cells, after lysis and spinning, was purified 
on the cobalamin column (Figure 5.6.2). The binding constant of BtuF is known to be 
between 10 and 30 nM, but Figure 5.6.2 shows 100 µM of cobalamin was needed to elute it 
from the column (Lewinson et al. 2010; Cadieux et al. 2002). To ensure that the column was 
washed sufficiently 50 mL of each wash buffer was passed through the 2 mL column 
followed by an 8 M urea wash to remove anything left on the column.   
The strains of M. tuberculosis used in this investigation were H37Rv, WT, ǻPHW( and 
ǻEDF$. A total of 1.35 L of the strain was grown, then spun and lysed. The supernatant was 
Figure 5.6.1: Synthesis of the cobalamin linked agarose column. A: Synthesis of the cobalamin 
column using CDI as the coupling reagent to link the ribose moiety of cobalamin to the amine group on 
the agarose beads (purple). B: the finished cobalamin column.
 




either applied directly to the column, or incubated overnight at 4°C with gentle rocking to 
maximise binding. The column was then washed with increasing concentrations of cobalamin 
until the protein eluted. Every elution was concentrated to ensure a clear band, and run on 
SDS-PAGE followed by MALDI-TOF analysis to identify the proteins. However, even after 
concentrating the elutions on a 5 kDa concentrator from 50 mL to 500 µL, bands were only 
observed in some samples on the SDS-PAGE. Most elutions had faint bands or none at all. A 
5 kDa filter was selected for the concentrator as the first purification showed a faint band at 
just over the 10 kDa marker band (Appendix C.6). In order to accommodate the 5 kDa to 180 














All of the strains were subjected to the same purification. The clearest elutions from 
all the purifications were chosen for MALDI-TOF analysis (Figure 5.6.3). MALDI-TOF was 
performed by excising the SDS-PAGE bands of interest (highlighted in Figure 5.6.3 in red 
boxes). These are washed thoroughly with ammonium carbonate, acetonitrile and 
iodoacetomide, and then left digesting overnight in a trypsin solution. This results in the 
production of a mixture peptides unique to each protein. The molecular mass of these peptides 
Figure 5.6.2: SDS PAGE gel of BtuF purified on the cobalamin column. 
BtuF purified on a cobalamin agarose column washed with increasing 
concentrations of cobalamin, and then finally with 8 M urea. M is the marker, 
Tot: total, Sn: supernatant, Tris: 20 mM Tris pH 8 wash, the concentrations refer 
to the concentration of cobalamin in 20 mM Tris pH 8 buffer, and urea: 8 M 
urea in 20 mM Tris pH 8 buffer. BtuF is 29 kDa with the His tag, seen here in 
the 100 µM, 1 mM and Urea elution fractions.
 




were measured in the mass spectrometer which generates a peptide mass fingerprint (PMF) 
dataset (Walker 2009). This dataset was compared with a database of theoretical PMFs 
produced by in silico trypsin digestion. The closest match is flagged, but a scoring method is 
used to show how similar the match is (the coloured column in Table 5.4.4, the higher the 
score the better the match) as there are often more than one possible hit. MS/MS uses the 
initial PMF dataset and selects a range of mass to charge (m/z) values to fragment further. 
These are detected generating a second dataset for the same sample. By combining these two 
datasets from the original PMF and the MS/MS a more accurate database match can be 
performed.  
The MS/MS results can be seen in Table 5.6.4, whilst the initial mass spectrometry 
results can be found in Appendix C.7. The bands were numbered from the top down and 
Figure 5.6.3: MALDI reference gel. 1: ǻPHW( overnight with the resin urea wash. 2: H37Rv 
overnight with the resin 100 nM wash. 3: H37Rv overnight with the resin urea wash. 4: ǻEDF$ 
overnight with the resin 1 µM wash. 5: ǻEDF$ overnight with the resin urea wash. 6: WT urea 
wash. 7: H37Rv 10 nM wash. 8: H37Rv 1 µM wash. 9: H37Rv urea wash. The only wash that 
shows up on the gel apart from the urea washes is the 1 µM ǻEDF$ wash which was 100 times 
less concentrated wash than the one overexpressed BtuF elutes in, but is still promising. The red 
dotted boxes indicate bands which were excised for MALDI-TOF. These were numbered from 
top to bottom and prefixed with the name of the elution. No bands were cut from elution 3 
because they looked identical to elution 1. The results are in Table 5.6.4. 




prefixed with the name of the elution e.g. ǻEDF$ O/N 1 µM B12-1 refers to the top band of 
lane 4. ǻEDF$ is the strain, O/N means it was incubated overnight at 4 °C with the cobalamin 
resin and 1 µM B12 is the concentration of cobalamin in the wash buffer which eluted this 
sample. 
Many of these results are background proteins which often appear in MALDI, such as the 
various 30s ribosomal proteins and DNA K, a chaperone protein. Others such as bovine serum 
albumin (BSA) are figments of the experiment as this is present in the media. The presence of 
E. coli BtuF in the WT elution must be cross contamination as this was purified before the 
column was tested with E. coli BtuF. The more distinct results are glutamine synthetase I, 
citrate synthase I, and ketol-acid reductoisomerase. Citrate synthase I (gene identification 
Rv0896, gene name gltA2) is one of the enzymes in the glyoxylate cycle which is part of the 
cobalamin independent propionate metabolism route in M. tuberculosis (see Chapter 1, Figure 
1.7.1.1). Glutamine synthetase I (gene identification Rv2220, gene name glnA1) converts 
glutamate into glutamine, but glutamate can also be converted into glyoxylate, which feeds 
into the glyoxylate cycle. The link between ketol-acid reductoisomerase and cobalamin is 
unclear, although both the gene and the protein have been identified in the RNA sequencing 
screen (Section 5.5) and the cobalamin binding investigation. MetE was also identified, even 
though it is MetH which binds cobalamin. The amino acid sequences of these two proteins are 
not similar at all (Appendix C.8) even after trypsin digestion. The lowest band in lane 6 
(Figure 5.6.3) was not cut out because it was too close to the excised bands in lane 5 to cut out 
cleanly. This was sacrificed in favour of the bands in lane 5 as the lane 6 band looks to be the 













Table 5.6.4: MALDI-TOF results (MS/MS)  




 This table shows a summary of the MALDI-TOF MS/MS results. The column entitles 
µ/DQH¶UHIHUVWRWKHODQHQXPEHUWKLVVDPSOHZDVUXQLQRQWKH0$/',UHIHUHQFHJHO)LJXUH
5.6.3). 7KHFROXPQµ%DQG¶GHWDLOVWKHbackground of the M. tuberculosis strain, e.g. ǻbacA, 
the wash it eluted from the cobalamin- column in, e.g. 1 µM B12, and the number band it was 
within this sample, e.g. 1 would indicate it was the top band in this SDS sample. 
5.7 Discussions 
Cobalamin and cobinamide are both taken up into M. tuberculosis in a concentration 
dependent manner with increasing concentrations of exogenous corrinoid. Pseudo-cobalamin 
appears to be absorbed in a similar fashion but because the S. enterica bioassay plate is less 
sensitive to pseudo-cobalamin, many of the samples taken from cells grown in lower 
exogenous concentrations of pseudo-cobalamin do not show any growth on the bioassay plate. 
In the ǻEDF$ strain when provided with 10 µM exogenous corrinoid all three are taken up into 
the M. tuberculosis cells. This indicates that another corrinoid uptake system may be present 
in M. tuberculosis. Cobinamide and pseudo-cobalamin are taken up to about 50 nM in the 
cells whereas cobalamin is half of this, which either means that the alternative uptake route 
prefers pseudo-cobalamin and cobinamide, or it may be that this transport route is negatively 
regulated by cobalamin, but not by pseudo-cobalamin and cobinamide. This negative 
regulation could limit the internal cell concentration of cobalamin, but not restrict pseudo-
cobalamin and cobinamide. 
The internal concentration of pseudo-cobalamin is much higher than either cobalamin 
or cobinamide when the same concentration of corrinoid is provided. This could be a figment 
of this experiment, for example M. tuberculosis may selectively import pseudo-cobalamin in 
preference to cobalamin and cobinamide. This would be strange if so because M. tuberculosis 
synthesises cobalamin, not pseudo-cobalamin when ǻPHW( is grown solely on cobinamide 
(Section 5.3.2). 
The two C5 and ribose linked BODIPY® TR-X fluorophore analogues were both 
taken up into M. tuberculosis. However, the ribose linked analogue was not taken up as well 
as the C5 analogue. This could be because the C5 analogue is smaller and impedes the uptake 
proteins less. It could also be because the BacA transport route is not as efficient at 
transporting the analogues as the hypothetical alternative route, which is less effective at 
transporting cobalamin compared to earlier intermediates. The superior uptake of the C5 
analogue into M. tuberculosis indicates a potential advantage for synthesising earlier 




intermediate analogues rather than cobalamin ones. In humans TCII, the transport protein 
which mediates cell uptake, only binds cobalamin (Greibe, Fedosov, and Nexo 2012). 
Therefore, in a M. tuberculosis infected individual if an earlier intermediate is in the blood 
this should only be taken up by M. tuberculosis cells and not human cells. This presents a 
possible way of targetting the analogues to M. tuberculosis cells in a clinical environment. 
 M. tuberculosis recognises cobalamin intermediates containing cobalt as both cobyric 
acid and cobinamide can rescue the cobalamin-dependent strain ǻPHW(. The chemical 
equivalent of cobyric acid without the cobalt, HBAH, does not rescue ǻPHW(. This suggests 
that either the HBAH is not recognised and taken up into the cell due to the lack of the cobalt 
ion, or that it is taken up but the cobalt chelation complex of M. tuberculosis and subsequent 
cobalamin biosynthesis enzymes are not sufficient to complete cofactor synthesis in 
concentrations needed to support growth. This could be due to limited cobalt availability in 
the media. The inability of WKHǻmetE M. tuberculosis strain to grow without exogenous 
cobalamin supplementation infers that M. tuberculosis does not produce enough cobalamin de 
novo to support itself under standard in vitro conditions, although it does not conclusively 
prove that M. tuberculosis cannot synthesise cobalamin de novo (Gopinath, Moosa, et al. 
2013).  
The only cobalamin biosynthesis gene flagged in the RNA sequencing experiment 
which was affected by the presence of a corrinoid was cobQ1, which had a higher 
concentration when cobinamide was added to the media (Appendix C.5). Cobalamin did not 
produce the same effect. The large subunit of MCM, mutB, has the same reaction to 
cobinamide as cobQ1. However, mutA, the smaller subunit of MCM does not. There is no 
known reason why only one subunit should be upregulated, especially as MCM is a 
cobalamin-dependent enzyme and yet cobalamin as no effect on RNA production. The two 
genes with known cobalamin riboswitches, metE and ppe2 are both in Table 5.5.2.3, along 
with the cobalamin-dependent methionine synthase encoding gene, metH. Of these genes, 
only ppe2 shows uniform increases in RNA when in the presence of cobinamide. This effect 
is less in the cobalamin samples. The reason cobinamide appears to have more effect on the 
genes than cobalamin may be due to the cobinamide entering the cells faster than the 
cobalamin (as with the fluorescent analogues) and, therefore, eliciting an effect on the genes 
earlier and more consistently than cobalamin. 




Proteins or genes identified in the cobalamin column experiment were mostly 
associated with cobalamin-dependent processes, if not already known to be linked to 
cobalamin. Glutamine synthetase I converts glutamate into glutamine Glutamate can also be 
converted into glyoxylate, which feeds into the glyoxylate cycle. Citrate synthase I is one of 
the enzymes in the glyoxylate cycle which is part of the cobalamin independent propionate 
metabolism route in M. tuberculosis, circumventing the methylmalonyl pathway (see Chapter 
1, Figure 1.7.1.1). Ketol-acid reductoisomerase, which was also highlighted in the RNA 
sequencing experiment, is connected to the metabolism of valine, leucine and isoleucine. The 
link between ketol-acid reductoisomerase and cobalamin is unclear, but the gene encoding it, 
ilvC (Rv3001c), is downregulated in the presence of both cobalamin and cobinamide, whilst 
the protein eluted off the cobalamin binding column in a 1 µM cobalamin wash. This suggests 
that ketol-acid reductoisomerase binds cobalamin but is also downregulated by it.  
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6.0 General discussion 
 The objectives of the research outlined in this thesis were to synthesise a corrin-ring 
modified analogue of cobalamin, to attach a fluorophore or drug to this position, to analyse 
the efficacy of the resultant analogues in different organisms, and to identify corrinoid 
specificity and localisation in M. tuberculosis and C. elegans. Corrin-ring modified analogues 
have potential to be used to target cells infected with M. tuberculosis, certain cancer cells, or 
parasitic worms, all of which have an increased cobalamin requirement (Mclean et al. 1997; 
Waibel et al. 2008; Allen 2008). Previous cobalamin analogues have been made by modifying 
the peripheries of the molecule but none have directly altered the macrocycle ring component 
(Clardy et al. 2011). Such modifications can be done either chemically or enzymatically using 
the cobalamin biosynthetic pathway. Chemically, it is hard to precisely modify one residue 
when the same functional groups occur at many different positions on the ring. Enzymatically, 
it is difficult because many of the biosynthesis enzymes which modify positions on the corrin 
macrocycle use the same cofactors. This means if a cofactor analogue is used to alter a 
position, other biosynthesis enzymes could use the same cofactor analogue and target a 
different position to the intended one. The results presented in the previous chapters show that 
by using a combination of the native cobalamin biosynthesis enzymes and chemical 
techniques, individual macrocycle modifications are possible, and result in biologically active 
analogues. Corrin fluorophore conjugates prove the biological viability of these analogues and 
show where they localise in vivo. 
6.1 Cobalamin analogue synthesis 
 The method chosen for corrin modification was a combination of in vitro incubation 
with cobalamin biosynthesis enzymes, and chemical modifications. There are two routes of 
cobalamin biosynthesis, termed the Early and the Late cobalt insertion pathways, but the 
Early insertion pathway proved to be unusable for analogue synthesis. Although the 
intermediates of this pathway had the benefit of the cobalt ion already in the macrocycle, this 
actually made them very oxygen sensitive and unstable. The instability of the intermediates 
resulted in degradation of the desired product after synthesis. 
 The Late insertion pathway was successful in synthesising a C5 corrin analogue of 
cobyric acid by using allyl-SAM incubated with CobL to transfer the allyl group on to the C5 
position of precorrin-7 in place of a methyl group. The cobalamin biosynthesis enzymes 
CobH, B, and Q, along with their cofactors, converted the C5-allyl precorrin-8 into C5-allyl 





HBAH. The mass and absorbance of each intermediate was confirmed by HPLC MS. The 
CobH enzyme used in this synthesis is a T85A mutant as this was found to convert more C5-
allyl precorrin-8 into C5-allyl HBA than the wild type protein. The reason for this could be 
seen in the crystal structure of CobH T85A when co-crystallised with C5-allyl HBA which 
revealed that the alanine residue, being much smaller than the threonine, creates more space 
in the active site around the C5 position, allowing the allyl group to fit. The co-crystal also 
confirmed the structure of C5-allyl HBA, conclusively showing that the allyl group has been 
transferred to the C5 position. Following this, the amidation reactions catalysed by CobB and 
CobQ both worked well, producing C5-allyl HBAH. The structure of this intermediate was 
verified by NMR, which showed the presence of the C5 allyl and the six amides on the a, b, c, 
d, e, and g sidechains. To produce the metal-free HBAH analogues involves using CobQ out 
of sequence. The CobQ used is from A. vinosum as R. capsulatus CobQ only amidates after 
metal insertion and adenosylation of the cobalt. The NMR confirmation of this C5-allyl 
HBAH not only validates the structure of this novel intermediate, but also demonstrates that a 
cobalt-less hexa-amidated intermediate, HBAH, is a stable intermediate. 
 The allyl group was extended and the cobalt ion inserted using previously published 
chemical methods (Wang et al. 2011; Kräutler 2006). The fluorophore was attached to the 
primary amine of the extended C5 group using a peptide reaction. Fluorescein was initially 
used, but it was found to photobleach very quickly so BODIPY® TR-X and Oregon green® 
514 equivalents were synthesised. Alongside the synthesis of the C5 analogues, ribose linked 
analogues were also manufactured. This was necessary as the C5 analogues were not taken 
further than cobyric acid and many organisms which require cobalamin but cannot make it, do 
not recognise any corrinoid bar cobalamin (Nielsen et al. 2012). Thus the ribose linked 
analogues were synthesised to allow a direct comparison to the C5 cobyric acid compounds. 
6.2 Cobalamin recognition in Salmonella enterica and Escherichia coli 
 The three C5 cobyric acid derivatives and the two ribose linked conjugates were tested 
for functionality on both S. enterica bioassay plates and for uptake in E. coli. To work as a 
cofactor for S. enterica MetH and induce growth, the analogues must have a completed lower 
QXFOHRWLGHORRSDQGDPHWK\OJURXSDVWKHȕOLJDQGIRUWKHFREDOWLRQ$OORIWKHV\QWKHVLVHG
analogues supported growth on the bioassay plates, proving that they were all taken up by the 
bacteria, and converted into cofactor precursors which could be functionalised in vivo. On the 
S. enterica bioassay plates the BODIPY® TR-X analogues generated less growth than their 





Oregon green® 514 counterparts. As they are identical in all but the fluorophore it must be 
this which differentiates them, indicating that the fluorophores are still attached to the 
analogues at this stage. It could be that Oregon green® 514 is easier to cleave off the cobyric 
acid than BODIPY® TR-X, and this is what causes the growth difference on the bioassay 
plate. On the other hand, this may be caused by the BODIPY® TR-X having a longer linker 
compared to the Oregon green® 514 (Figure 6.2.1), resulting in the BODIPY® TR-X 
conjugates requiring more space to fit into enzyme binding pockets than the Oregon green® 
514 ones. Alternatively this difference may be due to the differing chemical properties of the 
two fluorophores or the flexibility of the molecules themselves. A more flexible molecule 
could bend and pack into the binding site; much like the allyl group does in the CobH (T85A) 
crystal, whereas a more rigid molecule would bind less favourably or not at all. In terms of 
size, the BODIPY® TR-X fluorophore has a marginally larger molecular weight of 634.5 
gmol-1 compared to the 609.4 gmol-1 of Oregon green® 514. This molecular weight 
discrepancy is due to difference in the length of the linker to the succinimidyl ester so, unless 
this is the issue, the molecular weight difference is of little relevance. 
The ribose linked cobalamin derivatives produced bigger rings of growth on the S. 
enterica bioassay plates, signifying that they were converted into the active cofactor form 
better than the C5-cobyric acid analogues. The reason the cobalamin analogues are taken up 
better than the cobyric acid analogues is almost certainly because the ribose linked analogues 
DUHµFRPSOHWH¶RQO\QHHGLQJWRVZDSWKHXSSHUD[LDOOLJDQGLQRUGHUWRIRUPWKHDFWLYH
cofactor. Cobyric acid, on the other hand, requires the addition of the entire nucleotide loop, 
Figure 6.2.1: The structures of the Oregon green® 514 and BODIPY® TR-X 
fluorophores. These were two of the fluorophores used in the conjugation to the terminal 
amine at the C5 position. The leaving groups are circled in red. 





catalysed by some 6 enzymes in S. enterica, plus cofactors, as well as DMB synthesis, to 
generate the same cofactor molecule (Maggio-Hall and Escalante-Semerena 1999; Warren et 
al. 2002). Even though S. enterica can complete cofactor synthesis from cobyric acid it is 
prudent in a metabolic sense to absorb preferentially the cobalamin form (Maggio-Hall and 
Escalante-Semerena 1999). 
In E. coli both the C5 ring modified and ribose linked corrinoid analogues were taken 
up and exhibited excellent co-localisation of the fluorophore fluorescence with DIC 
(differential interference contrast) imaging of the bacterial cells. E. coli cannot convert 
cobyric acid into the cofactor form as it lacks the cobD gene responsible for the synthesis of 
aminopropanol-O-2-phosphate which is subsequently attached to the f sidechain (Warren et al. 
2002). However, cobyric acid was observed to be absorbed. This means that the E. coli BtuB-
F-CD transport system has no selection against cobyric acid and it is essentially taking up a 
dead-end metabolite.  
6.3 Cobalamin analogue recognition in Caenorhabditis elegans 
C. elegans requires cobalamin for a normal life cycle, but the cobalamin transporter 
expressed in the intestine is unknown as C. elegans has no orthologues of human HC, TCII, 
or IF (Bito et al. 2013). Remarkably a megalin orthologue has been identified (Christensen 
and Willnow 1999). Megalin is the endocytic receptor of TCII-cobalamin complex present on 
cell surfaces which is necessary for renal retention of cobalamin in humans (Moestrup et al. 
1996). Megalin is not exclusively used for cobalamin endocytosis as it is also involved in 
hormone (e.g. insulin (Orlando et al. 1998)), protein (e.g. PAI-1(Stefansson et al. 1996)), and 
other vitamins (e.g. vitamin D  and retinol (Nykjaer et al. 1999; Christensen et al. 1999)) 
uptake in humans (Christensen and Willnow 1999). As there is no TCII orthologue in C. 
elegans, megalin is unlikely to have a role in cobalamin endocytosis.  





There are a number of intracellular cobalamin processing proteins in humans most of 
which have been shown to have orthologues in C. elegans (Figure 6.3.1) (Froese and Gravel 
2010). These are involved in functionalising cobalamin into the cofactor and coenzyme forms. 
Significantly, there has been no orthologue identified for CblF, the protein responsible for 
trafficking cobalamin from the lysosome into the cytosol. This indicates that the lysosome 
may not be involved in cobalamin internalisation. In humans TCII is degraded in the 
lysosome in order to release cobalamin, but, as mentioned above, C. elegans does not have a 
TCII orthologue. Together this information implies that C. elegans imports cobalamin in a 
novel way without utilising the lysosome, and reiterates that megalin is probably not involved 
in cobalamin uptake. 
 
Figure 6.3.1: A schematic representation of the human intracellular processing of cobalamin and 
the C. elegans gene orthologues. Cobalamin intermediates are in red. Cbl-R denotes a cobalamin with 
DQXQGHILQHGJURXSDWWKHȕSRVLWLRQRQWKHFREDOWLRQZKLOVW0HDQG$GRUHIHUWRPHWK\ODQGDGHQRV\O
respectively. The human proteins are in light blue with the C. elegans gene orthologues in light purple. 
Y76A2B.5 has only been implicated in a bioinformatics search and has not been proven to be the CblD 
orthologue which is why there is a question mark after the gene (Froese et al. 2015). All of the other 
genes have been shown to catalyse their reactions in assays and to exhibit either methylmalonyl acidemia 
or homocysteinemia or both, as appropriate, in knock out mutants (J. Park and Kim 2015; Kuwabara and 
2¶1HLO&KDQGOHUHWDO&KDQGOHUDQG9HQGLWWL)URHVHHWDO.  





Results presented in Chapter 4 show that the C5 modified cobyric acid analogue is not 
recognised by the C. elegans transport protein(s). As previously stated, this was expected as 
these nematodes have no cobalamin biosynthesis genes and cannot use any corrinoid earlier 
than cobalamin. In some animals, e.g. humans (H. sapiens), rainbow trout (O. mykiss), and 
zebrafish (D. rerio), earlier intermediates can bind to the transport proteins, but cannot be 
used as they cannot be converted into cofactors in these organisms (Banerjee et al. 2009; 
Greibe, Fedosov, Sorensen, et al. 2012; Greibe, Fedosov, and Nexo 2012). The C. elegans gut 
transporter is not so promiscuous. Although it is possible that it will take up later 
intermediates than cobyric acid this is improbable as most transport proteins which do not 
recognise the earlier intermediates bind the nucleotide loop region, and it is only cobalamin 
which has a complete DMB loop (Mathews et al. 2007; Furger et al. 2013; Wuerges et al. 
2006). Human HC recognises cobalamin and earlier intermediates but changes conformation 
depending on the bound ligand, binding cobalamin tighter than cobinamide (Furger et al. 
2013). In fact, all the incomplete corrinoid binding transport proteins bind cobalamin more 
efficiently than the earlier intermediates (Furger et al. 2013; Greibe, Fedosov, and Nexo 2012; 
Greibe, Fedosov, Sorensen, et al. 2012). If the C. elegans transporter did bind the C5-cobyric 
acid analogue there would have been a high enough concentration of C5- BODIPY® TR-X 
cobyric acid in the nematode to image, but as it is not observed the C. elegans transporter is 
almost certainly cobalamin specific. 
 Upon uptake, the BODIPY® TR-X-ribose linked cobalamin localised exclusively in 
the coelomocytes when fed to C. elegans. As this is the first experiment of this kind, and only 
one of a handful of investigations into the relationship between cobalamin and C. elegans, 
there is little information available from which to draw conclusions. Coelomocytes are 
theorised to be rudimentary immune system, endocytosing foreign substances from the 
pseudocoelom (Altun and Hall 2009a). There are six in every nematode, in 3 pairs: behind the 
pharynx, near the vulva and by the anus. They contain many membrane bound vesicles and 
are known to endocytose injected foreign substances such as GFP, India ink etc. which are 
deposited in the lysosome for degradation or stored if that does not work (Fares and 
Greenwald 2001; Treusch et al. 2004; Fares and Grant 2002). Surprisingly, ablation of a few 
coelomocytes does not affect C. elegans fertility or survival, and even after a total loss the 
nematodes will develop and procreate (Fares and Greenwald 2001; Altun and Hall 2009a). It 
has been shown that yolk particles, which are not normally endocytosed by coelomocytes, can 
be induced to do so if tagged with GFP (Paupard et al. 2001). This is most probably due to the 





presence of the GFP which adds credence to the argument that the BODIPY® TR-X-ribose 
linked cobalamin analogue is taken up into the coelomocytes because of the BODIPY® TR-X 
and not the cobalamin molecule. 
C. elegans are cobalamin-dependent and display a loss of fertility, a shortened life 
span and an elongated life cycle when deficient (Bito et al. 2013). There are two cobalamin-
dependent proteins identified in C. elegans, MCM and MS (Bito et al. 2013). The localisation 
of these proteins is ubiquitous, so why there is a link to the coelomocytes is currently a 
mystery. A possible explanation for this is that the cobalamin analogue may have been 
recognised by the gut transport protein as cobalamin but not by the next binding protein. This 
could either have resulted in the analogue being released in the pseudocoelom until the 
BODIPY® TR-X moiety was recognised as foreign and the molecule was targeted/ engulfed 
by the coelomocytes. Alternatively, the pseudocoelom transport protein also recognised the 
cobalamin analogue and transported it to the coelomocytes where the cobalamin is stored in 
the nematode, whereupon it was targeted into vesicles. The nature of these vesicles is open to 
speculation; they might be storage vesicles or they could be lysosomal/ degradation vesicles.  
The BODIPY® TR-X-ribose linked analogue persists in the coelomocyte through 
many life stages. It is, however, not present in the ova at any stage, before or after expulsion 
from the adult (Chapter 4, Figure 4.7.1.1). Even though C. elegans is a hermaphrodite it still 
produces unfertilised oocytes which are subsequently fertilised in the spermatheca (Altun and 
Hall 2009b). Interestingly in O. mykiss (rainbow trout) the cobalamin binding protein, HIT, is 
present in immature oocytes but not in mature ones, although it was not investigated as to 
whether or not this coincided with a high cobalamin concentration (Greibe, Fedosov, 
Sorensen, et al. 2012). In O. mykiss the immature ova may require high levels of cobalamin 
where the mature ova do not, if the presence of the transporter correlates to that of cobalamin. 
In C. elegans the lack of fluorescence in the egg area suggests that the parent does not provide 
the ova or zygote with cobalamin, although the unidentified transporter may be present.    
Overall, it is not clear whether the BODIPY® TR-X analogue is in the coelomocytes 
due to their accumulation of foreign material or because cobalamin is stored in the 
coelomocytes. C. elegans has no endoderm derived organs, like the liver, where cobalamin is 
stored in more complex organisms, e.g. humans, so cobalamin is likely to be stored 
somewhere novel (McGhee et al. 2014; Nielsen et al. 2012). To see if the analogues are 
localising to the same place as foreign compounds, nematodes fed with E. coli containing 





BODIPY® TR-X-ribose linked cobalamin could be injected with India ink, and the 
fluorescence of the BODIPY® TR-X and the India ink can be compared in vivo (Fares and 
Greenwald 2001). To determine if the BODIPY® TR-X-ribose linked cobalamin is 
functioning as a cofactor C. elegans could be grown with the ribose analogue as the only 
source of cobalamin for many generations to ascertain whether a cobalamin deficiency 
phenotype is induced. Considering that C. elegans can survive without coelomocytes, feeding 
E. coli  containing BODIPY® TR-X-ribose linked cobalamin to the nematode after 
coelomocyte ablation would allow the visualisation of the localisation of the analogue without 
the presence of the potential storage cell (Fares and Greenwald 2001; Altun and Hall 2009a). 
6.4 Cobalamin analogue recognition in Arabidopsis thaliana and Lepidium sativum 
 Land plants do not synthesise or require cobalamin, owing to their lack of the 
cobalamin-dependent enzymes (Helliwell et al. 2011). The investigation into the uptake of 
cobalamin in plants was initiated due to data showing some plants could take up cobalamin 
and a growing concern that people who restricted their diets to omit meat (and eggs) could 
inadvertently self-impose cobalamin deficiency (Watanabe et al. 2013). It was thought that if 
SODQWVFRXOGEHµIRUWLILHG¶ZLWKFREDODPLQLQWKHVDPHZD\PRVWEUHDNIDVWFHUHDOVDUHWKHVH
people could obtain their necessary cobalamin quota from plants. L. sativum was shown in 
Chapter 4 to take up commercial cobalamin (cyanocobalamin) in a concentration dependent 
manner. Therefore it can be fortified with cobalamin. In order to know where the cobalamin 
localised in the plant, Oregon green® 514 analogues were added to the media. Remarkably, 
the fluorescence was only visible in the L. sativum vacuoles of the cotyledons and not in the 
roots or hypocotyl (data not shown). A. thaliana did not take it up at all. It is surprising that 
there is a difference in uptake between the two plants. There should be no cobalamin specific 
selectivity variation in plants at all and yet these two plants have root absorption regulation 
differences, which result in cobalamin exclusion in A. thaliana. It is feasible that the 
analogues are being taken up promiscuously in L. sativum by a separate transport system 
which is either under tighter regulation in A. thaliana or is not present.  
 Ultimately these experiments prove that L. sativum will take up cobalamin into the 
cotyledons. Therefore, in principle this proves that cobalamin enriched plants is a possible 
way to provide this vitamin to people with restricted diets which are prone to causing 
cobalamin insufficiency, potentially reducing the incidence of diet-mediated cobalamin 





deficiency. For commercialisation and product development, the uptake of cobalamin in 
major cereal crops and other legumes should be investigated. 
6.5 Corrinoid uptake, regulation and characterisation in Mycobacterium tuberculosis 
 A link between cobalamin and M. tuberculosis has been speculated for many years but 
there is much still unknown about the role of cobalamin in relation to the lifecycle of this 
bacterium (Corcino et al. 1971; Herbert 1983). Cobalamin, cobinamide and pseudocobalamin 
are all absorbed by M. tuberculosis in a concentration dependent way. The ǻEDF$strain, a 
gene knockout of the one known cobalamin transporter BacA, shows a reduced uptake but not 
a complete loss of absorbance. The results presented in Chapter 5 show that there is uptake of 
cobalamin, cobinamide and pseudocobalamin, although cobalamin uptake is halved compared 
to the other two corrinoids. If the absorbance of these corrinoids was serendipitous then there 
should not be a tangible reduction of cobalamin absorption in relation to cobinamide or 
pseudocobalamin.  As there is, this absorption is possibly due to a second uptake mechanism. 
This alternative route could favour cobinamide and pseudocobalamin absorption over 
cobalamin uptake, but as cobalamin is the corrinoid that M. tuberculosis produces when given 
cobinamide in the growth media, it is most likely to select cobalamin over the other two. 
Therefore, this alternative uptake passage could be negatively regulated by cobalamin but not 
by cobinamide or pseudocobalamin. This would mean that the alternative route can recognise 
all three corrinoids, but once internal cell cobalamin concentrations reach around 20 nM it is 
down regulated. Meanwhile, cobinamide and pseudocobalamin, unrecognised by the 
regulation system, continue to be absorbed. 
As with E. coli and S. enterica, the C5 and the ribose analogues are both taken up in M. 
tuberculosis, although the uptake mechanisms are different. Curiously in M. tuberculosis the 
C5-BODIPY® TR-X cobyric acid analogue was taken up more readily than the ribose linked 
BODIPY® TR-X cobalamin analogue.  The superior uptake of the C5-cobyric acid analogues 
may simply be due to their smaller size; M. tuberculosis has a single membrane but also thick 
waxy layer surrounding this which has been postulated to affect transport into and out of the 
cell (T. Smith et al. 2013). Owing to the hydrophobic nature of BODIPY® TR-X these 
analogues may be held up in this waxy coat more than cobyric acid or cobalamin would. This 
would mean that the smaller of the two slips through easier resulting in faster uptake.  
It may be that the C5 analogue is taken up via the possible alternative uptake route, 
which limits cobalamin absorption (or does not absorb cobalamin as well as cobyric acid), as 





well. If this is the case then the C5 analogue enters the M. tuberculosis cell via two routes, 
making the accumulation faster. The position of the fluorophore may also have an effect on 
the uptake: the BODIPY® TR-X ribose could interfere more with the uptake proteins than the 
BODIPY® TR-X at the C5 position on the macrocycle. 
If there is a separate uptake pathway for earlier intermediates of cobalamin synthesis 
in M. tuberculosis, this is a potentially exploitable route for drug trafficking into M. 
tuberculosis cells. Therapeutics linked to earlier cobalamin intermediates introduced 
intravenously to humans will not be recognised and taken up into healthy human cells, as 
TCII only binds cobalamin (Nielsen et al. 2012). This means the drug-corrinoid conjugate 
will specifically enter infecting cells. Some cancers have also been implicated in taking up 
earlier cobalamin intermediates, so treatment of these cancers is another possible application 
for early intermediate conjugated therapeutics (Waibel et al. 2008; Sah et al. 2014). The 
viability of such compounds can be tested in cell cultures of M. tuberculosis infected 
macrophages or cancer cell lines, as well as in model organisms, e.g. mice.  
6.6 Corrinoid functionality in Mycobacterium tuberculosis 
M. tuberculosis has never been shown to synthesise cobalamin de novo although it has 
all of the cobalamin biosynthesis genes apart from cobF. It may be possible for de novo 
synthesis of cobalamin to occur if another, undefined, protein compensates for CobF. 
However, a cobalamin-dependent mutant of M. tuberculosis, ǻPHW(, cannot grow without 
exogenous supplementation of corrinoids (Chapter 5, Section 5.2.1). Cobyric acid and 
cobinamide can both rescue ǻPHW( which proves that these intermediates can be transported 
into the bacterium and converted into an active cofactor form, capable of supporting growth. 
This early intermediate rescue is dependent on the presence of the cobalt ion as HBAH, the 
synthetic cobalt less equivalent of cobyric acid, does not elicit growth of the bacteria. It is not 
explicit as to whether the cobalt-less intermediates are taken up into the M. tuberculosis. The 
lack of cobalt in the media may have prevented the insertion of cobalt into these early 
intermediates, and, therefore, their conversion into cofactor form. To discover if M. 
tuberculosis is capable of inserting cobalt into early intermediates, such as HBAH, cobalt can 
be added to the media of a culture containing ǻPHW(. If the bacteria reproduce then the HBAH 
has been converted into an active cofactor form. 
 





6.7 Cobalamin binding proteins and corrinoid mediated regulation in Mycobacterium 
tuberculosis 
In the RNA sequencing experiment (Chapter 5, 5.5), the expectation was that the 
riboswitch regulated genes metE and ppe2 would be highlighted, but only the ppe2 gene 
showed a significant increase in transcripts in the presence of cobinamide, and only ǻPHW+
and ǻPHW(strains showed increases with cobalamin. The effect on the metE gene was not as 
distinct. The RNA transcripts decreased in the ǻEDF$ strain, but increased in the WT and 
H37Rv strains with both cobinamide and cobalamin. This difference could be a result of 
lower internal concentration of corrinoid in ǻEDF$ not being sufficient to cause the same 
response as in the WT and H37Rv strains.  
Curiously, ilvC, the gene encoding a ketol acid reductoisomerase, was downregulated 
in all of the tested M. tuberculosis strains supplemented with both cobalamin and cobinamide. 
This was the only gene which was significantly affected by the presence of the corrinoids, yet 
without any known link to cobalamin homeostasis in M. tuberculosis. In itself this is not 
particularly interesting, but the protein was also identified as binding to a cobalamin column. 
This would mean that the gene is suppressed by the corrinoids and yet the protein binds 
cobalamin. It could be that this gene and protein have some unknown connection to 
cobalamin. At present all that is known is that ketol acid reductoisomerase is involved in 
amino acid synthesis. 
The two other proteins highlighted in the cobalamin binding column experiment were 
Glutamine synthetase I and Citrate synthase I, both of which are involved in MCM 
independent propionate metabolism pathways in M. tuberculosis (Figure 1.7.1) (Savvi et al. 
2008). Strangely, the cobalamin independent methionine synthase MetE also purified off the 
cobalamin binding column. These three proteins are all involved in cobalamin independent 
processes, but were implicated in cobalamin binding. There is no obvious reason as to why 
they should bind cobalamin. 
This cobalamin column binding experiment excludes membrane bound cobalamin 
binding proteins of which there is at least one known, BacA. Although some proteins were 
identified as potential cobalamin binding, there are none that could unequivocally be defined 
as cobalamin binding proteins. 
 





6.8 Developing analogue synthesis 
6.8.1 Clickable SAM analogues 
 There is a potential problem with the C5 modified corrin-ring analogues synthesised. 
The linker used to conjugate the fluorophore to the corrin-ring can theoretically be cleaved by 
native proteases. Therefore, there is a need to change this linker to a non-hydrolysable 
equivalent. A possible alternative is to transfer a terminal alkyne moiety to the C5 position 
instead of the allyl group. This alkyne can be used in copper catalysed click chemistry with 
terminal azides which would form a non-labile bond between the corrin macrocycle and the 
conjugate (Kolb and Sharpless 2003). Fluorophores with terminal azides are available for 
purchase so fluorescent analogue synthesis is still possible. However, as these alkyne groups 
are rapidly hydrolysed, the hydrocarbon chain will probably have to be longer to increase 
stability. Consequently, the activity of the biosynthesis proteins may be compromised because 
of the increase in size of the transferred group. 
6.8.2 C5-analogue synthesis 
The modifications at the C5 position of the corrin-ring can have some adverse effects 
on the reaction rate of some of the biosynthesis enzymes. This issue was touched upon 
relating to CobH in Chapter 3. The T85A substitution of CobH increased the volume of the 
active site but, even though it catalysed the reaction, the allyl group was strained. A T85G 
substitution would increase the space even more as glycine is smaller than alanine, but this 
PD\KDYHUHGXFHGDFWLYLW\FRPSDUHGWRWKH7$PXWDQW7KH7UHVLGXHLVSDUWRIDQĮ
helix, and is, in fact, close to the terminus. It may be possible to remodel this helix so it 
terminates earlier, generating a larger active site volume which would allow the C5 analogues 
to fit better, especially if the longer alkyne moieties are conjugated. The early termination of 
WKLVĮKHOL[PD\UHVXOWLQDODFNRIHQ]\PHIXQFWLRQDOLW\DQGDQ\QHZPXWDQWVPXVWEHWHVWHG
for activity. 
6.8.3 Early intermediate analogue biomedical applications 
 It has been shown in mice that analogues of cobalamin with radioactive conjugates 
attached to the sidechains no longer bind TCII or IF but retain recognition by HC.  These 
analogues have increased specificity of tumour labelling in mice compared to analogues 
which can be bound by all three uptake proteins (Waibel et al. 2008). In this previous 
experiment the analogue is a full cobalamin with a secondary macrocycle attached to the b 





sidechain coordinating 99mTc with a butyl linker from the amide. The authors of this paper 
postulated that tumours have an increased expression of HC to supply the cobalamin needed 
for a high proliferation rate (Waibel et al. 2008). HC is the cobalamin transporter which does 
bind incomplete corrinoids, such as cobinamide, and it was shown that competition between 
cobinamide and the 99mTc analogue results in the complete blocking of tumour binding of the 
analogue as effectively as cobalamin competition. Immunohistochemical staining of HC has 
been shown to localise to the surface membrane and cytoplasm in various tumours of the 
digestive tract, urinary tract, lung, salivary gland, and breast (Kim et al. 1993).  This means 
that C5-cobyric acid analogues can be used to specifically target tumours that express a high 
level of HC as a way of increasing their cobalamin uptake. A paper published in 1971 
postulated the link between cobalamin deficiency and leukaemia retardation after observing a 
patient diagnosed with both chronic myeloid leukaemia and pernicious anaemia before and 
after withholding therapeutic cobalamin (Corcino et al. 1971). In 1983 the same group 
showed that an aniline conjugated to a sidechain of cobalamin could treat acute myelogenous 
leukaemia, again in a single patient (Herbert 1983). These investigations have not been 
furthered since. 
 The same overexpression of HC may occur in M. tuberculosis infected cells, and, as M. 
tuberculosis absorbs the C5-cobyric acid analogues more efficiently than cobalamin 
analogues, an early intermediate conjugated drug could be specifically targeted to M. 
tuberculosis infected cells. Current knowledge of the relationship between cobalamin and M. 
tuberculosis is that the biosynthesis genes cobK and cobL are expressed during M. 
tuberculosis infection of immune-competent mice, and cobI and Rv2067c (a putative 
precorrin-3b methyltransferase) have been detected in human pulmonary patients (Gopinath, 
Moosa, et al. 2013). This is odd as the results presented in Chapter 5 shows that M. 
tuberculosis does not synthesise cobalamin de novo and these genes are not required in 
completing cobalamin biosynthesis from scavenged corrinoids. This combined data begs the 
question, has M. tuberculosis somehow compensated for the lack of cobF and is able to 
synthesise cobalamin during host infection?  





 Tumour specificity linked to HC expression could be immensely beneficial in targeted 
drug-conjugated corrinoid therapeutics. HC is the only human uptake protein which binds 
incomplete corrinoids, so indiscriminate absorbance could be removed by using an earlier 
intermediate conjugate instead of cobalamin. The incomplete corrinoid-drug conjugate should 
localise to the tumour(s) in much the same as the radioactive sidechain b conjugate did 
(Waibel et al. 2008). In terms of therapeutics, this means that a broader range of drugs can be 
used, not just the cyto-accumulation toxic ones. Using incomplete corrinoid conjugates is also 
beneficial in drug conjugate biosynthesis as there are fewer steps required to make them. 
These corrinoid analogues would have to be tested in different disease backgrounds to tailor 
the best intermediate for drug conjugation in each case. 
6.9 Concluding remarks  
The investigations reported in this thesis have shown a novel mechanism of cobalamin 
modification which can be further adapted to carry a fluorophore. The synthesised analogues 
were used to elucidate cobalamin uptake and storage across different living systems including 
bacteria, plants and animals. The fluorophore conjugated analogues can be used to further 
understanding the role of cobalamin in health and disease. 
The synthesised analogues can also be recognised and used by M. tuberculosis which 
ultimately could lead to a new therapeutic role for cobalamin in targetting drugs to cells with 
high proliferation rates. Although the analogues currently have fluorophore conjugates, these 
can be replaced with drugs, such as Rifampicin. Rifampicin is a similar size to BODIPY ® 
TR-X (Figure 6.9.1); therefore, the activities of the fluorophore conjugates are indicative of 
how the drug equivalents could work. 
 
Figure 6.9.1: The structures of BODIPY® TR-X and Rifampicin The BODIPY® 
TR-X fluorophore used (left) compared to the rifampicin, a standard first-line 
treatment drug for M. tuberculosis infection. 
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A.2: Graph showing the change in spectra during the formation of Cobalt-precorrin-6B 
from Cobalt-factor-III 
  





A.3: SDS gel of CbiF purification frozen and fresh pellets 
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0.1 M Sodium Cacodylate pH6.5 (NaCac) 
0.2 M Calcium acetate hydrate (CaAH) 
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The alcohols were added to the wells and the glycerol to the drops themselves. 
  





A.5: Collected data for the apo-crystal CobH (T85A) compared to the co-crystal and the 
previously published wild type CobH from Rhodobacter capsulatus 








Wavelength (Å) 0.92819 0.92819 0.97630 
High resolution 
limit 1.57 (7.02 - 1.57) 1.17 (4.53 - 1.17) 1.68 
Low resolution 
limit 48.38 (48.38 - 1.61) 48.34 (48.34 - 1.21) 34.7 
Completeness 98.8 (91.6 - 99.7) 98.8 (99.9 - 96.7) 97.4 
Multiplicity 3.3 (3.4 - 3.2) 2.9 (3.3 - 1.9) 4.1 (redundancy) 
I/sigma 6.3 (12.6 - 1.3) 12.6 (53.4 - 1.4) 16.9 (6.6) 
Rmerge 
0.237 (0.249 - 
0.899) 0.026 (0.017 - 0.626) 0.059 
Anomalous 
completeness 85.8 (87.3 - 81.9) 79.4 (93.7 - 49.1)  
Anomalous 
multiplicity 1.5 (1.9 - 1.7) 1.3 (1.7 - 1.3)  
Unit cell 
dimensions: a (Å) 71.230 71.415 70.250 
b (Å) 66.630 66.491 66.030 
c (Å) 48.920 49.101 48.480 
Į 90.000 90.000 90.000 
ȕ 99.030 99.652 98.980 
Ȗ 90.000 90.000 90.000 




Your data do not 
appear twinned 
1.92 









A.6: The sequence alignment of Allochromatium vinosum and Rhodobacter capsulatus 
CobQ 





































Chemical shift assignments:  
Eight carbons were not assignable (mostly 
due to lack of signal). The terminal vinyl 
protons (C53) and C19 were only 
observable in the sensitivity enhanced 
HSQC (possibly due to water suppression 



















Assignment į&>SSP@ į+>SSP@ 
C1 83.2 -   
C1A 24.4 1.20   
C2 48.8 -   
C2A 18.4 1.39   
C21 43.6 2.27   
C22 ? -   
C3 57.8 3.31   
C31 28.0 1.82 / 2.05 
C32 37.4 2.35 / 2.47 
C33 ? -   
C4 ? -   
C5 ? -   
C51 33.1 3.11 / 3.51 
C52 140.2 5.97   
C53 119.0 4.96 / 5.07 
C6 162.5 -   
C7 49.1 -   
C7A 22.9 1.53   
C71 47.7 2.59   
C72 177.7 -   
C8 55.6 3.35   
C81 27.8 1.96 / 2.14 
C82 35.0 2.31 / 2.37 
C83 ? -   
C9 171.4 -   
C10 92.1 5.61   
C11 193.3 -   
C12 51.7 -   
C12A 21.6 1.33   
C12B 33.6 1.14   
C13 56.0 3.18   
C131 28.0 1.76 / 2.02 
C132 34.6 1.96 / 2.07 
C133 ? -   
C14 ? -   
C15 105.7 -   
C151 16.6 2.18   
C16 182.1 -   
C17 60.1 -   
C17B 22.2 1.37   
C171 34.9 1.84 / 2.27 
C172 36.1 1.95 / 2.45 
C173 ? -   
C18 42.2 2.94   
C181 35.7 2.72   
C182 178.9 -   
C19 69.5 4.29   





Observed ROE interactions 
From To 
C1A C31, C32, C18, C19 
C2A C21, C3, C18, C31, C32, C181 
C21 C2A, C3, C19 
C3 C2A, C21, C51 
C31 C1A, C2A, C51 
C32 C1A, C2A 
C51 C3, C31, C7A, C71 
C52  
C53 C71 
C7A C51, C71, C8, C81, C82 
C71 C51, C53, C7A, C8 
C8 C7A, C71, C10 
C81 C7A, C10 
C82 C7A, C10 
C10 C8, C81, C82, C12A, C12B 
C12A C10, C12B, C13, C131 
C12B C10, C13, C12A 
C13 C12A, C12B, C151 
C131 C12A 
C132 C172 
C151 C13, C17B, C171 
C17B C151, C171, C181, C19 
C171 C151, C17B, C18 
C172 C132, C18 
C18 C1A, C2A, C171, C172 
C181 C2A, C171, C17B 
C19 C1A, C21, C17B 





A.8: C5-thioamine-cobyric acid NMR  
Chemical shift assignments 
 į+>SSP@ į&>SSP@ 
C1  85.34 
C1A 1.43 24.28 
C2  49.27 
C2A 1.46 19.19 
C21 2.21, 2.28 43.74 
C22  178.09 
C3 3.89 58.16 
C31 1.93, 2.24 28.56 
C32 2.45, 2.53 37.55 
C33  183.99 
C4  179.48 
C5  108.28 
C51 2.35 17.90 
C52 1.61, 1.84 34.42 
C53 3.02 41.58 
C55 2.77 32.96 
C56 3.06 41.48 
C6  166.71 
C7  52.09 
C7A 1.7 22.60 
C71 2.28, 2.54 47.23 
C72  177.67 
C8 3.28 57.35 
C81 1.67, 2.24 28.96 
C82 2.64, 2.68 35.45 
C83  178.83 
C9  174.70 
C10 5.82 93.80 
C11  180.65 
C12  49.78 
C12A 1.37 21.07 
C12B 1.13 32.89 
C13 3.24 55.67 
C131 1.75, 2.06 28.68 
C132 2.07, 2.29 34.45 
C133  181.83 
C14  165.44 
C15  106.92 
C151 2.26 17.59 
C16  180.71 
C17  61.92 
C17A 1.24 20.00 
C171 1.96, 2.32 35.96 
C172 1.80, 2.43 35.87 

















   
C173  180.63 
C18 2.82 41.83 
C181 2.24 44.51 
C182  180.60 
C19 3.68 78.28 





A.9: C5-fluorescein-cobyric acid HPLC MS to check conversion 
 
 
The extracted ion chromatogram (EIC) detects a m/z of 1536.5 (±0.2) in the mass 
spectrometry data. The peaks correspond to the smaller peaks either side of 25 minutes. 
The larger peaks at 30 minutes in the UV chromatogram had no clear cobalamin absorption 
































The T7 promoter and terminator are in white whilst the ampicillin resistance gene, AmpR is in 
green. BtuF is shown in yellow. There is a His tag present at the start of the gene which is not 
shown on the Figure. The Ec after btuF is present because the gene was taken from E. coli. 
  
pET14b-btuFEc 

































Pseudo-cobalamin standards repeated 
without the 10nM sample which did not 
grow. The 1µM standard is roughly 
equivalent to the 50nM standard of 






















































cobalamin without being scaled up to 50 ml, but still using the 20 ml values.
 





C.3 Extracted ion chromatogram for cobinamide in the sample ǻPHW( grown on cobinamide 
and run on the HPLC-MS 
 





The extracted ion chromatogram for cobinamide in the singly and doubly charged state: 
1041.5 and 521.25 respectively. The mass spectrometry data that follows is for the three 
biggest peaks. None of the show the m/z for cobinamide or the 350nm, 526nm absorbance 









C.4 Alignment of the DNA from the two M. tuberculosis cobQ genes 
Alignment produced using MultAlin  
 





C.5 Table of the effect of cobalamin and cobinamide on the cobalamin biosynthesis gene 
RNA levels  
 
 















7KHILUVWSXULILFDWLRQRIǻEDF$UXQRQD-20 % gel after the elutions were concentrated. M is 
the marker; Sn: supernatant; Tris: 20 mM Tris pH 8 wash; the concentrations refer to the 
concentration of cobalamin in 20 mM Tris pH 8 buffer; and urea: 8 M urea in 20 mM Tris pH 











































C.7 Initial Mass Spectrometry results of MALDI from the cobalamin column 
 






























































Alignment produced using MultAlin  
 
